P-value | ln(P) | Term | GO Tree | GO ID | # of Genes in Term | # of Target Genes in Term | # of Total Genes | # of Target Genes | Common Genes |
1.086e-11 | -25.25 | Burkitt_lymphoma | COSMIC cancer mutations | Burkitt_lymphoma | 2119 | 26 | 16828 | 49 |
ADCY2,NHSL1,LSAMP,FBXL7,STON2,ATP13A4,RYR3,CTNND2,CPE,NTRK2,FMN2,GNA14,SHROOM3,PREX2,SLC1A3,SLC1A2,GPM6A,GLI3,GABRB1,RFX4,GPC5,NPAS3,CACHD1,NKAIN3,BMPR1B,SOX5 |
1.086e-11 | -25.25 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Burkitt_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Burkitt_lymphoma | 2119 | 26 | 16828 | 49 |
GPC5,NPAS3,CACHD1,NKAIN3,BMPR1B,SOX5,SLC1A3,PREX2,SLC1A2,GPM6A,GLI3,GABRB1,RFX4,STON2,ATP13A4,RYR3,CTNND2,CPE,NTRK2,FMN2,GNA14,SHROOM3,ADCY2,NHSL1,LSAMP,FBXL7 |
1.647e-09 | -20.22 | brainstem | COSMIC cancer mutations | brainstem | 3102 | 28 | 16828 | 49 |
PREX2,SLC1A3,ZNRF3,SLC1A2,GLI3,RORA,GPM6A,GABRB1,NPAS3,GPC5,SOX5,NKAIN3,CACHD1,RANBP3L,ADCY2,LSAMP,FBXL7,SFXN5,TNIK,ATP13A4,STON2,CTNND2,RYR3,FMN2,CPE,SHROOM3,FGFR3,GNA14 |
3.796e-09 | -19.39 | central_nervous_system-brainstem-glioma-astrocytoma_Grade_IV | COSMIC cancer mutations | central_nervous_system-brainstem-glioma-astrocytoma_Grade_IV | 2531 | 25 | 16828 | 49 |
GPM6A,RORA,GLI3,GABRB1,ZNRF3,SLC1A3,PREX2,CACHD1,NKAIN3,SOX5,RANBP3L,GPC5,SFXN5,FBXL7,TNIK,ADCY2,LSAMP,CPE,FMN2,GNA14,SHROOM3,STON2,ATP13A4,RYR3,CTNND2 |
5.459e-09 | -19.03 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | 3511 | 29 | 16828 | 49 |
SLC4A4,NPAS3,GPC5,MACF1,BMPR1B,CACHD1,RANBP3L,SLC1A3,PREX2,PAMR1,ZNRF3,GLI3,DTNA,GABRB1,STON2,CTNND2,RYR3,FMN2,NTRK2,CPE,PARD3B,SHROOM3,MGAT4C,PITPNC1,ADCY2,LSAMP,FBXL7,MSI2,TNIK |
5.459e-09 | -19.03 | chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | COSMIC cancer mutations | chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | 3511 | 29 | 16828 | 49 |
TNIK,MSI2,FBXL7,LSAMP,MGAT4C,PITPNC1,ADCY2,SHROOM3,PARD3B,FMN2,CPE,NTRK2,CTNND2,RYR3,STON2,GABRB1,GLI3,DTNA,PAMR1,SLC1A3,PREX2,ZNRF3,RANBP3L,BMPR1B,MACF1,CACHD1,NPAS3,SLC4A4,GPC5 |
8.164e-09 | -18.62 | mantle_cell_lymphoma | COSMIC cancer mutations | mantle_cell_lymphoma | 2849 | 26 | 16828 | 49 |
LSAMP,HIF3A,ADCY2,FBXL7,SFXN5,CTNND2,RYR3,ATP13A4,SHROOM3,PARD3B,GNA14,FMN2,NTRK2,CPE,SLC1A2,PREX2,SLC1A3,ZNRF3,RFX4,GABRB1,GLI3,GPM6A,GPC5,SOX5,NKAIN3,CACHD1 |
8.189e-09 | -18.62 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia | 3828 | 30 | 16828 | 49 |
FBXL7,TNIK,MGAT4C,HIF3A,ADCY2,LSAMP,FMN2,GLIS3,NTRK2,CPE,SHROOM3,GNA14,ATP13A4,CTNND2,RYR3,GLI3,RORA,GPM6A,GABRB1,SLC1A3,PREX2,PAMR1,SLC1A2,SOX5,BMPR1B,NKAIN3,CACHD1,NTM,SLC4A4,GPC5 |
8.189e-09 | -18.62 | acute_lymphoblastic_B_cell_leukaemia | COSMIC cancer mutations | acute_lymphoblastic_B_cell_leukaemia | 3828 | 30 | 16828 | 49 |
GABRB1,GPM6A,GLI3,RORA,SLC1A2,PREX2,SLC1A3,PAMR1,NTM,CACHD1,SOX5,NKAIN3,BMPR1B,GPC5,SLC4A4,TNIK,FBXL7,LSAMP,HIF3A,ADCY2,MGAT4C,GNA14,SHROOM3,GLIS3,NTRK2,CPE,FMN2,RYR3,CTNND2,ATP13A4 |
1.166e-08 | -18.27 | diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | diffuse_large_B_cell_lymphoma | 4151 | 31 | 16828 | 49 |
GPC5,NKAIN3,MACF1,SOX5,CACHD1,ATP1A2,RANBP3L,SLC1A3,PREX2,SPARCL1,SLC1A2,RORA,GLI3,DTNA,GPM6A,GABRB1,STON2,ATP13A4,CTNND2,RYR3,FMN2,CPE,NTRK2,FGFR3,SHROOM3,GNA14,AQP4,ADCY2,LSAMP,FBXL7,TNIK |
1.500e-08 | -18.01 | myelodysplastic_syndrome | COSMIC cancer mutations | myelodysplastic_syndrome | 1174 | 17 | 16828 | 49 |
FGFR3,GNA14,NKAIN3,BMPR1B,SOX5,CACHD1,NTRK2,ATP1A2,RYR3,NPAS3,TNIK,GABRB1,FBXL7,LSAMP,SLC1A2,PREX2,ADCY2 |
1.500e-08 | -18.01 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelodysplastic_syndrome | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelodysplastic_syndrome | 1174 | 17 | 16828 | 49 |
SLC1A2,LSAMP,ADCY2,PREX2,GABRB1,TNIK,FBXL7,RYR3,NPAS3,GNA14,FGFR3,ATP1A2,NTRK2,CACHD1,SOX5,BMPR1B,NKAIN3 |
1.947e-08 | -17.75 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-mantle_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-mantle_cell_lymphoma | 2737 | 25 | 16828 | 49 |
GPC5,SOX5,NKAIN3,CACHD1,SLC1A2,PREX2,SLC1A3,ZNRF3,RFX4,GABRB1,GLI3,GPM6A,CTNND2,RYR3,SHROOM3,PARD3B,GNA14,FMN2,NTRK2,CPE,LSAMP,HIF3A,ADCY2,FBXL7,SFXN5 |
2.157e-08 | -17.65 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm | 764 | 14 | 16828 | 49 |
FBXL7,GABRB1,ADCY2,PREX2,SLC1A2,LSAMP,ATP1A2,NTRK2,CACHD1,SOX5,NKAIN3,GNA14,GPC5,RYR3 |
2.815e-08 | -17.39 | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma | COSMIC cancer mutations | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma | 7205 | 40 | 16828 | 49 |
FMN2,CPE,NTRK2,GLIS3,FGFR3,SHROOM3,PARD3B,ABLIM1,GNA14,STON2,ATP13A4,CTNND2,SORBS1,RYR3,SFXN5,FBXL7,GLUD1,TNIK,NHSL1,PITPNC1,ADCY2,LSAMP,NKAIN3,SOX5,MACF1,CACHD1,NTM,RANBP3L,SLC4A4,NPAS3,GPC5,RORA,GLI3,GPM6A,RFX4,GABRB1,PAMR1,PREX2,SLC1A3,SLC1A2 |
2.942e-08 | -17.34 | plasma membrane | cellular component | GO:0005886 | 5538 | 33 | 19108 | 49 |
ATP13A4,NTM,GNA14,NKAIN3,TNIK,NTRK2,CTNND2,CTNNA2,BMPR1B,ZNRF3,FMN2,FGFR3,SORBS1,GPM6A,CACHD1,RYR3,STON2,HIF3A,GPC5,GABRB1,SLC1A3,DTNA,SHROOM3,AQP4,PARD3B,ATP1A2,ADCY2,CPE,PREX2,LSAMP,SLC4A4,MACF1,SLC1A2 |
5.023e-08 | -16.81 | prostate-carcinoma | COSMIC cancer mutations | prostate-carcinoma | 9000 | 44 | 16828 | 49 |
ATP13A4,RYR3,GLIS3,FMN2,GNA14,SHROOM3,PARD3B,ADCY2,PITPNC1,NPAS3,BMPR1B,SLC1A3,GPM6A,STON2,SORBS1,CTNND2,NTRK2,CPE,ABLIM1,FGFR3,HIF3A,NHSL1,LSAMP,FBXL7,GLUD1,SFXN5,MSI2,TNIK,GPC5,SLC4A4,CACHD1,MACF1,SOX5,NKAIN3,NTM,SPARCL1,ZNRF3,PREX2,SLC1A2,DTNA,GLI3,RORA,GABRB1,RFX4 |
5.448e-08 | -16.73 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | 3608 | 28 | 16828 | 49 |
GPC5,RANBP3L,SOX5,MACF1,NKAIN3,ATP1A2,CACHD1,SLC1A2,PREX2,SPARCL1,GABRB1,GLI3,RORA,GPM6A,CTNND2,RYR3,ATP13A4,STON2,SHROOM3,FGFR3,GNA14,FMN2,CPE,LSAMP,AQP4,ADCY2,TNIK,FBXL7 |
5.657e-08 | -16.69 | cell periphery | cellular component | GO:0071944 | 6020 | 34 | 19108 | 49 |
CPE,PREX2,ADCY2,MACF1,SLC1A2,LSAMP,SLC4A4,SLC1A3,DTNA,AQP4,PARD3B,ATP1A2,SHROOM3,GPM6A,SORBS1,CACHD1,RYR3,BMPR1B,FMN2,ZNRF3,FGFR3,HIF3A,GPC5,GABRB1,STON2,GNA14,ATP13A4,NTM,NTRK2,CTNND2,CTNNA2,NKAIN3,TNIK,SPARCL1 |
1.593e-07 | -15.65 | lymphoid_neoplasm | COSMIC cancer mutations | lymphoid_neoplasm | 12233 | 49 | 16828 | 49 |
RYR3,ATP13A4,SHROOM3,PARD3B,GNA14,FMN2,GLIS3,AQP4,PITPNC1,ADCY2,NPAS3,RANBP3L,BMPR1B,ATP1A2,PAMR1,SLC1A3,GPM6A,CTNND2,SORBS1,STON2,FGFR3,ABLIM1,CPE,NTRK2,LSAMP,NHSL1,MGAT4C,HIF3A,TNIK,MSI2,SFXN5,FBXL7,GLUD1,SLC4A4,GPC5,NTM,NKAIN3,SOX5,MACF1,CACHD1,SLC1A2,PREX2,ZNRF3,SPARCL1,RFX4,GABRB1,RORA,DTNA,GLI3 |
2.894e-07 | -15.06 | chondroblastoma | COSMIC cancer mutations | chondroblastoma | 534 | 11 | 16828 | 49 |
ADCY2,LSAMP,GPM6A,SFXN5,GABRB1,GPC5,CTNND2,RYR3,SOX5,NKAIN3,FMN2 |
5.280e-07 | -14.45 | PRNP (prion protein (Kanno blood group)) | protein interactions | 5621 | 1118 | 14 | 19454 | 50 |
GLUD1,MACF1,SLC4A4,CPE,ATP1A2,SORBS1,NHSL1,SPARCL1,ABLIM1,LSAMP,GPM6A,MSI2,AQP4,SLC1A3 |
6.069e-07 | -14.31 | lymph_node | COSMIC cancer mutations | lymph_node | 1703 | 18 | 16828 | 49 |
FGFR3,RANBP3L,PARD3B,SHROOM3,SOX5,NTRK2,CTNND2,RYR3,STON2,ATP13A4,GPC5,TNIK,GABRB1,DTNA,GPM6A,SFXN5,LSAMP,SLC1A3 |
6.567e-07 | -14.24 | acute_myeloid_leukaemia_therapy_related | COSMIC cancer mutations | acute_myeloid_leukaemia_therapy_related | 1523 | 17 | 16828 | 49 |
CACHD1,NTRK2,FMN2,NKAIN3,SOX5,SHROOM3,GPC5,RYR3,CTNND2,FBXL7,RORA,GLI3,GABRB1,ADCY2,SLC1A3,PREX2,LSAMP |
6.567e-07 | -14.24 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_therapy_related | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_therapy_related | 1523 | 17 | 16828 | 49 |
CTNND2,RYR3,GPC5,SHROOM3,FMN2,NKAIN3,SOX5,CACHD1,NTRK2,LSAMP,PREX2,SLC1A3,ADCY2,GABRB1,RORA,GLI3,FBXL7 |
1.565e-06 | -13.37 | nervous system development | biological process | GO:0007399 | 2185 | 19 | 18204 | 49 |
GLUD1,RORA,GLI3,GABRB1,SOX5,RFX4,SLC1A3,NTM,TNIK,LSAMP,CTNND2,CTNNA2,NTRK2,BMPR1B,PREX2,GPM6A,ATP1A2,MSI2,SLC1A2 |
1.742e-06 | -13.26 | pharynx | COSMIC cancer mutations | pharynx | 2696 | 22 | 16828 | 49 |
SORBS1,CTNND2,RYR3,SLC4A4,ATP13A4,NPAS3,GPC5,SHROOM3,PARD3B,FGFR3,MACF1,FMN2,NTRK2,ATP1A2,SLC1A2,PREX2,PITPNC1,NHSL1,RFX4,GABRB1,DTNA,SFXN5 |
2.277e-06 | -12.99 | bone-humerus-other-chondroblastoma | COSMIC cancer mutations | bone-humerus-other-chondroblastoma | 301 | 8 | 16828 | 49 |
GABRB1,SFXN5,GPM6A,SOX5,NKAIN3,FMN2,GPC5,ADCY2 |
3.130e-06 | -12.67 | humerus | COSMIC cancer mutations | humerus | 546 | 10 | 16828 | 49 |
GPM6A,SFXN5,SOX5,NKAIN3,FMN2,GABRB1,PARD3B,HIF3A,GPC5,ADCY2 |
4.959e-06 | -12.21 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm | 7307 | 37 | 16828 | 49 |
GLUD1,FBXL7,SFXN5,TNIK,MGAT4C,NHSL1,ADCY2,LSAMP,FMN2,GLIS3,NTRK2,CPE,PARD3B,SHROOM3,ABLIM1,GNA14,ATP13A4,STON2,CTNND2,RYR3,GLI3,RORA,GPM6A,RFX4,GABRB1,SLC1A3,PREX2,PAMR1,SPARCL1,SLC1A2,MACF1,SOX5,BMPR1B,NKAIN3,CACHD1,RANBP3L,GPC5 |
5.631e-06 | -12.09 | follicular_lymphoma | COSMIC cancer mutations | follicular_lymphoma | 1209 | 14 | 16828 | 49 |
SOX5,NKAIN3,CACHD1,RANBP3L,GNA14,STON2,GPC5,CTNND2,RORA,TNIK,GABRB1,AQP4,ADCY2,LSAMP |
6.125e-06 | -12.00 | multicellular organism development | biological process | GO:0007275 | 3957 | 25 | 18204 | 49 |
RFX4,NTM,TNIK,CPE,NTRK2,GPM6A,HIF3A,ATP1A2,SLC1A2,LSAMP,SHROOM3,SLC1A3,FGFR3,GLUD1,RORA,SOX5,GABRB1,GLI3,BMPR1B,CTNNA2,PREX2,ZNRF3,MSI2,RANBP3L,CTNND2 |
7.967e-06 | -11.74 | generation of neurons | biological process | GO:0048699 | 1158 | 13 | 18204 | 49 |
PREX2,GPM6A,CTNNA2,BMPR1B,NTRK2,CTNND2,TNIK,SLC1A3,NTM,GLI3,GABRB1,SOX5,RORA |
9.320e-06 | -11.58 | plasma_cell_myeloma | COSMIC cancer mutations | plasma_cell_myeloma | 1263 | 14 | 16828 | 49 |
NTRK2,FMN2,MACF1,ABLIM1,NTM,FGFR3,ATP13A4,RYR3,CTNND2,GPM6A,GLI3,TNIK,ADCY2,PAMR1 |
9.320e-06 | -11.58 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-plasma_cell_myeloma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-plasma_cell_myeloma | 1263 | 14 | 16828 | 49 |
GPM6A,GLI3,TNIK,ADCY2,PAMR1,NTRK2,MACF1,FMN2,ABLIM1,NTM,FGFR3,ATP13A4,RYR3,CTNND2 |
1.167e-05 | -11.36 | oesophagus-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | oesophagus-carcinoma-squamous_cell_carcinoma | 6486 | 34 | 16828 | 49 |
CACHD1,ATP1A2,BMPR1B,MACF1,SOX5,RANBP3L,GPC5,NPAS3,SLC4A4,GPM6A,GLI3,SPARCL1,PREX2,CPE,GLIS3,FMN2,ABLIM1,GNA14,FGFR3,PARD3B,STON2,ATP13A4,RYR3,CTNND2,SORBS1,SFXN5,FBXL7,GLUD1,TNIK,ADCY2,HIF3A,AQP4,MGAT4C,PITPNC1 |
1.167e-05 | -11.36 | system development | biological process | GO:0048731 | 3533 | 23 | 18204 | 49 |
MSI2,CTNNA2,BMPR1B,PREX2,RANBP3L,CTNND2,SLC1A3,FGFR3,RORA,GLUD1,GLI3,GABRB1,SOX5,ATP1A2,SLC1A2,NTRK2,HIF3A,GPM6A,LSAMP,NTM,TNIK,RFX4,CPE |
1.353e-05 | -11.21 | C11orf52 (chromosome 11 open reading frame 52) | protein interactions | 91894 | 310 | 7 | 19454 | 50 |
STON2,ABLIM1,DTNA,MACF1,CACHD1,FMN2,TNIK |
1.359e-05 | -11.21 | neuron development | biological process | GO:0048666 | 859 | 11 | 18204 | 49 |
CTNND2,PREX2,GPM6A,CTNNA2,BMPR1B,NTRK2,GABRB1,GLI3,TNIK,NTM,SLC1A3 |
1.598e-05 | -11.04 | nodular | COSMIC cancer mutations | nodular | 1515 | 15 | 16828 | 49 |
PREX2,SPARCL1,HIF3A,FGFR3,ABLIM1,FMN2,MACF1,CPE,ATP1A2,GLIS3,NTRK2,CTNND2,SLC4A4,ATP13A4,NPAS3 |
1.836e-05 | -10.91 | CTNNA1 (catenin alpha 1) | protein interactions | 1495 | 325 | 7 | 19454 | 50 |
MACF1,DTNA,ABLIM1,CTNNA2,NHSL1,TNIK,SORBS1 |
2.023e-05 | -10.81 | positive regulation of chondrocyte differentiation | biological process | GO:0032332 | 20 | 3 | 18204 | 49 |
GLI3,SOX5,BMPR1B |
2.153e-05 | -10.75 | neuron differentiation | biological process | GO:0030182 | 1081 | 12 | 18204 | 49 |
SLC1A3,NTM,TNIK,RORA,GABRB1,GLI3,CTNNA2,BMPR1B,NTRK2,PREX2,GPM6A,CTNND2 |
2.188e-05 | -10.73 | tibia | COSMIC cancer mutations | tibia | 836 | 11 | 16828 | 49 |
TNIK,GPM6A,LSAMP,PREX2,RANBP3L,FGFR3,ABLIM1,MACF1,NKAIN3,CPE,CTNND2 |
2.256e-05 | -10.70 | MAPT (microtubule associated protein tau) | protein interactions | 4137 | 948 | 11 | 19454 | 50 |
ABLIM1,NTM,LSAMP,CTNND2,GPM6A,SLC1A3,SLC1A2,ATP1A2,TNIK,SORBS1,CTNNA2 |
2.257e-05 | -10.70 | monoatomic ion transmembrane transporter activity | molecular function | GO:0015075 | 752 | 10 | 18094 | 48 |
SLC1A2,ATP13A4,SFXN5,GPM6A,GABRB1,RYR3,CACHD1,SLC1A3,ATP1A2,SLC4A4 |
2.353e-05 | -10.66 | right_lower_lobe | COSMIC cancer mutations | right_lower_lobe | 5692 | 31 | 16828 | 49 |
GNA14,SHROOM3,PARD3B,NTRK2,FMN2,RYR3,CTNND2,SORBS1,STON2,ATP13A4,FBXL7,GLUD1,LSAMP,ADCY2,MGAT4C,NTM,CACHD1,ATP1A2,NKAIN3,SOX5,MACF1,GPC5,SLC4A4,NPAS3,GABRB1,GPM6A,DTNA,GLI3,ZNRF3,PAMR1,SLC1A3 |
2.353e-05 | -10.66 | lung-right_lower_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-right_lower_lobe-carcinoma-adenocarcinoma | 5692 | 31 | 16828 | 49 |
NTRK2,FMN2,GNA14,PARD3B,SHROOM3,ATP13A4,STON2,RYR3,SORBS1,CTNND2,GLUD1,FBXL7,ADCY2,MGAT4C,LSAMP,ATP1A2,CACHD1,MACF1,SOX5,NKAIN3,NTM,GPC5,SLC4A4,NPAS3,GPM6A,DTNA,GLI3,GABRB1,ZNRF3,SLC1A3,PAMR1 |
2.698e-05 | -10.52 | anatomical structure development | biological process | GO:0048856 | 5207 | 28 | 18204 | 49 |
SHROOM3,LSAMP,NTRK2,HIF3A,GPM6A,ATP1A2,SLC1A2,CPE,RFX4,NTM,TNIK,RANBP3L,CTNND2,CTNNA2,BMPR1B,PREX2,ABLIM1,ZNRF3,MSI2,FMN2,RORA,GLUD1,GABRB1,GLI3,SOX5,SPARCL1,SLC1A3,FGFR3 |
2.933e-05 | -10.44 | plasma membrane bounded cell projection | cellular component | GO:0120025 | 2285 | 17 | 19108 | 49 |
ADCY2,BMPR1B,FMN2,GPM6A,STON2,GABRB1,MACF1,SLC1A2,DTNA,SLC1A3,GLI3,NTRK2,AQP4,CTNND2,ABLIM1,ATP1A2,CTNNA2 |
3.021e-05 | -10.41 | cellular response to organic cyclic compound | biological process | GO:0071407 | 464 | 8 | 18204 | 49 |
ADCY2,SLC1A2,ATP1A2,SLC1A3,RYR3,GABRB1,GNA14,RORA |
3.254e-05 | -10.33 | autonomic_ganglia | COSMIC cancer mutations | autonomic_ganglia | 4005 | 25 | 16828 | 49 |
HIF3A,ADCY2,PITPNC1,AQP4,NHSL1,FBXL7,TNIK,RYR3,CTNND2,GLIS3,NTRK2,FMN2,PARD3B,FGFR3,ZNRF3,PREX2,SLC1A2,GPM6A,GLI3,RFX4,SLC4A4,NPAS3,ATP1A2,CACHD1,MACF1 |
3.599e-05 | -10.23 | neurogenesis | biological process | GO:0022008 | 1334 | 13 | 18204 | 49 |
TNIK,NTM,SLC1A3,GLI3,GABRB1,SOX5,RORA,PREX2,GPM6A,CTNNA2,NTRK2,BMPR1B,CTNND2 |
3.641e-05 | -10.22 | upper_aerodigestive_tract-pharynx-carcinoma-nasopharyngeal_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-pharynx-carcinoma-nasopharyngeal_carcinoma | 1425 | 14 | 16828 | 49 |
PITPNC1,PREX2,NHSL1,SLC1A2,SFXN5,RFX4,ATP13A4,SLC4A4,CTNND2,ATP1A2,NTRK2,FMN2,SHROOM3,FGFR3 |
3.641e-05 | -10.22 | nasopharyngeal_carcinoma | COSMIC cancer mutations | nasopharyngeal_carcinoma | 1425 | 14 | 16828 | 49 |
SFXN5,RFX4,PREX2,PITPNC1,NHSL1,SLC1A2,NTRK2,ATP1A2,FMN2,SHROOM3,FGFR3,ATP13A4,SLC4A4,CTNND2 |
4.204e-05 | -10.08 | RHOB (ras homolog family member B) | protein interactions | 388 | 832 | 10 | 19454 | 50 |
STON2,DTNA,ABLIM1,CACHD1,MACF1,FMN2,SLC1A3,PARD3B,SHROOM3,TNIK |
4.284e-05 | -10.06 | Proximal tubule bicarbonate reclamation | KEGG pathways | hsa04964 | 23 | 3 | 7161 | 22 |
SLC4A4,ATP1A2,GLUD1 |
4.284e-05 | -10.06 | Proximal tubule bicarbonate reclamation | KEGG pathways | ko04964 | 23 | 3 | 7161 | 22 |
SLC4A4,ATP1A2,GLUD1 |
4.581e-05 | -9.99 | monoatomic ion transmembrane transport | biological process | GO:0034220 | 804 | 10 | 18204 | 49 |
GABRB1,SLC1A3,RYR3,CACHD1,ATP1A2,SFXN5,SLC1A2,ATP13A4,SLC4A4,GPM6A |
4.917e-05 | -9.92 | Astrocytic Glutamate-Glutamine Uptake And Metabolism | REACTOME pathways | R-HSA-210455 | 4 | 2 | 10285 | 30 |
SLC1A2,SLC1A3 |
4.917e-05 | -9.92 | Neurotransmitter uptake and Metabolism In Glial Cells | REACTOME pathways | R-HSA-112313 | 4 | 2 | 10285 | 30 |
SLC1A2,SLC1A3 |
5.135e-05 | -9.88 | right_upper_lobe | COSMIC cancer mutations | right_upper_lobe | 10376 | 43 | 16828 | 49 |
FBXL7,SFXN5,TNIK,MGAT4C,HIF3A,LSAMP,NTRK2,CPE,FGFR3,ABLIM1,STON2,SORBS1,CTNND2,DTNA,GLI3,RORA,RFX4,GABRB1,PREX2,ZNRF3,SLC1A2,SOX5,MACF1,NKAIN3,CACHD1,NTM,SLC4A4,GPC5,PITPNC1,ADCY2,FMN2,GLIS3,SHROOM3,PARD3B,ATP13A4,RYR3,GPM6A,SLC1A3,PAMR1,BMPR1B,ATP1A2,RANBP3L,NPAS3 |
5.135e-05 | -9.88 | lung-right_upper_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-right_upper_lobe-carcinoma-adenocarcinoma | 10376 | 43 | 16828 | 49 |
SFXN5,FBXL7,TNIK,PITPNC1,MGAT4C,ADCY2,HIF3A,LSAMP,FMN2,CPE,NTRK2,GLIS3,FGFR3,SHROOM3,PARD3B,ABLIM1,STON2,ATP13A4,CTNND2,SORBS1,RYR3,RORA,GLI3,DTNA,GPM6A,RFX4,GABRB1,PAMR1,SLC1A3,PREX2,ZNRF3,SLC1A2,BMPR1B,NKAIN3,SOX5,MACF1,CACHD1,ATP1A2,NTM,RANBP3L,SLC4A4,NPAS3,GPC5 |
5.275e-05 | -9.85 | central nervous system development | biological process | GO:0007417 | 995 | 11 | 18204 | 49 |
RORA,GLUD1,GLI3,GABRB1,CTNNA2,BMPR1B,RFX4,NTRK2,ATP1A2,MSI2,SLC1A2 |
5.381e-05 | -9.83 | developmental process | biological process | GO:0032502 | 5716 | 29 | 18204 | 49 |
SPARCL1,FGFR3,SLC1A3,GLI3,GABRB1,SOX5,FMN2,RORA,GLUD1,PREX2,ABLIM1,CTNNA2,BMPR1B,MSI2,ZNRF3,CTNND2,RANBP3L,RFX4,TNIK,NTM,CPE,HIF3A,GPM6A,NTRK2,SLC1A2,ATP1A2,SHROOM3,LSAMP,NHSL1 |
5.476e-05 | -9.81 | pancreas-carcinoid-endocrine_tumour | COSMIC cancer mutations | pancreas-carcinoid-endocrine_tumour | 7250 | 35 | 16828 | 49 |
SLC1A2,PAMR1,PREX2,SLC1A3,RFX4,GABRB1,RORA,GLI3,GPM6A,SLC4A4,GPC5,RANBP3L,NKAIN3,BMPR1B,MACF1,SOX5,CACHD1,ATP1A2,LSAMP,NHSL1,ADCY2,SFXN5,FBXL7,CTNND2,RYR3,STON2,ATP13A4,FGFR3,SHROOM3,GNA14,ABLIM1,FMN2,CPE,NTRK2,GLIS3 |
5.477e-05 | -9.81 | cell projection | cellular component | GO:0042995 | 2398 | 17 | 19108 | 49 |
STON2,MACF1,GABRB1,SLC1A2,BMPR1B,ADCY2,FMN2,GPM6A,AQP4,CTNND2,NTRK2,ABLIM1,ATP1A2,CTNNA2,DTNA,SLC1A3,GLI3 |
5.590e-05 | -9.79 | transporter activity | molecular function | GO:0005215 | 1211 | 12 | 18094 | 48 |
SLC1A2,PITPNC1,SFXN5,ATP13A4,CACHD1,RYR3,GABRB1,GPM6A,SLC4A4,ATP1A2,AQP4,SLC1A3 |
5.672e-05 | -9.78 | Bile secretion | KEGG pathways | hsa04976 | 71 | 4 | 7161 | 22 |
ADCY2,AQP4,ATP1A2,SLC4A4 |
5.672e-05 | -9.78 | Bile secretion | KEGG pathways | ko04976 | 71 | 4 | 7161 | 22 |
SLC4A4,ATP1A2,AQP4,ADCY2 |
6.028e-05 | -9.72 | superficial_spreading | COSMIC cancer mutations | superficial_spreading | 1110 | 12 | 16828 | 49 |
MACF1,FGFR3,NTM,ATP13A4,SLC4A4,SORBS1,CTNND2,GLI3,GABRB1,MGAT4C,PREX2,ADCY2 |
6.287e-05 | -9.67 | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-mantle_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-mantle_cell_lymphoma | 476 | 8 | 16828 | 49 |
SFXN5,GPM6A,GABRB1,ATP13A4,GPC5,CTNND2,RYR3,LSAMP |
6.504e-05 | -9.64 | upper_aerodigestive_tract-mouth-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-mouth-carcinoma-squamous_cell_carcinoma | 6953 | 34 | 16828 | 49 |
ATP1A2,MACF1,SOX5,RANBP3L,NTM,GPC5,SLC4A4,GPM6A,DTNA,GLI3,RORA,RFX4,ZNRF3,PREX2,PAMR1,SLC1A2,FMN2,ABLIM1,SHROOM3,PARD3B,FGFR3,ATP13A4,RYR3,SORBS1,CTNND2,FBXL7,SFXN5,TNIK,HIF3A,ADCY2,PITPNC1,MGAT4C,NHSL1,LSAMP |
6.856e-05 | -9.59 | glutamate:sodium symporter activity | molecular function | GO:0015501 | 5 | 2 | 18094 | 48 |
SLC1A2,SLC1A3 |
6.856e-05 | -9.59 | high-affinity L-glutamate transmembrane transporter activity | molecular function | GO:0005314 | 5 | 2 | 18094 | 48 |
SLC1A3,SLC1A2 |
6.922e-05 | -9.58 | plasma membrane region | cellular component | GO:0098590 | 1278 | 12 | 19108 | 49 |
SORBS1,GPM6A,SLC1A3,AQP4,ATP1A2,PARD3B,SLC1A2,GABRB1,MACF1,TNIK,SHROOM3,SLC4A4 |
7.061e-05 | -9.56 | D-aspartate import across plasma membrane | biological process | GO:0070779 | 5 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
7.061e-05 | -9.56 | D-aspartate transmembrane transport | biological process | GO:0070777 | 5 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
7.070e-05 | -9.56 | neurotransmitter uptake | biological process | GO:0001504 | 30 | 3 | 18204 | 49 |
SLC1A2,ATP1A2,SLC1A3 |
7.817e-05 | -9.46 | cell morphogenesis | biological process | GO:0000902 | 687 | 9 | 18204 | 49 |
TNIK,SLC1A3,PREX2,GPM6A,CTNNA2,BMPR1B,GLI3,CTNND2,SHROOM3 |
7.937e-05 | -9.44 | prostate | COSMIC cancer mutations | prostate | 13883 | 49 | 16828 | 49 |
RANBP3L,BMPR1B,ATP1A2,NPAS3,GPM6A,SLC1A3,PAMR1,SHROOM3,PARD3B,GNA14,FMN2,GLIS3,RYR3,ATP13A4,PITPNC1,AQP4,ADCY2,NTM,SOX5,MACF1,NKAIN3,CACHD1,SLC4A4,GPC5,RFX4,GABRB1,GLI3,DTNA,RORA,SLC1A2,PREX2,ZNRF3,SPARCL1,FGFR3,ABLIM1,NTRK2,CPE,SORBS1,CTNND2,STON2,MSI2,TNIK,FBXL7,GLUD1,SFXN5,LSAMP,MGAT4C,NHSL1,HIF3A |
7.991e-05 | -9.43 | chondrocyte differentiation | biological process | GO:0002062 | 85 | 4 | 18204 | 49 |
FGFR3,GLI3,SOX5,BMPR1B |
8.255e-05 | -9.40 | NTM (neurotrimin) | protein interactions | 50863 | 33 | 3 | 19454 | 50 |
GPM6A,LSAMP,NTM |
8.305e-05 | -9.40 | cell junction | cellular component | GO:0030054 | 2224 | 16 | 19108 | 49 |
GABRB1,SLC1A2,STON2,GPM6A,SORBS1,FGFR3,ATP1A2,PARD3B,CTNNA2,NTRK2,CTNND2,SPARCL1,SHROOM3,TNIK,DTNA,SLC1A3 |
8.349e-05 | -9.39 | multicellular organismal process | biological process | GO:0032501 | 6177 | 30 | 18204 | 49 |
ATP1A2,RYR3,SLC1A2,SLC4A4,NTRK2,HIF3A,GPM6A,SHROOM3,LSAMP,DTNA,NTM,TNIK,RFX4,AQP4,CPE,ZNRF3,MSI2,CTNNA2,BMPR1B,PREX2,ABLIM1,RANBP3L,CTNND2,SLC1A3,FGFR3,GLUD1,RORA,GLI3,GABRB1,SOX5 |
8.364e-05 | -9.39 | transport across blood-brain barrier | biological process | GO:0150104 | 86 | 4 | 18204 | 49 |
ATP1A2,SLC1A3,SLC1A2,SLC4A4 |
8.364e-05 | -9.39 | vascular transport | biological process | GO:0010232 | 86 | 4 | 18204 | 49 |
SLC1A2,SLC1A3,ATP1A2,SLC4A4 |
8.604e-05 | -9.36 | positive regulation of cartilage development | biological process | GO:0061036 | 32 | 3 | 18204 | 49 |
BMPR1B,SOX5,GLI3 |
8.970e-05 | -9.32 | Transmembrane transport of small molecules | REACTOME pathways | R-HSA-382551 | 677 | 9 | 10285 | 30 |
GABRB1,SLC1A2,SLC4A4,ATP1A2,RYR3,ADCY2,ATP13A4,AQP4,SLC1A3 |
8.991e-05 | -9.32 | carcinoid-endocrine_tumour | COSMIC cancer mutations | carcinoid-endocrine_tumour | 7752 | 36 | 16828 | 49 |
RFX4,GABRB1,RORA,GLI3,GPM6A,SLC1A2,PAMR1,PREX2,SLC1A3,RANBP3L,NKAIN3,BMPR1B,SOX5,MACF1,CACHD1,ATP1A2,SLC4A4,GPC5,TNIK,SFXN5,FBXL7,LSAMP,NHSL1,ADCY2,FGFR3,SHROOM3,GNA14,ABLIM1,FMN2,CPE,GLIS3,NTRK2,CTNND2,RYR3,STON2,ATP13A4 |
9.290e-05 | -9.28 | inorganic molecular entity transmembrane transporter activity | molecular function | GO:0015318 | 714 | 9 | 18094 | 48 |
SLC4A4,AQP4,ATP1A2,SLC1A3,CACHD1,RYR3,GPM6A,GABRB1,SLC1A2 |
9.314e-05 | -9.28 | autonomic_ganglia-neuroblastoma | COSMIC cancer mutations | autonomic_ganglia-neuroblastoma | 3970 | 24 | 16828 | 49 |
PARD3B,FGFR3,NTRK2,GLIS3,FMN2,RYR3,CTNND2,TNIK,FBXL7,HIF3A,ADCY2,PITPNC1,AQP4,ATP1A2,CACHD1,MACF1,NPAS3,SLC4A4,RFX4,GPM6A,GLI3,SLC1A2,ZNRF3,PREX2 |
9.354e-05 | -9.28 | neuroblastoma | COSMIC cancer mutations | neuroblastoma | 3971 | 24 | 16828 | 49 |
ATP1A2,CACHD1,MACF1,SLC4A4,NPAS3,RFX4,GPM6A,GLI3,SLC1A2,ZNRF3,PREX2,PARD3B,FGFR3,NTRK2,GLIS3,FMN2,RYR3,CTNND2,TNIK,FBXL7,HIF3A,ADCY2,PITPNC1,AQP4 |
9.404e-05 | -9.27 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-follicular_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-follicular_lymphoma | 981 | 11 | 16828 | 49 |
CTNND2,LSAMP,STON2,ADCY2,GPC5,GABRB1,GNA14,NKAIN3,RORA,SOX5,CACHD1 |
9.782e-05 | -9.23 | blood_vessel | COSMIC cancer mutations | blood_vessel | 2211 | 17 | 16828 | 49 |
GPC5,RYR3,CTNND2,NTRK2,SOX5,NKAIN3,FMN2,FGFR3,ADCY2,SLC1A3,PREX2,LSAMP,SLC1A2,FBXL7,GPM6A,GLI3,GABRB1 |
1.012e-04 | -9.20 | oesophagus-carcinoma | COSMIC cancer mutations | oesophagus-carcinoma | 4269 | 25 | 16828 | 49 |
ATP13A4,RYR3,SORBS1,CTNND2,NTRK2,FMN2,SHROOM3,PARD3B,FGFR3,HIF3A,ADCY2,NHSL1,FBXL7,TNIK,SLC4A4,CACHD1,SOX5,MACF1,RANBP3L,NTM,PREX2,GPM6A,GLI3,GABRB1,RFX4 |
1.023e-04 | -9.19 | neuron projection | cellular component | GO:0043005 | 1331 | 12 | 19108 | 49 |
GPM6A,ADCY2,BMPR1B,SLC1A2,GABRB1,STON2,DTNA,SLC1A3,ATP1A2,CTNNA2,CTNND2,NTRK2 |
1.023e-04 | -9.19 | bone | COSMIC cancer mutations | bone | 8157 | 37 | 16828 | 49 |
ABLIM1,GNA14,PARD3B,SHROOM3,FGFR3,GLIS3,NTRK2,CPE,FMN2,RYR3,SORBS1,CTNND2,ATP13A4,STON2,TNIK,SFXN5,LSAMP,HIF3A,ADCY2,RANBP3L,ATP1A2,CACHD1,SOX5,MACF1,NKAIN3,GPC5,NPAS3,SLC4A4,GABRB1,GPM6A,DTNA,GLI3,RORA,SPARCL1,SLC1A3,PREX2,PAMR1 |
1.057e-04 | -9.15 | D-amino acid transport | biological process | GO:0042940 | 6 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
1.057e-04 | -9.15 | L-aspartate import across plasma membrane | biological process | GO:0140009 | 6 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
1.064e-04 | -9.15 | GLI-like | interpro domains | IPR043359 | 6 | 2 | 18521 | 50 |
GLI3,GLIS3 |
1.078e-04 | -9.13 | central nervous system neuron differentiation | biological process | GO:0021953 | 176 | 5 | 18204 | 49 |
RORA,GABRB1,GLI3,NTRK2,BMPR1B |
1.173e-04 | -9.05 | adherens junction | cellular component | GO:0005912 | 188 | 5 | 19108 | 49 |
CTNNA2,PARD3B,SORBS1,CTNND2,SHROOM3 |
1.217e-04 | -9.01 | transmembrane transporter activity | molecular function | GO:0022857 | 1110 | 11 | 18094 | 48 |
SLC4A4,ATP1A2,AQP4,SLC1A3,CACHD1,RYR3,GPM6A,GABRB1,SFXN5,ATP13A4,SLC1A2 |
1.342e-04 | -8.92 | mouth | COSMIC cancer mutations | mouth | 9004 | 39 | 16828 | 49 |
NHSL1,MGAT4C,PITPNC1,ADCY2,HIF3A,LSAMP,SFXN5,FBXL7,TNIK,STON2,ATP13A4,CTNND2,SORBS1,RYR3,FMN2,NTRK2,FGFR3,PARD3B,SHROOM3,ABLIM1,PAMR1,SLC1A3,PREX2,ZNRF3,SLC1A2,RORA,DTNA,GLI3,GPM6A,RFX4,GABRB1,NPAS3,SLC4A4,GPC5,SOX5,MACF1,ATP1A2,NTM,RANBP3L |
1.487e-04 | -8.81 | Na-dicarboxylate_symporter_CS | interpro domains | IPR018107 | 7 | 2 | 18521 | 50 |
SLC1A2,SLC1A3 |
1.487e-04 | -8.81 | Na:dicarbo_symporter_sf | interpro domains | IPR036458 | 7 | 2 | 18521 | 50 |
SLC1A3,SLC1A2 |
1.487e-04 | -8.81 | Na-dicarboxylate_symporter | interpro domains | IPR001991 | 7 | 2 | 18521 | 50 |
SLC1A2,SLC1A3 |
1.489e-04 | -8.81 | anatomical structure morphogenesis | biological process | GO:0009653 | 2225 | 16 | 18204 | 49 |
TNIK,FGFR3,SLC1A3,GLI3,SOX5,RORA,CPE,HIF3A,PREX2,GPM6A,ABLIM1,CTNNA2,BMPR1B,NTRK2,CTNND2,SHROOM3 |
1.490e-04 | -8.81 | FLOT1 (flotillin 1) | protein interactions | 10211 | 453 | 7 | 19454 | 50 |
SORBS1,FMN2,ABLIM1,GLUD1,DTNA,MACF1,SOX5 |
1.534e-04 | -8.78 | metal ion transmembrane transporter activity | molecular function | GO:0046873 | 442 | 7 | 18094 | 48 |
GPM6A,SLC1A2,CACHD1,RYR3,SLC1A3,SLC4A4,ATP1A2 |
1.546e-04 | -8.77 | SDF | pfam domains | PF00375 | 7 | 2 | 17795 | 49 |
SLC1A2,SLC1A3 |
1.565e-04 | -8.76 | cellular response to alkaloid | biological process | GO:0071312 | 39 | 3 | 18204 | 49 |
SLC1A3,RYR3,SLC1A2 |
1.711e-04 | -8.67 | cellular response to endogenous stimulus | biological process | GO:0071495 | 1135 | 11 | 18204 | 49 |
GABRB1,SOX5,GNA14,NTRK2,BMPR1B,FGFR3,SLC1A2,ATP1A2,RYR3,SORBS1,SLC1A3 |
1.841e-04 | -8.60 | beta-catenin binding | molecular function | GO:0008013 | 107 | 4 | 18094 | 48 |
GLI3,CTNNA2,RORA,CTNND2 |
1.874e-04 | -8.58 | bone-tibia-other-chondroblastoma | COSMIC cancer mutations | bone-tibia-other-chondroblastoma | 98 | 4 | 16828 | 49 |
LSAMP,CTNND2,GPM6A,NKAIN3 |
1.879e-04 | -8.58 | Sodium:dicarboxylate symporter | gene3d domains | 1.10.3860.10 | 7 | 2 | 14470 | 44 |
SLC1A2,SLC1A3 |
2.060e-04 | -8.49 | monoatomic ion transport | biological process | GO:0006811 | 964 | 10 | 18204 | 49 |
ATP13A4,SLC4A4,GPM6A,SLC1A3,RYR3,CACHD1,ATP1A2,SFXN5,SLC1A2,GABRB1 |
2.276e-04 | -8.39 | monoatomic cation transmembrane transporter activity | molecular function | GO:0008324 | 630 | 8 | 18094 | 48 |
ATP13A4,SLC1A2,SLC1A3,SLC4A4,ATP1A2,GPM6A,CACHD1,RYR3 |
2.300e-04 | -8.38 | cervix-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | cervix-carcinoma-squamous_cell_carcinoma | 11789 | 45 | 16828 | 49 |
GLUD1,FBXL7,SFXN5,TNIK,HIF3A,MGAT4C,NHSL1,LSAMP,NTRK2,CPE,ABLIM1,FGFR3,STON2,SORBS1,CTNND2,DTNA,GLI3,RORA,GABRB1,RFX4,SPARCL1,ZNRF3,PREX2,SLC1A2,CACHD1,MACF1,SOX5,NTM,GPC5,SLC4A4,ADCY2,PITPNC1,GLIS3,FMN2,SHROOM3,PARD3B,ATP13A4,RYR3,GPM6A,SLC1A3,PAMR1,ATP1A2,BMPR1B,RANBP3L,NPAS3 |
2.304e-04 | -8.38 | NEGR1 (neuronal growth regulator 1) | protein interactions | 257194 | 9 | 2 | 19454 | 50 |
LSAMP,NTM |
2.304e-04 | -8.38 | LSAMP (limbic system associated membrane protein) | protein interactions | 4045 | 9 | 2 | 19454 | 50 |
LSAMP,NTM |
2.328e-04 | -8.37 | cervix | COSMIC cancer mutations | cervix | 11793 | 45 | 16828 | 49 |
NTRK2,CPE,ABLIM1,FGFR3,STON2,SORBS1,CTNND2,GLUD1,FBXL7,SFXN5,TNIK,HIF3A,MGAT4C,NHSL1,LSAMP,CACHD1,SOX5,MACF1,NTM,GPC5,SLC4A4,GLI3,DTNA,RORA,GABRB1,RFX4,ZNRF3,SPARCL1,PREX2,SLC1A2,GLIS3,FMN2,SHROOM3,PARD3B,ATP13A4,RYR3,ADCY2,PITPNC1,ATP1A2,BMPR1B,RANBP3L,NPAS3,GPM6A,SLC1A3,PAMR1 |
2.396e-04 | -8.34 | PAS domain | gene3d domains | 3.30.450.20 | 40 | 3 | 14470 | 44 |
HIF3A,CACHD1,NPAS3 |
2.402e-04 | -8.33 | acidic amino acid transport | biological process | GO:0015800 | 45 | 3 | 18204 | 49 |
NTRK2,SLC1A3,SLC1A2 |
2.531e-04 | -8.28 | skin-trunk-malignant_melanoma-nodular | COSMIC cancer mutations | skin-trunk-malignant_melanoma-nodular | 1291 | 12 | 16828 | 49 |
ABLIM1,MACF1,CPE,ATP1A2,GLIS3,NTRK2,CTNND2,ATP13A4,NPAS3,PREX2,SPARCL1,HIF3A |
2.564e-04 | -8.27 | OCLN (occludin) | protein interactions | 100506658 | 495 | 7 | 19454 | 50 |
MACF1,TNIK,CACHD1,ABLIM1,DTNA,NTRK2,FMN2 |
2.645e-04 | -8.24 | NA_DICARBOXYL_SYMP_1 | prosite domains | PS00713 | 7 | 2 | 12186 | 44 |
SLC1A2,SLC1A3 |
2.645e-04 | -8.24 | NA_DICARBOXYL_SYMP_2 | prosite domains | PS00714 | 7 | 2 | 12186 | 44 |
SLC1A3,SLC1A2 |
2.665e-04 | -8.23 | uveal_tract | COSMIC cancer mutations | uveal_tract | 587 | 8 | 16828 | 49 |
ADCY2,PREX2,CTNND2,CPE,MACF1,RANBP3L,SHROOM3,FGFR3 |
2.810e-04 | -8.18 | membrane protein complex | cellular component | GO:0098796 | 1261 | 11 | 19108 | 49 |
CTNNA2,SLC1A2,ATP1A2,GABRB1,STON2,CACHD1,GNA14,SORBS1,RYR3,BMPR1B,SLC1A3 |
2.855e-04 | -8.16 | upper_aerodigestive_tract-larynx-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-larynx-carcinoma-squamous_cell_carcinoma | 1946 | 15 | 16828 | 49 |
MGAT4C,ZNRF3,GLI3,RORA,GPM6A,TNIK,NPAS3,SLC4A4,RYR3,MACF1,SOX5,BMPR1B,FMN2,PARD3B,FGFR3 |
2.887e-04 | -8.15 | larynx | COSMIC cancer mutations | larynx | 1948 | 15 | 16828 | 49 |
FGFR3,PARD3B,BMPR1B,FMN2,MACF1,SOX5,RYR3,NPAS3,SLC4A4,TNIK,RORA,GLI3,GPM6A,MGAT4C,ZNRF3 |
3.013e-04 | -8.11 | neuron projection morphogenesis | biological process | GO:0048812 | 486 | 7 | 18204 | 49 |
GLI3,CTNND2,TNIK,GPM6A,PREX2,BMPR1B,CTNNA2 |
3.021e-04 | -8.10 | haematopoietic_and_lymphoid_tissue-small_intestine-lymphoid_neoplasm-enteropathy_type_T_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-small_intestine-lymphoid_neoplasm-enteropathy_type_T_cell_lymphoma | 45 | 3 | 16828 | 49 |
ZNRF3,MGAT4C,MACF1 |
3.021e-04 | -8.10 | enteropathy_type_T_cell_lymphoma | COSMIC cancer mutations | enteropathy_type_T_cell_lymphoma | 45 | 3 | 16828 | 49 |
MGAT4C,MACF1,ZNRF3 |
3.129e-04 | -8.07 | soft_tissue-blood_vessel-angiosarcoma | COSMIC cancer mutations | soft_tissue-blood_vessel-angiosarcoma | 2192 | 16 | 16828 | 49 |
RYR3,CTNND2,GPC5,NTRK2,NKAIN3,FMN2,SOX5,SLC1A2,LSAMP,ADCY2,SLC1A3,PREX2,GABRB1,GPM6A,FBXL7,GLI3 |
3.129e-04 | -8.07 | angiosarcoma | COSMIC cancer mutations | angiosarcoma | 2192 | 16 | 16828 | 49 |
GABRB1,GLI3,GPM6A,FBXL7,SLC1A2,LSAMP,SLC1A3,PREX2,ADCY2,FMN2,NKAIN3,SOX5,NTRK2,CTNND2,RYR3,GPC5 |
3.150e-04 | -8.06 | cellular response to cocaine | biological process | GO:0071314 | 10 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
3.150e-04 | -8.06 | action potential propagation | biological process | GO:0098870 | 10 | 2 | 18204 | 49 |
ATP1A2,NTRK2 |
3.150e-04 | -8.06 | neuronal action potential propagation | biological process | GO:0019227 | 10 | 2 | 18204 | 49 |
NTRK2,ATP1A2 |
3.190e-04 | -8.05 | EDTRNSPORT | prints domains | PR00173 | 7 | 2 | 5227 | 21 |
SLC1A3,SLC1A2 |
3.205e-04 | -8.05 | plasma membrane bounded cell projection morphogenesis | biological process | GO:0120039 | 491 | 7 | 18204 | 49 |
CTNND2,GLI3,TNIK,BMPR1B,CTNNA2,GPM6A,PREX2 |
3.234e-04 | -8.04 | upper_aerodigestive_tract-mouth-carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-mouth-carcinoma | 6426 | 31 | 16828 | 49 |
RFX4,GABRB1,GLI3,RORA,GPM6A,SLC1A2,PREX2,SLC1A3,PAMR1,NTM,SOX5,MACF1,NPAS3,SLC4A4,GPC5,FBXL7,SFXN5,MGAT4C,PITPNC1,NHSL1,HIF3A,ADCY2,PARD3B,SHROOM3,FGFR3,ABLIM1,FMN2,SORBS1,CTNND2,RYR3,STON2 |
3.288e-04 | -8.02 | cerebellum | COSMIC cancer mutations | cerebellum | 769 | 9 | 16828 | 49 |
NPAS3,GPC5,CTNND2,RYR3,CPE,NTRK2,PARD3B,GABRB1,ABLIM1 |
3.303e-04 | -8.02 | eye | COSMIC cancer mutations | eye | 606 | 8 | 16828 | 49 |
CTNND2,ADCY2,PREX2,FGFR3,RANBP3L,SHROOM3,CPE,MACF1 |
3.346e-04 | -8.00 | central_nervous_system-brainstem-glioma-oligoastrocytoma_Grade_III | COSMIC cancer mutations | central_nervous_system-brainstem-glioma-oligoastrocytoma_Grade_III | 114 | 4 | 16828 | 49 |
SOX5,PREX2,RYR3,SLC1A2 |
3.407e-04 | -7.98 | cell projection morphogenesis | biological process | GO:0048858 | 496 | 7 | 18204 | 49 |
GLI3,CTNND2,TNIK,BMPR1B,CTNNA2,GPM6A,PREX2 |
3.844e-04 | -7.86 | L-glutamate import across plasma membrane | biological process | GO:0098712 | 11 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
3.844e-04 | -7.86 | L-aspartate transmembrane transport | biological process | GO:0070778 | 11 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
3.906e-04 | -7.85 | regulation of chondrocyte differentiation | biological process | GO:0032330 | 53 | 3 | 18204 | 49 |
BMPR1B,SOX5,GLI3 |
4.282e-04 | -7.76 | haematopoietic_and_lymphoid_tissue | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue | 14368 | 49 | 16828 | 49 |
GPC5,SLC4A4,CACHD1,NKAIN3,MACF1,SOX5,NTM,ZNRF3,SPARCL1,PREX2,SLC1A2,RORA,GLI3,DTNA,GABRB1,RFX4,STON2,CTNND2,SORBS1,CPE,NTRK2,ABLIM1,FGFR3,HIF3A,NHSL1,MGAT4C,LSAMP,SFXN5,FBXL7,GLUD1,TNIK,MSI2,NPAS3,ATP1A2,BMPR1B,RANBP3L,PAMR1,SLC1A3,GPM6A,ATP13A4,RYR3,GLIS3,FMN2,GNA14,SHROOM3,PARD3B,ADCY2,AQP4,PITPNC1 |
4.301e-04 | -7.75 | LYN (LYN proto-oncogene, Src family tyrosine kinase) | protein interactions | 4067 | 713 | 8 | 19454 | 50 |
TNIK,MSI2,FMN2,SLC1A3,ABLIM1,DTNA,MACF1,CACHD1 |
4.342e-04 | -7.74 | transmembrane transport | biological process | GO:0055085 | 1264 | 11 | 18204 | 49 |
RYR3,ATP1A2,CACHD1,SLC1A2,ATP13A4,SLC4A4,GPM6A,AQP4,GABRB1,SLC1A3,SFXN5 |
4.347e-04 | -7.74 | amino acid transport | biological process | GO:0006865 | 132 | 4 | 18204 | 49 |
NTRK2,SFXN5,SLC1A2,SLC1A3 |
4.404e-04 | -7.73 | Ig_I-set | interpro domains | IPR013098 | 132 | 4 | 18521 | 50 |
FGFR3,NTRK2,NTM,LSAMP |
4.724e-04 | -7.66 | diffuse_adenocarcinoma | COSMIC cancer mutations | diffuse_adenocarcinoma | 4383 | 24 | 16828 | 49 |
MGAT4C,NHSL1,HIF3A,ADCY2,CTNND2,RYR3,SHROOM3,FGFR3,ABLIM1,FMN2,GLIS3,SLC1A3,PREX2,ZNRF3,RFX4,GABRB1,DTNA,GLI3,GPM6A,RANBP3L,MACF1,SOX5,ATP1A2,CACHD1 |
4.724e-04 | -7.66 | stomach-carcinoma-diffuse_adenocarcinoma | COSMIC cancer mutations | stomach-carcinoma-diffuse_adenocarcinoma | 4383 | 24 | 16828 | 49 |
RANBP3L,SOX5,MACF1,CACHD1,ATP1A2,PREX2,SLC1A3,ZNRF3,RFX4,GABRB1,GLI3,DTNA,GPM6A,CTNND2,RYR3,FGFR3,SHROOM3,ABLIM1,FMN2,GLIS3,NHSL1,MGAT4C,ADCY2,HIF3A |
4.733e-04 | -7.66 | I-set | pfam domains | PF07679 | 132 | 4 | 17795 | 49 |
LSAMP,NTRK2,NTM,FGFR3 |
4.778e-04 | -7.65 | sarcolemma | cellular component | GO:0042383 | 142 | 4 | 19108 | 49 |
AQP4,ATP1A2,RYR3,DTNA |
5.433e-04 | -7.52 | central_nervous_system-cerebellum-primitive_neuroectodermal_tumour-medulloblastoma-SHH_subtype | COSMIC cancer mutations | central_nervous_system-cerebellum-primitive_neuroectodermal_tumour-medulloblastoma-SHH_subtype | 653 | 8 | 16828 | 49 |
RYR3,CTNND2,NPAS3,GABRB1,ABLIM1,PARD3B,NTRK2,CPE |
5.442e-04 | -7.52 | NAKATPASE | prints domains | PR00121 | 9 | 2 | 5227 | 21 |
ATP13A4,ATP1A2 |
5.488e-04 | -7.51 | SHH_subtype | COSMIC cancer mutations | SHH_subtype | 654 | 8 | 16828 | 49 |
NPAS3,CTNND2,RYR3,CPE,NTRK2,PARD3B,ABLIM1,GABRB1 |
5.726e-04 | -7.47 | monoatomic anion transmembrane transport | biological process | GO:0098656 | 142 | 4 | 18204 | 49 |
SLC1A3,SLC1A2,GABRB1,SLC4A4 |
6.089e-04 | -7.40 | lung-carcinoma-small_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-small_cell_carcinoma | 9908 | 40 | 16828 | 49 |
HIF3A,PITPNC1,MGAT4C,MSI2,TNIK,GLUD1,FBXL7,RYR3,SORBS1,CTNND2,ATP13A4,STON2,ABLIM1,GNA14,PARD3B,FGFR3,NTRK2,CPE,FMN2,SPARCL1,ZNRF3,PREX2,PAMR1,GABRB1,RFX4,GPM6A,GLI3,DTNA,RORA,GPC5,NPAS3,SLC4A4,RANBP3L,NTM,ATP1A2,CACHD1,MACF1,SOX5,BMPR1B,NKAIN3 |
6.145e-04 | -7.39 | L-glutamate transmembrane transporter activity | molecular function | GO:0005313 | 14 | 2 | 18094 | 48 |
SLC1A3,SLC1A2 |
6.176e-04 | -7.39 | small_cell_carcinoma | COSMIC cancer mutations | small_cell_carcinoma | 9913 | 40 | 16828 | 49 |
GLI3,DTNA,RORA,GPM6A,RFX4,GABRB1,PREX2,PAMR1,SPARCL1,ZNRF3,SOX5,MACF1,NKAIN3,BMPR1B,ATP1A2,CACHD1,RANBP3L,NTM,SLC4A4,NPAS3,GPC5,GLUD1,FBXL7,MSI2,TNIK,MGAT4C,PITPNC1,HIF3A,FMN2,NTRK2,CPE,PARD3B,FGFR3,GNA14,ABLIM1,ATP13A4,STON2,SORBS1,CTNND2,RYR3 |
6.327e-04 | -7.37 | sodium ion export across plasma membrane | biological process | GO:0036376 | 14 | 2 | 18204 | 49 |
ATP1A2,SLC4A4 |
6.401e-04 | -7.35 | brain development | biological process | GO:0007420 | 724 | 8 | 18204 | 49 |
GLI3,GLUD1,RORA,NTRK2,RFX4,CTNNA2,SLC1A2,ATP1A2 |
6.803e-04 | -7.29 | dendrite morphogenesis | biological process | GO:0048813 | 64 | 3 | 18204 | 49 |
CTNND2,PREX2,CTNNA2 |
7.592e-04 | -7.18 | CNTNAP2 (contactin associated protein 2) | protein interactions | 26047 | 16 | 2 | 19454 | 50 |
MACF1,CPE |
7.640e-04 | -7.18 | central_nervous_system-brain-glioma-oligodendroglioma_Grade_III | COSMIC cancer mutations | central_nervous_system-brain-glioma-oligodendroglioma_Grade_III | 249 | 5 | 16828 | 49 |
SHROOM3,FGFR3,GLIS3,MACF1,MGAT4C |
7.721e-04 | -7.17 | active monoatomic ion transmembrane transporter activity | molecular function | GO:0022853 | 274 | 5 | 18094 | 48 |
SLC1A2,SLC1A3,ATP13A4,SLC4A4,ATP1A2 |
7.779e-04 | -7.16 | small_intestine | COSMIC cancer mutations | small_intestine | 250 | 5 | 16828 | 49 |
FGFR3,TNIK,ZNRF3,MACF1,MGAT4C |
7.941e-04 | -7.14 | plasma membrane protein complex | cellular component | GO:0098797 | 600 | 7 | 19108 | 49 |
ATP1A2,CTNNA2,STON2,CACHD1,SORBS1,GNA14,BMPR1B |
8.077e-04 | -7.12 | sodium ion transmembrane transporter activity | molecular function | GO:0015081 | 158 | 4 | 18094 | 48 |
SLC4A4,ATP1A2,SLC1A3,SLC1A2 |
8.309e-04 | -7.09 | PARD3 (par-3 family cell polarity regulator) | protein interactions | 56288 | 287 | 5 | 19454 | 50 |
SHROOM3,DTNA,SORBS1,PARD3B,NTRK2 |
8.421e-04 | -7.08 | membrane | cellular component | GO:0016020 | 9220 | 35 | 19108 | 49 |
RYR3,SORBS1,GPM6A,CACHD1,ZNRF3,FMN2,FGFR3,BMPR1B,GABRB1,HIF3A,GPC5,SFXN5,STON2,GNA14,NTM,ATP13A4,CTNNA2,NTRK2,CTNND2,NKAIN3,TNIK,PREX2,CPE,MGAT4C,ADCY2,MACF1,SLC1A2,SLC4A4,LSAMP,SLC1A3,DTNA,ATP1A2,PARD3B,AQP4,SHROOM3 |
8.516e-04 | -7.07 | spindle | COSMIC cancer mutations | spindle | 386 | 6 | 16828 | 49 |
SHROOM3,CTNND2,FGFR3,PREX2,MACF1,CPE |
8.541e-04 | -7.07 | telencephalon development | biological process | GO:0021537 | 276 | 5 | 18204 | 49 |
SLC1A2,GLI3,ATP1A2,NTRK2,RFX4 |
8.632e-04 | -7.05 | inorganic cation transmembrane transporter activity | molecular function | GO:0022890 | 589 | 7 | 18094 | 48 |
SLC1A3,SLC4A4,ATP1A2,SLC1A2,GPM6A,CACHD1,RYR3 |
8.745e-04 | -7.04 | monoatomic anion transport | biological process | GO:0006820 | 159 | 4 | 18204 | 49 |
SLC4A4,GABRB1,SLC1A2,SLC1A3 |
9.554e-04 | -6.95 | Wnt signaling pathway | biological process | GO:0016055 | 283 | 5 | 18204 | 49 |
ZNRF3,CTNND2,TNIK,CPE,MACF1 |
9.621e-04 | -6.95 | dendrite | cellular component | GO:0030425 | 620 | 7 | 19108 | 49 |
NTRK2,CTNND2,GABRB1,ATP1A2,GPM6A,BMPR1B,ADCY2 |
9.623e-04 | -6.95 | actin binding | molecular function | GO:0003779 | 434 | 6 | 18094 | 48 |
MACF1,ABLIM1,SORBS1,FMN2,SHROOM3,CTNNA2 |
9.763e-04 | -6.93 | oligoastrocytoma_Grade_III | COSMIC cancer mutations | oligoastrocytoma_Grade_III | 263 | 5 | 16828 | 49 |
FGFR3,RYR3,SLC1A2,PREX2,SOX5 |
9.803e-04 | -6.93 | dendritic tree | cellular component | GO:0097447 | 622 | 7 | 19108 | 49 |
GABRB1,ATP1A2,CTNND2,NTRK2,GPM6A,ADCY2,BMPR1B |
9.890e-04 | -6.92 | head development | biological process | GO:0060322 | 774 | 8 | 18204 | 49 |
RFX4,NTRK2,CTNNA2,ATP1A2,SLC1A2,GLUD1,RORA,GLI3 |
9.985e-04 | -6.91 | regulation of cartilage development | biological process | GO:0061035 | 73 | 3 | 18204 | 49 |
BMPR1B,SOX5,GLI3 |
1.022e-03 | -6.89 | Htt (huntingtin) | protein interactions | 15194 | 77 | 3 | 19454 | 50 |
GPM6A,LSAMP,NTM |
1.026e-03 | -6.88 | acidic amino acid transmembrane transporter activity | molecular function | GO:0015172 | 18 | 2 | 18094 | 48 |
SLC1A2,SLC1A3 |
1.028e-03 | -6.88 | soft_tissue | COSMIC cancer mutations | soft_tissue | 5828 | 28 | 16828 | 49 |
FBXL7,NHSL1,AQP4,ADCY2,LSAMP,FMN2,NTRK2,GLIS3,FGFR3,PARD3B,CTNND2,SORBS1,RYR3,RORA,GLI3,GPM6A,GABRB1,PAMR1,PREX2,SLC1A3,ZNRF3,SPARCL1,SLC1A2,NKAIN3,SOX5,MACF1,NPAS3,GPC5 |
1.034e-03 | -6.87 | response to endogenous stimulus | biological process | GO:0009719 | 1402 | 11 | 18204 | 49 |
NTRK2,BMPR1B,RYR3,SORBS1,ATP1A2,SLC1A2,SLC1A3,FGFR3,GNA14,SOX5,GABRB1 |
1.043e-03 | -6.87 | synapse | cellular component | GO:0045202 | 1473 | 11 | 19108 | 49 |
NTRK2,CTNND2,ATP1A2,SLC1A2,GABRB1,TNIK,STON2,SPARCL1,GPM6A,SLC1A3,DTNA |
1.063e-03 | -6.85 | ATPase_P-typ_cation-transptr_N | interpro domains | IPR004014 | 18 | 2 | 18521 | 50 |
ATP1A2,ATP13A4 |
1.066e-03 | -6.84 | lung-left_upper_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-left_upper_lobe-carcinoma-adenocarcinoma | 556 | 7 | 16828 | 49 |
FBXL7,NTRK2,CACHD1,SLC4A4,ADCY2,CTNND2,RYR3 |
1.071e-03 | -6.84 | astrocyte projection | cellular component | GO:0097449 | 19 | 2 | 19108 | 49 |
AQP4,SLC1A2 |
1.089e-03 | -6.82 | left_upper_lobe | COSMIC cancer mutations | left_upper_lobe | 558 | 7 | 16828 | 49 |
RYR3,CTNND2,ADCY2,CACHD1,FBXL7,NTRK2,SLC4A4 |
1.105e-03 | -6.81 | Cation_ATPase_N | pfam domains | PF00690 | 18 | 2 | 17795 | 49 |
ATP13A4,ATP1A2 |
1.158e-03 | -6.76 | cell morphogenesis involved in neuron differentiation | biological process | GO:0048667 | 443 | 6 | 18204 | 49 |
SLC1A3,CTNND2,GLI3,CTNNA2,BMPR1B,PREX2 |
1.165e-03 | -6.76 | lung-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-squamous_cell_carcinoma | 14664 | 49 | 16828 | 49 |
ATP13A4,RYR3,GLIS3,FMN2,GNA14,PARD3B,SHROOM3,ADCY2,AQP4,PITPNC1,NPAS3,ATP1A2,BMPR1B,RANBP3L,PAMR1,SLC1A3,GPM6A,STON2,CTNND2,SORBS1,CPE,NTRK2,ABLIM1,FGFR3,HIF3A,NHSL1,MGAT4C,LSAMP,SFXN5,GLUD1,FBXL7,TNIK,MSI2,GPC5,SLC4A4,CACHD1,NKAIN3,MACF1,SOX5,NTM,ZNRF3,SPARCL1,PREX2,SLC1A2,RORA,DTNA,GLI3,GABRB1,RFX4 |
1.179e-03 | -6.74 | cartilage condensation | biological process | GO:0001502 | 19 | 2 | 18204 | 49 |
SOX5,BMPR1B |
1.186e-03 | -6.74 | PAS_fold | interpro domains | IPR013767 | 19 | 2 | 18521 | 50 |
NPAS3,HIF3A |
1.196e-03 | -6.73 | cartilage development | biological process | GO:0051216 | 173 | 4 | 18204 | 49 |
BMPR1B,FGFR3,GLI3,SOX5 |
1.210e-03 | -6.72 | dicarboxylic acid transport | biological process | GO:0006835 | 78 | 3 | 18204 | 49 |
SLC1A3,SLC1A2,NTRK2 |
1.222e-03 | -6.71 | skin-head_neck-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-head_neck-malignant_melanoma-superficial_spreading | 923 | 9 | 16828 | 49 |
ADCY2,PREX2,ATP13A4,MGAT4C,CTNND2,SORBS1,GLI3,MACF1,GABRB1 |
1.233e-03 | -6.70 | PAS | pfam domains | PF00989 | 19 | 2 | 17795 | 49 |
HIF3A,NPAS3 |
1.246e-03 | -6.69 | somatodendritic compartment | cellular component | GO:0036477 | 842 | 8 | 19108 | 49 |
BMPR1B,ADCY2,SLC1A3,GPM6A,CTNND2,NTRK2,ATP1A2,GABRB1 |
1.247e-03 | -6.69 | solute:sodium symporter activity | molecular function | GO:0015370 | 80 | 3 | 18094 | 48 |
SLC4A4,SLC1A3,SLC1A2 |
1.253e-03 | -6.68 | Endochondral Ossification | WikiPathways | WP474 | 65 | 3 | 5310 | 18 |
FGFR3,SOX5,GLI3 |
1.293e-03 | -6.65 | transmembrane receptor protein kinase activity | molecular function | GO:0019199 | 81 | 3 | 18094 | 48 |
NTRK2,FGFR3,BMPR1B |
1.307e-03 | -6.64 | aspartate transmembrane transport | biological process | GO:0015810 | 20 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
1.317e-03 | -6.63 | prostate-carcinoma-adenocarcinoma | COSMIC cancer mutations | prostate-carcinoma-adenocarcinoma | 12379 | 45 | 16828 | 49 |
STON2,CTNND2,SORBS1,CPE,NTRK2,ABLIM1,FGFR3,HIF3A,NHSL1,MGAT4C,LSAMP,SFXN5,GLUD1,FBXL7,TNIK,GPC5,CACHD1,NKAIN3,SOX5,MACF1,NTM,SPARCL1,PREX2,SLC1A2,RORA,GLI3,GABRB1,RFX4,ATP13A4,RYR3,GLIS3,FMN2,GNA14,SHROOM3,PARD3B,ADCY2,AQP4,PITPNC1,NPAS3,ATP1A2,BMPR1B,RANBP3L,PAMR1,SLC1A3,GPM6A |
1.318e-03 | -6.63 | TENM1 (teneurin transmembrane protein 1) | protein interactions | 10178 | 21 | 2 | 19454 | 50 |
MACF1,SORBS1 |
1.332e-03 | -6.62 | skin-mucosal-malignant_melanoma | COSMIC cancer mutations | skin-mucosal-malignant_melanoma | 2009 | 14 | 16828 | 49 |
CPE,ATP1A2,FMN2,BMPR1B,ABLIM1,FGFR3,ATP13A4,CTNND2,SORBS1,RORA,GABRB1,SPARCL1,PREX2,MGAT4C |
1.332e-03 | -6.62 | mucosal | COSMIC cancer mutations | mucosal | 2009 | 14 | 16828 | 49 |
SPARCL1,PREX2,MGAT4C,RORA,GABRB1,ATP13A4,SORBS1,CTNND2,ATP1A2,CPE,FMN2,BMPR1B,ABLIM1,FGFR3 |
1.383e-03 | -6.58 | trunk | COSMIC cancer mutations | trunk | 3554 | 20 | 16828 | 49 |
RYR3,CTNND2,NPAS3,ATP13A4,STON2,ABLIM1,FGFR3,ATP1A2,GLIS3,NTRK2,CACHD1,CPE,SOX5,MACF1,LSAMP,HIF3A,SPARCL1,PREX2,SLC1A3,MGAT4C |
1.443e-03 | -6.54 | cell aggregation | biological process | GO:0098743 | 21 | 2 | 18204 | 49 |
SOX5,BMPR1B |
1.465e-03 | -6.53 | Cation_ATPase_N | smart domains | SM00831 | 16 | 2 | 9717 | 35 |
ATP1A2,ATP13A4 |
1.474e-03 | -6.52 | monoatomic cation transmembrane transport | biological process | GO:0098655 | 636 | 7 | 18204 | 49 |
GPM6A,SLC4A4,ATP13A4,ATP1A2,CACHD1,SLC1A3,RYR3 |
1.489e-03 | -6.51 | localization | biological process | GO:0051179 | 4474 | 22 | 18204 | 49 |
TNIK,SFXN5,CPE,AQP4,GPM6A,SLC4A4,PITPNC1,ATP13A4,NTRK2,SLC1A2,CACHD1,ATP1A2,RYR3,MACF1,SHROOM3,STON2,PARD3B,SLC1A3,GLI3,GABRB1,FMN2,RANBP3L |
1.548e-03 | -6.47 | SFN (stratifin) | protein interactions | 2810 | 671 | 7 | 19454 | 50 |
FMN2,PARD3B,SHROOM3,ABLIM1,TNIK,SORBS1,MACF1 |
1.563e-03 | -6.46 | haematopoietic_neoplasm | COSMIC cancer mutations | haematopoietic_neoplasm | 11082 | 42 | 16828 | 49 |
SFXN5,FBXL7,TNIK,MSI2,NHSL1,ADCY2,HIF3A,LSAMP,FMN2,CPE,NTRK2,GLIS3,FGFR3,SHROOM3,PARD3B,GNA14,ABLIM1,STON2,ATP13A4,CTNND2,RYR3,RORA,GLI3,DTNA,RFX4,GABRB1,PAMR1,SLC1A3,PREX2,SPARCL1,SLC1A2,BMPR1B,NKAIN3,SOX5,MACF1,CACHD1,ATP1A2,NTM,RANBP3L,NPAS3,SLC4A4,GPC5 |
1.584e-03 | -6.45 | intracellular sodium ion homeostasis | biological process | GO:0006883 | 22 | 2 | 18204 | 49 |
SLC1A3,ATP1A2 |
1.594e-03 | -6.44 | DEP_dom | interpro domains | IPR000591 | 22 | 2 | 18521 | 50 |
PREX2,FMN2 |
1.595e-03 | -6.44 | establishment of localization | biological process | GO:0051234 | 3887 | 20 | 18204 | 49 |
STON2,RANBP3L,MACF1,ATP1A2,CACHD1,RYR3,SLC1A2,SLC4A4,PITPNC1,ATP13A4,NTRK2,GPM6A,FMN2,AQP4,GLI3,GABRB1,CPE,SLC1A3,SFXN5,PARD3B |
1.604e-03 | -6.44 | CTDSPL (CTD small phosphatase like) | protein interactions | 10217 | 90 | 3 | 19454 | 50 |
DTNA,CACHD1,FMN2 |
1.683e-03 | -6.39 | amino acid:sodium symporter activity | molecular function | GO:0005283 | 23 | 2 | 18094 | 48 |
SLC1A2,SLC1A3 |
1.707e-03 | -6.37 | response to organic cyclic compound | biological process | GO:0014070 | 843 | 8 | 18204 | 49 |
GABRB1,GNA14,RORA,SLC1A2,ADCY2,ATP1A2,SLC1A3,RYR3 |
1.715e-03 | -6.37 | human chr5p13.2 | chromosome location | human chr5p13.2 | 32 | 2 | 26134 | 50 |
RANBP3L,SLC1A3 |
1.728e-03 | -6.36 | transport | biological process | GO:0006810 | 3615 | 19 | 18204 | 49 |
RANBP3L,STON2,MACF1,RYR3,CACHD1,ATP1A2,SLC1A2,ATP13A4,NTRK2,SLC4A4,PITPNC1,GPM6A,AQP4,FMN2,GABRB1,GLI3,CPE,SLC1A3,SFXN5 |
1.740e-03 | -6.35 | middle_lobe | COSMIC cancer mutations | middle_lobe | 1382 | 11 | 16828 | 49 |
CACHD1,CPE,ATP1A2,MACF1,FGFR3,PARD3B,SHROOM3,STON2,ATP13A4,RYR3,CTNND2 |
1.757e-03 | -6.34 | TIAM1 (TIAM Rac1 associated GEF 1) | protein interactions | 7074 | 201 | 4 | 19454 | 50 |
ATP1A2,DTNA,GLUD1,RYR3 |
1.758e-03 | -6.34 | cell development | biological process | GO:0048468 | 2236 | 14 | 18204 | 49 |
MSI2,PREX2,GPM6A,CTNNA2,NTRK2,BMPR1B,CTNND2,TNIK,SLC1A3,NTM,GABRB1,GLI3,FMN2,RORA |
1.826e-03 | -6.31 | oligodendroglioma_Grade_III | COSMIC cancer mutations | oligodendroglioma_Grade_III | 303 | 5 | 16828 | 49 |
SHROOM3,FGFR3,GLIS3,MGAT4C,MACF1 |
1.828e-03 | -6.30 | Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways | WikiPathways | WP706 | 162 | 4 | 5310 | 18 |
NTRK2,SLC1A3,RORA,AQP4 |
1.832e-03 | -6.30 | P-type ion transporter activity | molecular function | GO:0015662 | 24 | 2 | 18094 | 48 |
ATP1A2,ATP13A4 |
1.832e-03 | -6.30 | P-type transmembrane transporter activity | molecular function | GO:0140358 | 24 | 2 | 18094 | 48 |
ATP1A2,ATP13A4 |
1.856e-03 | -6.29 | bone development | biological process | GO:0060348 | 195 | 4 | 18204 | 49 |
RANBP3L,FGFR3,GLI3,BMPR1B |
1.909e-03 | -6.26 | breast-carcinoma-ductolobular_carcinoma | COSMIC cancer mutations | breast-carcinoma-ductolobular_carcinoma | 1619 | 12 | 16828 | 49 |
ABLIM1,FGFR3,PARD3B,CPE,RORA,FMN2,MACF1,DTNA,GLI3,CTNND2,SORBS1,PREX2 |
1.909e-03 | -6.26 | ductolobular_carcinoma | COSMIC cancer mutations | ductolobular_carcinoma | 1619 | 12 | 16828 | 49 |
PREX2,GLI3,DTNA,RORA,SORBS1,CTNND2,ABLIM1,PARD3B,FGFR3,CPE,MACF1,FMN2 |
1.911e-03 | -6.26 | cell-cell junction | cellular component | GO:0005911 | 513 | 6 | 19108 | 49 |
SORBS1,SHROOM3,CTNND2,ATP1A2,PARD3B,CTNNA2 |
1.913e-03 | -6.26 | human chr15q13.3-q14 | chromosome location | human chr15q13.3-q14 | 1 | 1 | 26134 | 50 |
RYR3 |
1.913e-03 | -6.26 | human chr12q21.31-q21.32 | chromosome location | human chr12q21.31-q21.32 | 1 | 1 | 26134 | 50 |
MGAT4C |
1.913e-03 | -6.26 | human chr3q26.2-q26.31 | chromosome location | human chr3q26.2-q26.31 | 1 | 1 | 26134 | 50 |
TNIK |
1.920e-03 | -6.26 | urinary_tract-bladder-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-bladder-carcinoma-transitional_cell_carcinoma | 6040 | 28 | 16828 | 49 |
MACF1,ATP1A2,CACHD1,SLC4A4,GPC5,GLI3,DTNA,GPM6A,RFX4,GABRB1,PREX2,SLC1A3,SPARCL1,FMN2,NTRK2,GLIS3,PARD3B,SHROOM3,FGFR3,ABLIM1,GNA14,ATP13A4,STON2,SORBS1,SFXN5,MGAT4C,HIF3A,ADCY2 |
1.931e-03 | -6.25 | transitional_cell_carcinoma | COSMIC cancer mutations | transitional_cell_carcinoma | 6042 | 28 | 16828 | 49 |
SLC1A3,PREX2,SPARCL1,RFX4,GABRB1,GLI3,DTNA,GPM6A,SLC4A4,GPC5,MACF1,CACHD1,ATP1A2,MGAT4C,ADCY2,HIF3A,SFXN5,SORBS1,STON2,ATP13A4,FGFR3,SHROOM3,PARD3B,GNA14,ABLIM1,FMN2,NTRK2,GLIS3 |
2.021e-03 | -6.20 | skin-face-malignant_melanoma-lentigo_maligna | COSMIC cancer mutations | skin-face-malignant_melanoma-lentigo_maligna | 23 | 2 | 16828 | 49 |
PREX2,FGFR3 |
2.023e-03 | -6.20 | NRCAM (neuronal cell adhesion molecule) | protein interactions | 4897 | 26 | 2 | 19454 | 50 |
MACF1,GLUD1 |
2.045e-03 | -6.19 | actin cytoskeleton | cellular component | GO:0015629 | 520 | 6 | 19108 | 49 |
SORBS1,CTNNA2,ABLIM1,MACF1,SHROOM3,FMN2 |
2.047e-03 | -6.19 | FRS2 (fibroblast growth factor receptor substrate 2) | protein interactions | 10818 | 98 | 3 | 19454 | 50 |
FGFR3,NTRK2,SORBS1 |
2.047e-03 | -6.19 | L-glutamate transmembrane transport | biological process | GO:0015813 | 25 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
2.118e-03 | -6.16 | regulation of Wnt signaling pathway | biological process | GO:0030111 | 339 | 5 | 18204 | 49 |
CTNND2,GLI3,GPC5,ZNRF3,MACF1 |
2.139e-03 | -6.15 | scalp | COSMIC cancer mutations | scalp | 2110 | 14 | 16828 | 49 |
GPC5,SLC4A4,ATP13A4,SORBS1,ATP1A2,MACF1,SOX5,FMN2,SHROOM3,FGFR3,NTM,PREX2,LSAMP,RORA |
2.152e-03 | -6.14 | extrinsic component of plasma membrane | cellular component | GO:0019897 | 100 | 3 | 19108 | 49 |
CTNNA2,GNA14,DTNA |
2.181e-03 | -6.13 | HPCAL4 (hippocalcin like 4) | protein interactions | 51440 | 27 | 2 | 19454 | 50 |
GPM6A,AQP4 |
2.181e-03 | -6.13 | KCNJ12 (potassium inwardly rectifying channel subfamily J member 12) | protein interactions | 3768 | 27 | 2 | 19454 | 50 |
DTNA,ABLIM1 |
2.181e-03 | -6.13 | Glutamate Neurotransmitter Release Cycle | REACTOME pathways | R-HSA-210500 | 24 | 2 | 10285 | 30 |
SLC1A2,SLC1A3 |
2.214e-03 | -6.11 | C4-dicarboxylate transport | biological process | GO:0015740 | 26 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
2.250e-03 | -6.10 | cellular response to organonitrogen compound | biological process | GO:0071417 | 505 | 6 | 18204 | 49 |
GABRB1,GNA14,SORBS1,SLC1A3,RYR3,SLC1A2 |
2.341e-03 | -6.06 | actin filament binding | molecular function | GO:0051015 | 211 | 4 | 18094 | 48 |
ABLIM1,MACF1,CTNNA2,SHROOM3 |
2.362e-03 | -6.05 | skin-head_neck-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-head_neck-carcinoma-squamous_cell_carcinoma | 14191 | 48 | 16828 | 49 |
GPM6A,SLC1A3,PAMR1,ATP1A2,BMPR1B,RANBP3L,NPAS3,ADCY2,PITPNC1,AQP4,GLIS3,FMN2,GNA14,PARD3B,SHROOM3,ATP13A4,RYR3,GLI3,DTNA,RORA,GABRB1,RFX4,ZNRF3,SPARCL1,PREX2,SLC1A2,CACHD1,SOX5,MACF1,NKAIN3,NTM,GPC5,SLC4A4,GLUD1,FBXL7,SFXN5,TNIK,HIF3A,MGAT4C,NHSL1,LSAMP,NTRK2,CPE,ABLIM1,FGFR3,STON2,SORBS1,CTNND2 |
2.398e-03 | -6.03 | bone morphogenesis | biological process | GO:0060349 | 99 | 3 | 18204 | 49 |
GLI3,FGFR3,BMPR1B |
2.401e-03 | -6.03 | neuron projection development | biological process | GO:0031175 | 693 | 7 | 18204 | 49 |
GLI3,TNIK,CTNND2,CTNNA2,BMPR1B,PREX2,GPM6A |
2.424e-03 | -6.02 | HUNK (hormonally up-regulated Neu-associated kinase) | protein interactions | 30811 | 104 | 3 | 19454 | 50 |
SORBS1,ABLIM1,SPARCL1 |
2.467e-03 | -6.00 | response to alkaloid | biological process | GO:0043279 | 100 | 3 | 18204 | 49 |
SLC1A3,RYR3,SLC1A2 |
2.487e-03 | -6.00 | Salivary secretion | KEGG pathways | hsa04970 | 90 | 3 | 7161 | 22 |
ADCY2,RYR3,ATP1A2 |
2.487e-03 | -6.00 | Salivary secretion | KEGG pathways | ko04970 | 90 | 3 | 7161 | 22 |
ADCY2,RYR3,ATP1A2 |
2.535e-03 | -5.98 | signaling | biological process | GO:0023052 | 4968 | 23 | 18204 | 49 |
BMPR1B,PREX2,ZNRF3,SORBS1,CTNND2,SPARCL1,SLC1A3,FGFR3,RORA,FMN2,GABRB1,GLI3,NTRK2,PITPNC1,RYR3,ATP1A2,SLC1A2,MACF1,DTNA,ADCY2,TNIK,CPE,GNA14 |
2.570e-03 | -5.96 | Lztr1 (leucine-zipper-like transcriptional regulator, 1) | protein interactions | 66863 | 1 | 1 | 19454 | 50 |
BMPR1B |
2.570e-03 | -5.96 | Dynlt1 (dynein light chain Tctex-type 1) | protein interactions | 83462 | 1 | 1 | 19454 | 50 |
NTRK2 |
2.570e-03 | -5.96 | Bdnf (brain derived neurotrophic factor) | protein interactions | 12064 | 1 | 1 | 19454 | 50 |
NTRK2 |
2.570e-03 | -5.96 | fgf3.L (fibroblast growth factor 3 L homeolog) | protein interactions | 373669 | 1 | 1 | 19454 | 50 |
FGFR3 |
2.570e-03 | -5.96 | Dcaf7 (DDB1 and CUL4 associated factor 7) | protein interactions | 71833 | 1 | 1 | 19454 | 50 |
BMPR1B |
2.570e-03 | -5.96 | Hipk3 (homeodomain interacting protein kinase 3) | protein interactions | 15259 | 1 | 1 | 19454 | 50 |
GLIS3 |
2.570e-03 | -5.96 | Agtrap (angiotensin II, type I receptor-associated protein) | protein interactions | 11610 | 1 | 1 | 19454 | 50 |
PITPNC1 |
2.570e-03 | -5.96 | 1700006A11Rik (RIKEN cDNA 1700006A11 gene) | protein interactions | 71824 | 1 | 1 | 19454 | 50 |
BMPR1B |
2.570e-03 | -5.96 | Sh2b1 (SH2B adaptor protein 1) | protein interactions | 20399 | 1 | 1 | 19454 | 50 |
FGFR3 |
2.570e-03 | -5.96 | Isl1 (ISL1 transcription factor, LIM/homeodomain) | protein interactions | 16392 | 1 | 1 | 19454 | 50 |
GLIS3 |
2.593e-03 | -5.95 | Calcium-transporting ATPase, transmembrane domain | gene3d domains | 1.20.1110.10 | 25 | 2 | 14470 | 44 |
ATP13A4,ATP1A2 |
2.626e-03 | -5.94 | embryonal | COSMIC cancer mutations | embryonal | 2659 | 16 | 16828 | 49 |
RORA,GLI3,ZNRF3,ADCY2,SPARCL1,AQP4,PREX2,FGFR3,PARD3B,GLIS3,FMN2,MACF1,RYR3,CTNND2,SORBS1,NPAS3 |
2.626e-03 | -5.94 | soft_tissue-striated_muscle-rhabdomyosarcoma-embryonal | COSMIC cancer mutations | soft_tissue-striated_muscle-rhabdomyosarcoma-embryonal | 2659 | 16 | 16828 | 49 |
RORA,GLI3,ZNRF3,SPARCL1,ADCY2,AQP4,PREX2,FGFR3,PARD3B,GLIS3,FMN2,MACF1,RYR3,CTNND2,SORBS1,NPAS3 |
2.653e-03 | -5.93 | brain-derived neurotrophic factor receptor activity | molecular function | GO:0060175 | 1 | 1 | 18094 | 48 |
NTRK2 |
2.673e-03 | -5.92 | amino acid:monoatomic cation symporter activity | molecular function | GO:0005416 | 29 | 2 | 18094 | 48 |
SLC1A3,SLC1A2 |
2.692e-03 | -5.92 | lateral ganglionic eminence cell proliferation | biological process | GO:0022018 | 1 | 1 | 18204 | 49 |
GLI3 |
2.692e-03 | -5.92 | subpallium cell proliferation in forebrain | biological process | GO:0022012 | 1 | 1 | 18204 | 49 |
GLI3 |
2.692e-03 | -5.92 | trans-synaptic signaling by neuropeptide | biological process | GO:0099540 | 1 | 1 | 18204 | 49 |
NTRK2 |
2.692e-03 | -5.92 | homologous chromosome movement towards spindle pole in meiosis I anaphase | biological process | GO:0051758 | 1 | 1 | 18204 | 49 |
FMN2 |
2.692e-03 | -5.92 | lambdoid suture morphogenesis | biological process | GO:0060366 | 1 | 1 | 18204 | 49 |
GLI3 |
2.692e-03 | -5.92 | anterior semicircular canal development | biological process | GO:0060873 | 1 | 1 | 18204 | 49 |
GLI3 |
2.692e-03 | -5.92 | olfactory cortex development | biological process | GO:0021989 | 1 | 1 | 18204 | 49 |
ATP1A2 |
2.692e-03 | -5.92 | sagittal suture morphogenesis | biological process | GO:0060367 | 1 | 1 | 18204 | 49 |
GLI3 |
2.692e-03 | -5.92 | negative regulation of calcium:sodium antiporter activity | biological process | GO:1903280 | 1 | 1 | 18204 | 49 |
ATP1A2 |
2.692e-03 | -5.92 | trans-synaptic signaling by neuropeptide, modulating synaptic transmission | biological process | GO:0099551 | 1 | 1 | 18204 | 49 |
NTRK2 |
2.692e-03 | -5.92 | lateral semicircular canal development | biological process | GO:0060875 | 1 | 1 | 18204 | 49 |
GLI3 |
2.700e-03 | -5.91 | Stonin2_N | interpro domains | IPR022699 | 1 | 1 | 18521 | 50 |
STON2 |
2.700e-03 | -5.91 | Sensor-like_sf | interpro domains | IPR029151 | 1 | 1 | 18521 | 50 |
CACHD1 |
2.700e-03 | -5.91 | M14_CPE_CPD | interpro domains | IPR034232 | 1 | 1 | 18521 | 50 |
CPE |
2.700e-03 | -5.91 | SORBS1_SH3_1 | interpro domains | IPR035610 | 1 | 1 | 18521 | 50 |
SORBS1 |
2.700e-03 | -5.91 | SORBS1_SH3 | interpro domains | IPR035606 | 1 | 1 | 18521 | 50 |
SORBS1 |
2.700e-03 | -5.91 | SPARC-like_p1 | interpro domains | IPR016359 | 1 | 1 | 18521 | 50 |
SPARCL1 |
2.700e-03 | -5.91 | ZNRF3_Znf_RING | interpro domains | IPR045903 | 1 | 1 | 18521 | 50 |
ZNRF3 |
2.700e-03 | -5.91 | SORBS1_SH3_2 | interpro domains | IPR035611 | 1 | 1 | 18521 | 50 |
SORBS1 |
2.700e-03 | -5.91 | NTRK2 | interpro domains | IPR020455 | 1 | 1 | 18521 | 50 |
NTRK2 |
2.700e-03 | -5.91 | Rex2_DEP_1 | interpro domains | IPR037367 | 1 | 1 | 18521 | 50 |
PREX2 |
2.700e-03 | -5.91 | STON2_MHD | interpro domains | IPR031228 | 1 | 1 | 18521 | 50 |
STON2 |
2.709e-03 | -5.91 | large_intestine-caecum-carcinoma-adenocarcinoma | COSMIC cancer mutations | large_intestine-caecum-carcinoma-adenocarcinoma | 14236 | 48 | 16828 | 49 |
TNIK,SFXN5,FBXL7,GLUD1,LSAMP,NHSL1,MGAT4C,HIF3A,FGFR3,ABLIM1,CPE,NTRK2,CTNND2,SORBS1,STON2,RFX4,GABRB1,RORA,GLI3,DTNA,SLC1A2,PREX2,ZNRF3,SPARCL1,NTM,NKAIN3,SOX5,MACF1,CACHD1,SLC4A4,GPC5,AQP4,PITPNC1,ADCY2,PARD3B,SHROOM3,GNA14,FMN2,GLIS3,RYR3,ATP13A4,GPM6A,PAMR1,SLC1A3,RANBP3L,BMPR1B,ATP1A2,NPAS3 |
2.754e-03 | -5.89 | Stonin2_N | pfam domains | PF12016 | 1 | 1 | 17795 | 49 |
STON2 |
2.754e-03 | -5.89 | FGFR3_TM | pfam domains | PF21165 | 1 | 1 | 17795 | 49 |
FGFR3 |
2.809e-03 | -5.87 | caecum | COSMIC cancer mutations | caecum | 14248 | 48 | 16828 | 49 |
STON2,SORBS1,CTNND2,NTRK2,CPE,FGFR3,ABLIM1,MGAT4C,NHSL1,HIF3A,LSAMP,FBXL7,GLUD1,SFXN5,TNIK,SLC4A4,GPC5,SOX5,MACF1,NKAIN3,CACHD1,NTM,PREX2,ZNRF3,SPARCL1,SLC1A2,GLI3,DTNA,RORA,RFX4,GABRB1,ATP13A4,RYR3,FMN2,GLIS3,SHROOM3,PARD3B,GNA14,PITPNC1,AQP4,ADCY2,NPAS3,BMPR1B,ATP1A2,RANBP3L,SLC1A3,PAMR1,GPM6A |
2.834e-03 | -5.87 | neural precursor cell proliferation | biological process | GO:0061351 | 105 | 3 | 18204 | 49 |
RORA,SOX5,GLI3 |
2.853e-03 | -5.86 | cell communication | biological process | GO:0007154 | 5010 | 23 | 18204 | 49 |
CPE,FMN2,RORA,GABRB1,GLI3,GNA14,SPARCL1,SLC1A3,TNIK,FGFR3,ADCY2,DTNA,MACF1,CTNND2,PITPNC1,BMPR1B,NTRK2,PREX2,ATP1A2,ZNRF3,RYR3,SORBS1,SLC1A2 |
2.857e-03 | -5.86 | cell body | cellular component | GO:0044297 | 556 | 6 | 19108 | 49 |
GPM6A,BMPR1B,SLC1A3,CTNND2,SLC1A2,ATP1A2 |
2.859e-03 | -5.86 | inorganic ion transmembrane transport | biological process | GO:0098660 | 715 | 7 | 18204 | 49 |
ATP1A2,CACHD1,SLC1A3,RYR3,GPM6A,SLC4A4,GABRB1 |
2.870e-03 | -5.85 | SH2B1 (SH2B adaptor protein 1) | protein interactions | 25970 | 31 | 2 | 19454 | 50 |
NTRK2,FGFR3 |
2.901e-03 | -5.84 | Pancreatic secretion | KEGG pathways | hsa04972 | 95 | 3 | 7161 | 22 |
ADCY2,SLC4A4,ATP1A2 |
2.901e-03 | -5.84 | Pancreatic secretion | KEGG pathways | ko04972 | 95 | 3 | 7161 | 22 |
ATP1A2,SLC4A4,ADCY2 |
2.917e-03 | -5.84 | t(4;14) translocations of FGFR3 | REACTOME pathways | R-HSA-2033515 | 1 | 1 | 10285 | 30 |
FGFR3 |
2.942e-03 | -5.83 | L-glutamate import | biological process | GO:0051938 | 30 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
2.993e-03 | -5.81 | YWHAB (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein beta) | protein interactions | 7529 | 965 | 8 | 19454 | 50 |
FGFR3,PARD3B,NHSL1,SORBS1,PITPNC1,SHROOM3,MACF1,ABLIM1 |
3.000e-03 | -5.81 | Ion channel transport | REACTOME pathways | R-HSA-983712 | 209 | 4 | 10285 | 30 |
ATP1A2,RYR3,ATP13A4,GABRB1 |
3.041e-03 | -5.80 | - | gene3d domains | 6.10.250.1740 | 1 | 1 | 14470 | 44 |
FGFR3 |
3.042e-03 | -5.80 | presynaptic active zone membrane | cellular component | GO:0048787 | 32 | 2 | 19108 | 49 |
GABRB1,GPM6A |
3.055e-03 | -5.79 | CDH1 (cadherin 1) | protein interactions | 999 | 757 | 7 | 19454 | 50 |
ABLIM1,MACF1,CTNND2,SHROOM3,SORBS1,CTNNA2,NHSL1 |
3.072e-03 | -5.79 | upper_aerodigestive_tract-pharynx-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-pharynx-carcinoma-squamous_cell_carcinoma | 1485 | 11 | 16828 | 49 |
DTNA,MACF1,FMN2,PARD3B,FGFR3,GABRB1,PREX2,NPAS3,GPC5,SORBS1,RYR3 |
3.132e-03 | -5.77 | acute_lymphoblastic_leukaemia | COSMIC cancer mutations | acute_lymphoblastic_leukaemia | 2197 | 14 | 16828 | 49 |
TNIK,GLI3,DTNA,ADCY2,PREX2,FGFR3,PARD3B,SHROOM3,CACHD1,NTRK2,ATP1A2,BMPR1B,SOX5,SLC4A4 |
3.202e-03 | -5.74 | presynapse | cellular component | GO:0098793 | 569 | 6 | 19108 | 49 |
STON2,TNIK,NTRK2,GPM6A,GABRB1,SLC1A2 |
3.224e-03 | -5.74 | human chr11p13 | chromosome location | human chr11p13 | 44 | 2 | 26134 | 50 |
PAMR1,SLC1A2 |
3.261e-03 | -5.73 | plasma membrane bounded cell projection organization | biological process | GO:0120036 | 1152 | 9 | 18204 | 49 |
CTNND2,GLI3,TNIK,CTNNA2,RFX4,BMPR1B,PREX2,ABLIM1,GPM6A |
3.266e-03 | -5.72 | skeletal system morphogenesis | biological process | GO:0048705 | 228 | 4 | 18204 | 49 |
BMPR1B,SOX5,FGFR3,GLI3 |
3.282e-03 | -5.72 | E1-E2_ATPase | pfam domains | PF00122 | 31 | 2 | 17795 | 49 |
ATP13A4,ATP1A2 |
3.344e-03 | -5.70 | transepithelial transport | biological process | GO:0070633 | 32 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
3.430e-03 | -5.68 | skin-malignant_melanoma-acral_lentiginous | COSMIC cancer mutations | skin-malignant_melanoma-acral_lentiginous | 30 | 2 | 16828 | 49 |
PREX2,FGFR3 |
3.430e-03 | -5.68 | lentigo_maligna | COSMIC cancer mutations | lentigo_maligna | 30 | 2 | 16828 | 49 |
FGFR3,PREX2 |
3.434e-03 | -5.67 | Transmission across Chemical Synapses | REACTOME pathways | R-HSA-112315 | 217 | 4 | 10285 | 30 |
ADCY2,GABRB1,SLC1A3,SLC1A2 |
3.476e-03 | -5.66 | connective tissue development | biological process | GO:0061448 | 232 | 4 | 18204 | 49 |
SOX5,GLI3,FGFR3,BMPR1B |
3.480e-03 | -5.66 | organic substance transport | biological process | GO:0071702 | 1881 | 12 | 18204 | 49 |
SLC1A3,SFXN5,CPE,FMN2,GLI3,PITPNC1,SLC4A4,NTRK2,ATP13A4,SLC1A2,MACF1,RANBP3L |
3.486e-03 | -5.66 | dendrite development | biological process | GO:0016358 | 113 | 3 | 18204 | 49 |
CTNND2,CTNNA2,PREX2 |
3.495e-03 | -5.66 | Cation_ATPase | pfam domains | PF13246 | 32 | 2 | 17795 | 49 |
ATP13A4,ATP1A2 |
3.553e-03 | -5.64 | response to auditory stimulus | biological process | GO:0010996 | 33 | 2 | 18204 | 49 |
SLC1A3,ATP1A2 |
3.590e-03 | -5.63 | PAS | smart domains | SM00091 | 25 | 2 | 9717 | 35 |
HIF3A,NPAS3 |
3.602e-03 | -5.63 | DELLA | smart domains | SM01129 | 1 | 1 | 9717 | 35 |
MACF1 |
3.624e-03 | -5.62 | Transport of inorganic cations/anions and amino acids/oligopeptides | REACTOME pathways | R-HSA-425393 | 107 | 3 | 10285 | 30 |
SLC4A4,SLC1A2,SLC1A3 |
3.624e-03 | -5.62 | upper_leg | COSMIC cancer mutations | upper_leg | 880 | 8 | 16828 | 49 |
PREX2,STON2,PAMR1,HIF3A,SHROOM3,FGFR3,FMN2,GLIS3 |
3.656e-03 | -5.61 | thyroid-carcinoma | COSMIC cancer mutations | thyroid-carcinoma | 4126 | 21 | 16828 | 49 |
GPC5,ATP13A4,STON2,RYR3,CTNND2,GLIS3,ATP1A2,CACHD1,CPE,MACF1,SOX5,SHROOM3,FGFR3,HIF3A,ZNRF3,ADCY2,SPARCL1,AQP4,LSAMP,DTNA,TNIK |
3.688e-03 | -5.60 | solute:monoatomic cation symporter activity | molecular function | GO:0015294 | 117 | 3 | 18094 | 48 |
SLC1A2,SLC4A4,SLC1A3 |
3.688e-03 | -5.60 | calcium channel activity | molecular function | GO:0005262 | 117 | 3 | 18094 | 48 |
GPM6A,CACHD1,RYR3 |
3.792e-03 | -5.57 | PAS | interpro domains | IPR000014 | 34 | 2 | 18521 | 50 |
HIF3A,NPAS3 |
3.792e-03 | -5.57 | PAS-like_dom_sf | interpro domains | IPR035965 | 34 | 2 | 18521 | 50 |
NPAS3,HIF3A |
3.878e-03 | -5.55 | organic acid:sodium symporter activity | molecular function | GO:0005343 | 35 | 2 | 18094 | 48 |
SLC1A2,SLC1A3 |
3.912e-03 | -5.54 | Ig_sub2 | interpro domains | IPR003598 | 239 | 4 | 18521 | 50 |
FGFR3,LSAMP,NTM,NTRK2 |
3.969e-03 | -5.53 | NCK2 (NCK adaptor protein 2) | protein interactions | 8440 | 252 | 4 | 19454 | 50 |
TNIK,SORBS1,NHSL1,NTRK2 |
3.978e-03 | -5.53 | eye-uveal_tract-malignant_melanoma-spindle | COSMIC cancer mutations | eye-uveal_tract-malignant_melanoma-spindle | 363 | 5 | 16828 | 49 |
CTNND2,SHROOM3,PREX2,MACF1,CPE |
4.018e-03 | -5.52 | AQUAPORIN4 | prints domains | PR02016 | 1 | 1 | 5227 | 21 |
AQP4 |
4.018e-03 | -5.52 | NTKRECEPTOR2 | prints domains | PR01941 | 1 | 1 | 5227 | 21 |
NTRK2 |
4.052e-03 | -5.51 | glial cell projection | cellular component | GO:0097386 | 37 | 2 | 19108 | 49 |
AQP4,SLC1A2 |
4.127e-03 | -5.49 | striated muscle contraction | biological process | GO:0006941 | 120 | 3 | 18204 | 49 |
RYR3,ATP1A2,DTNA |
4.183e-03 | -5.48 | monoatomic cation transport | biological process | GO:0006812 | 766 | 7 | 18204 | 49 |
RYR3,SLC1A3,ATP1A2,CACHD1,GPM6A,ATP13A4,SLC4A4 |
4.217e-03 | -5.47 | organic anion transport | biological process | GO:0015711 | 398 | 5 | 18204 | 49 |
SLC1A2,SFXN5,SLC1A3,SLC4A4,NTRK2 |
4.244e-03 | -5.46 | ATPase_P-typ_P_site | interpro domains | IPR018303 | 36 | 2 | 18521 | 50 |
ATP13A4,ATP1A2 |
4.244e-03 | -5.46 | P_typ_ATPase | interpro domains | IPR001757 | 36 | 2 | 18521 | 50 |
ATP1A2,ATP13A4 |
4.244e-03 | -5.46 | ATPase_P-typ_cyto_dom_N | interpro domains | IPR023299 | 36 | 2 | 18521 | 50 |
ATP1A2,ATP13A4 |
4.244e-03 | -5.46 | ATPase_P-typ_transduc_dom_A_sf | interpro domains | IPR008250 | 36 | 2 | 18521 | 50 |
ATP1A2,ATP13A4 |
4.244e-03 | -5.46 | P_typ_ATPase_HD_dom | interpro domains | IPR044492 | 36 | 2 | 18521 | 50 |
ATP13A4,ATP1A2 |
4.258e-03 | -5.46 | EPB41L4A (erythrocyte membrane protein band 4.1 like 4A) | protein interactions | 64097 | 127 | 3 | 19454 | 50 |
MACF1,ABLIM1,DTNA |
4.275e-03 | -5.45 | cell projection organization | biological process | GO:0030030 | 1200 | 9 | 18204 | 49 |
CTNND2,GLI3,TNIK,BMPR1B,RFX4,CTNNA2,ABLIM1,GPM6A,PREX2 |
4.335e-03 | -5.44 | kidney-other-neoplasm | COSMIC cancer mutations | kidney-other-neoplasm | 10653 | 40 | 16828 | 49 |
RFX4,GABRB1,RORA,GLI3,DTNA,GPM6A,SLC1A2,PAMR1,PREX2,SLC1A3,SPARCL1,RANBP3L,NKAIN3,MACF1,SOX5,CACHD1,ATP1A2,NPAS3,GPC5,TNIK,SFXN5,FBXL7,GLUD1,LSAMP,AQP4,NHSL1,MGAT4C,ADCY2,FGFR3,SHROOM3,ABLIM1,GNA14,FMN2,CPE,NTRK2,CTNND2,SORBS1,RYR3,STON2,ATP13A4 |
4.451e-03 | -5.41 | positive regulation of glucose import | biological process | GO:0046326 | 37 | 2 | 18204 | 49 |
SORBS1,SLC1A2 |
4.454e-03 | -5.41 | cellular response to nitrogen compound | biological process | GO:1901699 | 580 | 6 | 18204 | 49 |
SLC1A2,SLC1A3,SORBS1,RYR3,GNA14,GABRB1 |
4.470e-03 | -5.41 | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-large_cell | COSMIC cancer mutations | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-large_cell | 1117 | 9 | 16828 | 49 |
SOX5,FMN2,GNA14,GABRB1,ATP13A4,GPC5,ADCY2,SLC1A2,RYR3 |
4.478e-03 | -5.41 | ATPase_P-typ_TM_dom_sf | interpro domains | IPR023298 | 37 | 2 | 18521 | 50 |
ATP1A2,ATP13A4 |
4.491e-03 | -5.41 | intracellular chemical homeostasis | biological process | GO:0055082 | 581 | 6 | 18204 | 49 |
SLC4A4,ATP13A4,ATP1A2,SLC1A3,AQP4,RYR3 |
4.494e-03 | -5.41 | DIRAS3 (DIRAS family GTPase 3) | protein interactions | 9077 | 261 | 4 | 19454 | 50 |
DTNA,CACHD1,MACF1,FMN2 |
4.496e-03 | -5.40 | skin-face-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-face-carcinoma-squamous_cell_carcinoma | 2036 | 13 | 16828 | 49 |
FGFR3,ABLIM1,FMN2,MACF1,GPC5,MSI2,GABRB1,RORA,GPM6A,LSAMP,AQP4,PREX2,ZNRF3 |
4.523e-03 | -5.40 | action potential | biological process | GO:0001508 | 124 | 3 | 18204 | 49 |
GNA14,ATP1A2,NTRK2 |
4.543e-03 | -5.39 | animal organ morphogenesis | biological process | GO:0009887 | 988 | 8 | 18204 | 49 |
SOX5,GLI3,CPE,FGFR3,ABLIM1,NTRK2,BMPR1B,CTNNA2 |
4.604e-03 | -5.38 | PDZ | pfam domains | PF00595 | 122 | 3 | 17795 | 49 |
PARD3B,SHROOM3,PREX2 |
4.616e-03 | -5.38 | papillary_renal_cell_carcinoma | COSMIC cancer mutations | papillary_renal_cell_carcinoma | 6364 | 28 | 16828 | 49 |
BMPR1B,SOX5,MACF1,CACHD1,ATP1A2,NTM,SLC4A4,GPC5,RORA,GLI3,RFX4,GABRB1,PAMR1,PREX2,ZNRF3,FMN2,CPE,NTRK2,FGFR3,SHROOM3,ABLIM1,STON2,ATP13A4,CTNND2,RYR3,TNIK,PITPNC1,ADCY2 |
4.616e-03 | -5.38 | kidney-carcinoma-papillary_renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-papillary_renal_cell_carcinoma | 6364 | 28 | 16828 | 49 |
PITPNC1,ADCY2,TNIK,STON2,ATP13A4,CTNND2,RYR3,FMN2,CPE,NTRK2,FGFR3,SHROOM3,ABLIM1,PAMR1,PREX2,ZNRF3,RORA,GLI3,RFX4,GABRB1,SLC4A4,GPC5,BMPR1B,MACF1,SOX5,CACHD1,ATP1A2,NTM |
4.682e-03 | -5.36 | forebrain development | biological process | GO:0030900 | 408 | 5 | 18204 | 49 |
SLC1A2,GLI3,ATP1A2,RFX4,NTRK2 |
4.691e-03 | -5.36 | amino acid import across plasma membrane | biological process | GO:0089718 | 38 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
4.852e-03 | -5.33 | cellular process | biological process | GO:0009987 | 14996 | 47 | 18204 | 49 |
SLC1A3,FGFR3,SPARCL1,PARD3B,FMN2,RORA,GLUD1,GABRB1,GLI3,SOX5,ZNRF3,MSI2,ABLIM1,NTM,RFX4,MGAT4C,GNA14,ATP1A2,CACHD1,SLC1A2,GLIS3,NTRK2,ATP13A4,HIF3A,GPM6A,DTNA,FBXL7,SORBS1,CTNNA2,BMPR1B,PREX2,RANBP3L,GPC5,CTNND2,TNIK,SFXN5,ADCY2,AQP4,CPE,RYR3,PITPNC1,SLC4A4,STON2,NHSL1,SHROOM3,LSAMP,MACF1 |
4.853e-03 | -5.33 | Glutamatergic synapse | KEGG pathways | hsa04724 | 114 | 3 | 7161 | 22 |
SLC1A2,ADCY2,SLC1A3 |
4.853e-03 | -5.33 | Glutamatergic synapse | KEGG pathways | ko04724 | 114 | 3 | 7161 | 22 |
SLC1A3,ADCY2,SLC1A2 |
4.918e-03 | -5.31 | cell differentiation | biological process | GO:0030154 | 3645 | 18 | 18204 | 49 |
RANBP3L,NHSL1,CTNND2,MSI2,CTNNA2,NTRK2,BMPR1B,PREX2,GPM6A,FMN2,RORA,GABRB1,GLI3,SOX5,NTM,SLC1A3,FGFR3,TNIK |
4.936e-03 | -5.31 | sodium ion homeostasis | biological process | GO:0055078 | 39 | 2 | 18204 | 49 |
ATP1A2,SLC1A3 |
4.945e-03 | -5.31 | NUFIP1 (nuclear FMR1 interacting protein 1) | protein interactions | 26747 | 134 | 3 | 19454 | 50 |
CPE,NTM,GPM6A |
4.963e-03 | -5.31 | cellular developmental process | biological process | GO:0048869 | 3648 | 18 | 18204 | 49 |
RORA,FMN2,SOX5,GABRB1,GLI3,SLC1A3,NTM,FGFR3,TNIK,NHSL1,RANBP3L,CTNND2,MSI2,NTRK2,BMPR1B,CTNNA2,GPM6A,PREX2 |
4.975e-03 | -5.30 | ovary-carcinoma-serous_carcinoma | COSMIC cancer mutations | ovary-carcinoma-serous_carcinoma | 10710 | 40 | 16828 | 49 |
RYR3,SORBS1,CTNND2,ATP13A4,GNA14,SHROOM3,PARD3B,FGFR3,GLIS3,NTRK2,CPE,FMN2,LSAMP,ADCY2,MGAT4C,NHSL1,MSI2,TNIK,GLUD1,FBXL7,SFXN5,GPC5,NPAS3,SLC4A4,RANBP3L,NTM,ATP1A2,CACHD1,MACF1,SOX5,BMPR1B,SLC1A2,ZNRF3,PREX2,SLC1A3,PAMR1,GABRB1,GLI3,DTNA,RORA |
5.049e-03 | -5.29 | NTRK2 (neurotrophic receptor tyrosine kinase 2) | protein interactions | 4915 | 135 | 3 | 19454 | 50 |
ABLIM1,DTNA,NTRK2 |
5.090e-03 | -5.28 | cation binding | molecular function | GO:0043169 | 4341 | 20 | 18094 | 48 |
ZNRF3,ATP13A4,CPE,PAMR1,GLUD1,BMPR1B,SLC1A3,DTNA,ADCY2,ATP1A2,MACF1,SLC1A2,GLI3,RORA,SPARCL1,GNA14,MGAT4C,GLIS3,RYR3,ABLIM1 |
5.127e-03 | -5.27 | EF-hand-dom_pair | interpro domains | IPR011992 | 258 | 4 | 18521 | 50 |
MACF1,SPARCL1,DTNA,RYR3 |
5.134e-03 | -5.27 | Bmpr2 (bone morphogenetic protein receptor type 2) | protein interactions | 12168 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Mknk2 (MAP kinase-interacting serine/threonine kinase 2) | protein interactions | 17347 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Klhl1 (kelch-like 1) | protein interactions | 93688 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Ppp3cc (protein phosphatase 3, catalytic subunit, gamma isoform) | protein interactions | 19057 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Bcr (BCR activator of RhoGEF and GTPase) | protein interactions | 110279 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Sh3kbp1 (SH3-domain kinase binding protein 1) | protein interactions | 58194 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Fkbp1a (FK506 binding protein 1a) | protein interactions | 14225 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Irf7 (interferon regulatory factor 7) | protein interactions | 54123 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Kdm4c (lysine (K)-specific demethylase 4C) | protein interactions | 76804 | 2 | 1 | 19454 | 50 |
GLIS3 |
5.134e-03 | -5.27 | Fkbp1b (FK506 binding protein 1b) | protein interactions | 14226 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Zmym2 (zinc finger, MYM-type 2) | protein interactions | 76007 | 2 | 1 | 19454 | 50 |
GLIS3 |
5.134e-03 | -5.27 | Fbxo34 (F-box protein 34) | protein interactions | 78938 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.157e-03 | -5.27 | ovary-carcinoma | COSMIC cancer mutations | ovary-carcinoma | 933 | 8 | 16828 | 49 |
BMPR1B,MACF1,NTRK2,ATP1A2,TNIK,FGFR3,STON2,PREX2 |
5.187e-03 | -5.26 | cyclic purine nucleotide metabolic process | biological process | GO:0052652 | 40 | 2 | 18204 | 49 |
ADCY2,RORA |
5.198e-03 | -5.26 | PAS | prosite domains | PS50112 | 30 | 2 | 12186 | 44 |
HIF3A,NPAS3 |
5.299e-03 | -5.24 | glutamate dehydrogenase (NADP+) activity | molecular function | GO:0004354 | 2 | 1 | 18094 | 48 |
GLUD1 |
5.299e-03 | -5.24 | G protein-coupled neurotransmitter receptor activity involved in regulation of presynaptic membrane potential | molecular function | GO:0150047 | 2 | 1 | 18094 | 48 |
GABRB1 |
5.299e-03 | -5.24 | glutamate dehydrogenase [NAD(P)+] activity | molecular function | GO:0004353 | 2 | 1 | 18094 | 48 |
GLUD1 |
5.299e-03 | -5.24 | glutamate dehydrogenase (NAD+) activity | molecular function | GO:0004352 | 2 | 1 | 18094 | 48 |
GLUD1 |
5.299e-03 | -5.24 | oxidoreductase activity, acting on the CH-NH2 group of donors, NAD or NADP as acceptor | molecular function | GO:0016639 | 2 | 1 | 18094 | 48 |
GLUD1 |
5.312e-03 | -5.24 | SYNE3 (spectrin repeat containing nuclear envelope family member 3) | protein interactions | 161176 | 440 | 5 | 19454 | 50 |
SHROOM3,ABLIM1,SORBS1,MACF1,GLI3 |
5.331e-03 | -5.23 | Calcium-transporting ATPase, cytoplasmic transduction domain A | gene3d domains | 2.70.150.10 | 36 | 2 | 14470 | 44 |
ATP1A2,ATP13A4 |
5.331e-03 | -5.23 | Calcium-transporting ATPase, cytoplasmic domain N | gene3d domains | 3.40.1110.10 | 36 | 2 | 14470 | 44 |
ATP1A2,ATP13A4 |
5.356e-03 | -5.23 | lung-middle_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-middle_lobe-carcinoma-adenocarcinoma | 1368 | 10 | 16828 | 49 |
CPE,CACHD1,ATP1A2,MACF1,PARD3B,SHROOM3,STON2,ATP13A4,RYR3,CTNND2 |
5.376e-03 | -5.23 | larynx development | biological process | GO:0120224 | 2 | 1 | 18204 | 49 |
GLI3 |
5.376e-03 | -5.23 | fibroblast growth factor receptor apoptotic signaling pathway | biological process | GO:1902178 | 2 | 1 | 18204 | 49 |
FGFR3 |
5.376e-03 | -5.23 | mesenchymal cell differentiation involved in bone development | biological process | GO:1901706 | 2 | 1 | 18204 | 49 |
RANBP3L |
5.376e-03 | -5.23 | Wnt receptor catabolic process | biological process | GO:0038018 | 2 | 1 | 18204 | 49 |
ZNRF3 |
5.376e-03 | -5.23 | larynx morphogenesis | biological process | GO:0120223 | 2 | 1 | 18204 | 49 |
GLI3 |
5.376e-03 | -5.23 | smoothened signaling pathway involved in spinal cord motor neuron cell fate specification | biological process | GO:0021776 | 2 | 1 | 18204 | 49 |
GLI3 |
5.376e-03 | -5.23 | mammary gland specification | biological process | GO:0060594 | 2 | 1 | 18204 | 49 |
GLI3 |
5.392e-03 | -5.22 | Osteonectin_CS | interpro domains | IPR001999 | 2 | 1 | 18521 | 50 |
SPARCL1 |
5.392e-03 | -5.22 | Glu/Leu/Phe/Val/Trp_DH_dimer | interpro domains | IPR006097 | 2 | 1 | 18521 | 50 |
GLUD1 |
5.392e-03 | -5.22 | Distrobrevin | interpro domains | IPR017432 | 2 | 1 | 18521 | 50 |
DTNA |
5.392e-03 | -5.22 | Glu/Leu/Phe/Val_DH_AS | interpro domains | IPR033524 | 2 | 1 | 18521 | 50 |
GLUD1 |
5.392e-03 | -5.22 | MSI_RRM2 | interpro domains | IPR034126 | 2 | 1 | 18521 | 50 |
MSI2 |
5.392e-03 | -5.22 | NAD_bind_Glu_DH | interpro domains | IPR033922 | 2 | 1 | 18521 | 50 |
GLUD1 |
5.392e-03 | -5.22 | Formin_Cappuccino_subfam | interpro domains | IPR001265 | 2 | 1 | 18521 | 50 |
FMN2 |
5.392e-03 | -5.22 | Glu/Leu/Phe/Val/Trp_DH_C | interpro domains | IPR006096 | 2 | 1 | 18521 | 50 |
GLUD1 |
5.392e-03 | -5.22 | Par3/HAL_N | interpro domains | IPR021922 | 2 | 1 | 18521 | 50 |
PARD3B |
5.392e-03 | -5.22 | ZNRF-3_ecto | interpro domains | IPR040700 | 2 | 1 | 18521 | 50 |
ZNRF3 |
5.392e-03 | -5.22 | Glu/Leu/Phe/Val/Trp_DH | interpro domains | IPR006095 | 2 | 1 | 18521 | 50 |
GLUD1 |
5.443e-03 | -5.21 | cyclic nucleotide metabolic process | biological process | GO:0009187 | 41 | 2 | 18204 | 49 |
ADCY2,RORA |
5.462e-03 | -5.21 | lung-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-carcinoma-adenocarcinoma | 15133 | 49 | 16828 | 49 |
CPE,NTRK2,ABLIM1,FGFR3,STON2,CTNND2,SORBS1,SFXN5,GLUD1,FBXL7,TNIK,MSI2,HIF3A,NHSL1,MGAT4C,LSAMP,CACHD1,NKAIN3,SOX5,MACF1,NTM,GPC5,SLC4A4,RORA,GLI3,DTNA,GABRB1,RFX4,ZNRF3,SPARCL1,PREX2,SLC1A2,GLIS3,FMN2,GNA14,SHROOM3,PARD3B,ATP13A4,RYR3,ADCY2,AQP4,PITPNC1,ATP1A2,BMPR1B,RANBP3L,NPAS3,GPM6A,PAMR1,SLC1A3 |
5.492e-03 | -5.20 | organic anion transmembrane transporter activity | molecular function | GO:0008514 | 268 | 4 | 18094 | 48 |
SLC4A4,SFXN5,SLC1A3,SLC1A2 |
5.493e-03 | -5.20 | PK_Tyr_Ser-Thr | pfam domains | PF07714 | 130 | 3 | 17795 | 49 |
FGFR3,NTRK2,BMPR1B |
5.500e-03 | -5.20 | ZNRF_3_ecto | pfam domains | PF18212 | 2 | 1 | 17795 | 49 |
ZNRF3 |
5.500e-03 | -5.20 | Par3_HAL_N_term | pfam domains | PF12053 | 2 | 1 | 17795 | 49 |
PARD3B |
5.500e-03 | -5.20 | ELFV_dehydrog | pfam domains | PF00208 | 2 | 1 | 17795 | 49 |
GLUD1 |
5.500e-03 | -5.20 | ELFV_dehydrog_N | pfam domains | PF02812 | 2 | 1 | 17795 | 49 |
GLUD1 |
5.545e-03 | -5.19 | neutral L-amino acid transmembrane transporter activity | molecular function | GO:0015175 | 42 | 2 | 18094 | 48 |
SLC1A3,SLC1A2 |
5.547e-03 | -5.19 | Ser-Thr/Tyr_kinase_cat_dom | interpro domains | IPR001245 | 133 | 3 | 18521 | 50 |
NTRK2,BMPR1B,FGFR3 |
5.565e-03 | -5.19 | regulation of canonical Wnt signaling pathway | biological process | GO:0060828 | 265 | 4 | 18204 | 49 |
GLI3,GPC5,CTNND2,ZNRF3 |
5.612e-03 | -5.18 | calcium ion transmembrane transporter activity | molecular function | GO:0015085 | 136 | 3 | 18094 | 48 |
RYR3,CACHD1,GPM6A |
5.625e-03 | -5.18 | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | 748 | 7 | 16828 | 49 |
RANBP3L,DTNA,SOX5,NTRK2,CTNND2,SLC1A3,STON2 |
5.721e-03 | -5.16 | intracellular monoatomic cation homeostasis | biological process | GO:0030003 | 428 | 5 | 18204 | 49 |
SLC4A4,ATP13A4,ATP1A2,RYR3,SLC1A3 |
5.755e-03 | -5.16 | clear_cell_renal_cell_carcinoma | COSMIC cancer mutations | clear_cell_renal_cell_carcinoma | 13924 | 47 | 16828 | 49 |
FGFR3,ABLIM1,NTRK2,CPE,SORBS1,CTNND2,STON2,MSI2,TNIK,FBXL7,GLUD1,SFXN5,LSAMP,MGAT4C,NHSL1,HIF3A,MACF1,SOX5,NKAIN3,CACHD1,SLC4A4,GPC5,GABRB1,DTNA,GLI3,RORA,SLC1A2,PREX2,ZNRF3,SPARCL1,PARD3B,SHROOM3,GNA14,FMN2,GLIS3,RYR3,ATP13A4,PITPNC1,AQP4,ADCY2,RANBP3L,BMPR1B,ATP1A2,NPAS3,GPM6A,SLC1A3,PAMR1 |
5.755e-03 | -5.16 | kidney-carcinoma-clear_cell_renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-clear_cell_renal_cell_carcinoma | 13924 | 47 | 16828 | 49 |
BMPR1B,ATP1A2,RANBP3L,NPAS3,GPM6A,PAMR1,SLC1A3,FMN2,GLIS3,SHROOM3,PARD3B,GNA14,ATP13A4,RYR3,AQP4,PITPNC1,ADCY2,NKAIN3,SOX5,MACF1,CACHD1,SLC4A4,GPC5,RORA,DTNA,GLI3,GABRB1,PREX2,ZNRF3,SPARCL1,SLC1A2,CPE,NTRK2,FGFR3,ABLIM1,STON2,CTNND2,SORBS1,SFXN5,GLUD1,FBXL7,TNIK,MSI2,NHSL1,MGAT4C,HIF3A,LSAMP |
5.890e-03 | -5.13 | trans-synaptic signaling | biological process | GO:0099537 | 431 | 5 | 18204 | 49 |
SLC1A2,GABRB1,SLC1A3,DTNA,NTRK2 |
5.929e-03 | -5.13 | postsynapse | cellular component | GO:0098794 | 646 | 6 | 19108 | 49 |
GPM6A,TNIK,GABRB1,ATP1A2,CTNND2,NTRK2 |
5.941e-03 | -5.13 | rhythmic process | biological process | GO:0048511 | 270 | 4 | 18204 | 49 |
BMPR1B,NTRK2,RORA,GABRB1 |
6.001e-03 | -5.12 | YWHAH (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein eta) | protein interactions | 7533 | 1083 | 8 | 19454 | 50 |
MACF1,ABLIM1,SORBS1,PITPNC1,SHROOM3,PARD3B,NHSL1,FMN2 |
6.037e-03 | -5.11 | Calml3 (calmodulin-like 3) | protein interactions | 70405 | 144 | 3 | 19454 | 50 |
ABLIM1,MACF1,STON2 |
6.044e-03 | -5.11 | inorganic cation transmembrane transport | biological process | GO:0098662 | 618 | 6 | 18204 | 49 |
GPM6A,SLC4A4,RYR3,SLC1A3,CACHD1,ATP1A2 |
6.073e-03 | -5.10 | - | gene3d domains | 1.10.287.140 | 2 | 1 | 14470 | 44 |
GLUD1 |
6.073e-03 | -5.10 | - | gene3d domains | 6.20.350.10 | 2 | 1 | 14470 | 44 |
RYR3 |
6.073e-03 | -5.10 | Vinculin, Vh2 four-helix bundle | gene3d domains | 1.20.120.810 | 2 | 1 | 14470 | 44 |
CTNNA2 |
6.091e-03 | -5.10 | behavior | biological process | GO:0007610 | 619 | 6 | 18204 | 49 |
NTRK2,PREX2,ATP1A2,SLC1A3,GLI3,SLC1A2 |
6.127e-03 | -5.10 | cell-cell signaling | biological process | GO:0007267 | 822 | 7 | 18204 | 49 |
DTNA,CPE,NTRK2,SLC1A2,GABRB1,FGFR3,SLC1A3 |
6.164e-03 | -5.09 | GSK3A (glycogen synthase kinase 3 alpha) | protein interactions | 2931 | 456 | 5 | 19454 | 50 |
TNIK,MACF1,GLUD1,GLI3,NHSL1 |
6.174e-03 | -5.09 | vascular process in circulatory system | biological process | GO:0003018 | 273 | 4 | 18204 | 49 |
SLC1A2,SLC1A3,ATP1A2,SLC4A4 |
6.238e-03 | -5.08 | intracellular monoatomic ion homeostasis | biological process | GO:0006873 | 437 | 5 | 18204 | 49 |
SLC4A4,ATP13A4,ATP1A2,SLC1A3,RYR3 |
6.247e-03 | -5.08 | positive regulation of glucose transmembrane transport | biological process | GO:0010828 | 44 | 2 | 18204 | 49 |
SLC1A2,SORBS1 |
6.257e-03 | -5.07 | active transmembrane transporter activity | molecular function | GO:0022804 | 444 | 5 | 18094 | 48 |
ATP13A4,SLC1A3,SLC4A4,ATP1A2,SLC1A2 |
6.281e-03 | -5.07 | animal organ development | biological process | GO:0048513 | 2846 | 15 | 18204 | 49 |
RANBP3L,GPM6A,ABLIM1,NTRK2,BMPR1B,CTNNA2,SLC1A2,ATP1A2,CPE,SOX5,GLI3,RORA,GLUD1,RFX4,FGFR3 |
6.324e-03 | -5.06 | monoatomic anion transmembrane transporter activity | molecular function | GO:0008509 | 142 | 3 | 18094 | 48 |
SLC4A4,GABRB1,SLC1A2 |
6.335e-03 | -5.06 | neurotransmitter transport | biological process | GO:0006836 | 140 | 3 | 18204 | 49 |
SLC1A2,SLC1A3,ATP1A2 |
6.348e-03 | -5.06 | VASP (vasodilator stimulated phosphoprotein) | protein interactions | 7408 | 288 | 4 | 19454 | 50 |
SORBS1,SHROOM3,FMN2,NHSL1 |
6.372e-03 | -5.06 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia | 10418 | 39 | 16828 | 49 |
GABRB1,RFX4,GLI3,RORA,SLC1A2,SPARCL1,PREX2,SLC1A3,PAMR1,RANBP3L,NTM,ATP1A2,CACHD1,MACF1,SOX5,NKAIN3,GPC5,SLC4A4,NPAS3,MSI2,TNIK,FBXL7,SFXN5,LSAMP,HIF3A,ADCY2,NHSL1,ABLIM1,GNA14,PARD3B,SHROOM3,GLIS3,NTRK2,CPE,FMN2,RYR3,CTNND2,ATP13A4,STON2 |
6.372e-03 | -5.06 | acute_myeloid_leukaemia | COSMIC cancer mutations | acute_myeloid_leukaemia | 10418 | 39 | 16828 | 49 |
GPC5,NPAS3,SLC4A4,RANBP3L,NTM,ATP1A2,CACHD1,SOX5,MACF1,NKAIN3,SLC1A2,SPARCL1,SLC1A3,PREX2,PAMR1,GABRB1,RFX4,GLI3,RORA,RYR3,CTNND2,ATP13A4,STON2,ABLIM1,GNA14,PARD3B,SHROOM3,NTRK2,GLIS3,CPE,FMN2,LSAMP,HIF3A,ADCY2,NHSL1,MSI2,TNIK,FBXL7,SFXN5 |
6.441e-03 | -5.05 | membrane raft | cellular component | GO:0045121 | 290 | 4 | 19108 | 49 |
ADCY2,SLC1A2,ATP1A2,SORBS1 |
6.470e-03 | -5.04 | extrinsic component of cytoplasmic side of plasma membrane | cellular component | GO:0031234 | 47 | 2 | 19108 | 49 |
GNA14,DTNA |
6.493e-03 | -5.04 | spleen | COSMIC cancer mutations | spleen | 408 | 5 | 16828 | 49 |
SORBS1,PARD3B,TNIK,NTM,ADCY2 |
6.500e-03 | -5.04 | BDNF (brain derived neurotrophic factor) | protein interactions | 627 | 47 | 2 | 19454 | 50 |
NTRK2,CPE |
6.597e-03 | -5.02 | upper_arm | COSMIC cancer mutations | upper_arm | 582 | 6 | 16828 | 49 |
PREX2,SLC4A4,STON2,FMN2,PARD3B,FGFR3 |
6.597e-03 | -5.02 | membrane microdomain | cellular component | GO:0098857 | 292 | 4 | 19108 | 49 |
ADCY2,SORBS1,ATP1A2,SLC1A2 |
6.624e-03 | -5.02 | metal ion transport | biological process | GO:0030001 | 630 | 6 | 18204 | 49 |
CACHD1,ATP1A2,SLC1A3,RYR3,SLC4A4,GPM6A |
6.709e-03 | -5.00 | apical junction complex | cellular component | GO:0043296 | 150 | 3 | 19108 | 49 |
PARD3B,SORBS1,SHROOM3 |
6.841e-03 | -4.98 | face | COSMIC cancer mutations | face | 2139 | 13 | 16828 | 49 |
AQP4,PREX2,ZNRF3,GPC5,LSAMP,FMN2,RORA,MACF1,GPM6A,FGFR3,MSI2,ABLIM1,GABRB1 |
6.875e-03 | -4.98 | Ig_3 | pfam domains | PF13927 | 141 | 3 | 17795 | 49 |
FGFR3,NTM,LSAMP |
6.896e-03 | -4.98 | Vasopressin regulates renal water homeostasis via Aquaporins | REACTOME pathways | R-HSA-432040 | 43 | 2 | 10285 | 30 |
AQP4,ADCY2 |
6.941e-03 | -4.97 | bronchioloalveolar_adenocarcinoma | COSMIC cancer mutations | bronchioloalveolar_adenocarcinoma | 778 | 7 | 16828 | 49 |
BMPR1B,SOX5,NTRK2,FGFR3,TNIK,ADCY2,CTNND2 |
6.941e-03 | -4.97 | lung-carcinoma-bronchioloalveolar_adenocarcinoma | COSMIC cancer mutations | lung-carcinoma-bronchioloalveolar_adenocarcinoma | 778 | 7 | 16828 | 49 |
TNIK,FGFR3,BMPR1B,SOX5,NTRK2,CTNND2,ADCY2 |
7.087e-03 | -4.95 | symporter activity | molecular function | GO:0015293 | 148 | 3 | 18094 | 48 |
SLC1A2,SLC1A3,SLC4A4 |
7.111e-03 | -4.95 | adult behavior | biological process | GO:0030534 | 146 | 3 | 18204 | 49 |
PREX2,SLC1A2,ATP1A2 |
7.175e-03 | -4.94 | PDZ | interpro domains | IPR001478 | 146 | 3 | 18521 | 50 |
PREX2,SHROOM3,PARD3B |
7.191e-03 | -4.93 | ELFV_dehydrog | smart domains | SM00839 | 2 | 1 | 9717 | 35 |
GLUD1 |
7.209e-03 | -4.93 | OSTEONECTIN_2 | prosite domains | PS00613 | 2 | 1 | 12186 | 44 |
SPARCL1 |
7.209e-03 | -4.93 | OSTEONECTIN_1 | prosite domains | PS00612 | 2 | 1 | 12186 | 44 |
SPARCL1 |
7.209e-03 | -4.93 | GLFV_DEHYDROGENASE | prosite domains | PS00074 | 2 | 1 | 12186 | 44 |
GLUD1 |
7.363e-03 | -4.91 | Signaling by Hedgehog | REACTOME pathways | R-HSA-5358351 | 138 | 3 | 10285 | 30 |
GPC5,ADCY2,GLI3 |
7.426e-03 | -4.90 | ATPASE_E1_E2 | prosite domains | PS00154 | 36 | 2 | 12186 | 44 |
ATP1A2,ATP13A4 |
7.490e-03 | -4.89 | intestinal_adenocarcinoma | COSMIC cancer mutations | intestinal_adenocarcinoma | 7225 | 30 | 16828 | 49 |
RANBP3L,NTM,ATP1A2,CACHD1,MACF1,SOX5,NPAS3,SLC4A4,RFX4,GLI3,RORA,SLC1A2,ZNRF3,PREX2,GNA14,PARD3B,FGFR3,NTRK2,FMN2,RYR3,CTNND2,ATP13A4,STON2,FBXL7,SFXN5,LSAMP,ADCY2,PITPNC1,AQP4,NHSL1 |
7.490e-03 | -4.89 | stomach-carcinoma-intestinal_adenocarcinoma | COSMIC cancer mutations | stomach-carcinoma-intestinal_adenocarcinoma | 7225 | 30 | 16828 | 49 |
FMN2,NTRK2,PARD3B,FGFR3,GNA14,ATP13A4,STON2,CTNND2,RYR3,FBXL7,SFXN5,PITPNC1,AQP4,NHSL1,ADCY2,LSAMP,MACF1,SOX5,ATP1A2,CACHD1,RANBP3L,NTM,SLC4A4,NPAS3,GLI3,RORA,RFX4,PREX2,ZNRF3,SLC1A2 |
7.493e-03 | -4.89 | cell surface | cellular component | GO:0009986 | 896 | 7 | 19108 | 49 |
SLC1A3,FGFR3,AQP4,GPC5,SLC1A2,ATP1A2,SLC4A4 |
7.587e-03 | -4.88 | PDZ_sf | interpro domains | IPR036034 | 149 | 3 | 18521 | 50 |
PARD3B,SHROOM3,PREX2 |
7.617e-03 | -4.88 | Ndc80 (NDC80 kinetochore complex component) | protein interactions | 67052 | 51 | 2 | 19454 | 50 |
NHSL1,MACF1 |
7.640e-03 | -4.87 | synaptic signaling | biological process | GO:0099536 | 459 | 5 | 18204 | 49 |
NTRK2,DTNA,SLC1A3,GABRB1,SLC1A2 |
7.691e-03 | -4.87 | Rap2a (RAS related protein 2a) | protein interactions | 76108 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | Spop (speckle-type BTB/POZ protein) | protein interactions | 20747 | 3 | 1 | 19454 | 50 |
GLIS3 |
7.691e-03 | -4.87 | Plekhb1 (pleckstrin homology domain containing, family B (evectins) member 1) | protein interactions | 27276 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | QRFPR (pyroglutamylated RFamide peptide receptor) | protein interactions | 84109 | 3 | 1 | 19454 | 50 |
NTM |
7.691e-03 | -4.87 | Stk35 (serine/threonine kinase 35) | protein interactions | 67333 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | Usp45 (ubiquitin specific petidase 45) | protein interactions | 77593 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | Shh (sonic hedgehog) | protein interactions | 20423 | 3 | 1 | 19454 | 50 |
GLI3 |
7.691e-03 | -4.87 | BCO1 (beta-carotene oxygenase 1) | protein interactions | 53630 | 3 | 1 | 19454 | 50 |
ABLIM1 |
7.691e-03 | -4.87 | Atg16l1 (autophagy related 16 like 1) | protein interactions | 77040 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | Chn1 (chimerin 1) | protein interactions | 108699 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | Smad6 (SMAD family member 6) | protein interactions | 17130 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | Fbxw5 (F-box and WD-40 domain protein 5) | protein interactions | 30839 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.720e-03 | -4.86 | endometrium-carcinoma-serous_carcinoma | COSMIC cancer mutations | endometrium-carcinoma-serous_carcinoma | 1442 | 10 | 16828 | 49 |
TNIK,GABRB1,FMN2,CACHD1,CTNND2,SORBS1,RYR3,LSAMP,SLC4A4,GPC5 |
7.762e-03 | -4.86 | anchoring junction | cellular component | GO:0070161 | 902 | 7 | 19108 | 49 |
SHROOM3,ATP1A2,PARD3B,CTNNA2,CTNND2,FGFR3,SORBS1 |
7.800e-03 | -4.85 | abdomen | COSMIC cancer mutations | abdomen | 603 | 6 | 16828 | 49 |
FMN2,STON2,PREX2,FGFR3,CTNND2,RANBP3L |
7.909e-03 | -4.84 | SH2B2 (SH2B adaptor protein 2) | protein interactions | 10603 | 52 | 2 | 19454 | 50 |
SORBS1,NTRK2 |
7.917e-03 | -4.84 | regulation of membrane potential | biological process | GO:0042391 | 463 | 5 | 18204 | 49 |
NTRK2,SLC4A4,ATP1A2,GNA14,GABRB1 |
7.938e-03 | -4.84 | alpha-1,3-mannosylglycoprotein 4-beta-N-acetylglucosaminyltransferase activity | molecular function | GO:0008454 | 3 | 1 | 18094 | 48 |
MGAT4C |
7.938e-03 | -4.84 | cysteine transmembrane transporter activity | molecular function | GO:0033229 | 3 | 1 | 18094 | 48 |
SLC1A2 |
8.020e-03 | -4.83 | FORMIN | prints domains | PR00828 | 2 | 1 | 5227 | 21 |
FMN2 |
8.020e-03 | -4.83 | GLFDHDRGNASE | prints domains | PR00082 | 2 | 1 | 5227 | 21 |
GLUD1 |
8.054e-03 | -4.82 | formin-nucleated actin cable assembly | biological process | GO:0070649 | 3 | 1 | 18204 | 49 |
FMN2 |
8.054e-03 | -4.82 | radial glia guided migration of Purkinje cell | biological process | GO:0021942 | 3 | 1 | 18204 | 49 |
CTNNA2 |
8.054e-03 | -4.82 | smoothened signaling pathway involved in ventral spinal cord interneuron specification | biological process | GO:0021775 | 3 | 1 | 18204 | 49 |
GLI3 |
8.054e-03 | -4.82 | cysteine transmembrane transport | biological process | GO:1903712 | 3 | 1 | 18204 | 49 |
SLC1A2 |
8.054e-03 | -4.82 | cysteine transport | biological process | GO:0042883 | 3 | 1 | 18204 | 49 |
SLC1A2 |
8.054e-03 | -4.82 | smoothened signaling pathway involved in ventral spinal cord patterning | biological process | GO:0021910 | 3 | 1 | 18204 | 49 |
GLI3 |
8.054e-03 | -4.82 | meiotic chromosome movement towards spindle pole | biological process | GO:0016344 | 3 | 1 | 18204 | 49 |
FMN2 |
8.054e-03 | -4.82 | regulation of calcium:sodium antiporter activity | biological process | GO:1903279 | 3 | 1 | 18204 | 49 |
ATP1A2 |
8.054e-03 | -4.82 | formin-nucleated actin cable organization | biological process | GO:0110009 | 3 | 1 | 18204 | 49 |
FMN2 |
8.054e-03 | -4.82 | trans-synaptic signaling by BDNF, modulating synaptic transmission | biological process | GO:0099183 | 3 | 1 | 18204 | 49 |
NTRK2 |
8.054e-03 | -4.82 | nose morphogenesis | biological process | GO:0043585 | 3 | 1 | 18204 | 49 |
GLI3 |
8.078e-03 | -4.82 | SPRY1_RyR | interpro domains | IPR035761 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | ASD1_dom | interpro domains | IPR014800 | 3 | 1 | 18521 | 50 |
SHROOM3 |
8.078e-03 | -4.82 | Ryanodine_rcpt | interpro domains | IPR003032 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | SPRY2_RyR | interpro domains | IPR035764 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | RYDR_Jsol | interpro domains | IPR048581 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | Vinculin_CS | interpro domains | IPR000633 | 3 | 1 | 18521 | 50 |
CTNNA2 |
8.078e-03 | -4.82 | NR_DBD_ROR | interpro domains | IPR044101 | 3 | 1 | 18521 | 50 |
RORA |
8.078e-03 | -4.82 | SHD_dom | interpro domains | IPR012320 | 3 | 1 | 18521 | 50 |
STON2 |
8.078e-03 | -4.82 | HIF_alpha-like | interpro domains | IPR021537 | 3 | 1 | 18521 | 50 |
HIF3A |
8.078e-03 | -4.82 | Ryan_recept | interpro domains | IPR013333 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | GABAAb_rcpt | interpro domains | IPR002289 | 3 | 1 | 18521 | 50 |
GABRB1 |
8.078e-03 | -4.82 | NTRK | interpro domains | IPR020777 | 3 | 1 | 18521 | 50 |
NTRK2 |
8.078e-03 | -4.82 | ROR_rcpt | interpro domains | IPR003079 | 3 | 1 | 18521 | 50 |
RORA |
8.078e-03 | -4.82 | Stonin | interpro domains | IPR017110 | 3 | 1 | 18521 | 50 |
STON2 |
8.078e-03 | -4.82 | Myelin_PLP_CS | interpro domains | IPR018237 | 3 | 1 | 18521 | 50 |
GPM6A |
8.078e-03 | -4.82 | NTRK_LRRCT | interpro domains | IPR031635 | 3 | 1 | 18521 | 50 |
NTRK2 |
8.078e-03 | -4.82 | Ryanrecept_TM4-6 | interpro domains | IPR009460 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | SPRY3_RyR | interpro domains | IPR035762 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | Myelin_PLP | interpro domains | IPR001614 | 3 | 1 | 18521 | 50 |
GPM6A |
8.078e-03 | -4.82 | SoHo_dom | interpro domains | IPR003127 | 3 | 1 | 18521 | 50 |
SORBS1 |
8.088e-03 | -4.82 | amino acid binding | molecular function | GO:0016597 | 51 | 2 | 18094 | 48 |
SLC1A3,GLUD1 |
8.100e-03 | -4.82 | AFDN (afadin, adherens junction formation factor) | protein interactions | 4301 | 309 | 4 | 19454 | 50 |
MACF1,SORBS1,DTNA,SHROOM3 |
8.124e-03 | -4.81 | neuronal cell body | cellular component | GO:0043025 | 489 | 5 | 19108 | 49 |
BMPR1B,SLC1A3,CTNND2,GPM6A,ATP1A2 |
8.238e-03 | -4.80 | SR_plectin_7 | pfam domains | PF21097 | 3 | 1 | 17795 | 49 |
MACF1 |
8.238e-03 | -4.80 | HIF-1 | pfam domains | PF11413 | 3 | 1 | 17795 | 49 |
HIF3A |
8.238e-03 | -4.80 | RR_TM4-6 | pfam domains | PF06459 | 3 | 1 | 17795 | 49 |
RYR3 |
8.238e-03 | -4.80 | RyR | pfam domains | PF02026 | 3 | 1 | 17795 | 49 |
RYR3 |
8.238e-03 | -4.80 | RYDR_Jsol | pfam domains | PF21119 | 3 | 1 | 17795 | 49 |
RYR3 |
8.238e-03 | -4.80 | Myelin_PLP | pfam domains | PF01275 | 3 | 1 | 17795 | 49 |
GPM6A |
8.238e-03 | -4.80 | ASD1 | pfam domains | PF08688 | 3 | 1 | 17795 | 49 |
SHROOM3 |
8.238e-03 | -4.80 | Sorb | pfam domains | PF02208 | 3 | 1 | 17795 | 49 |
SORBS1 |
8.238e-03 | -4.80 | LRRCT_2 | pfam domains | PF16920 | 3 | 1 | 17795 | 49 |
NTRK2 |
8.267e-03 | -4.80 | carboxylic acid transport | biological process | GO:0046942 | 297 | 4 | 18204 | 49 |
NTRK2,SLC1A2,SFXN5,SLC1A3 |
8.301e-03 | -4.79 | breast-carcinoma-basal_(triple-negative)_carcinoma | COSMIC cancer mutations | breast-carcinoma-basal_(triple-negative)_carcinoma | 2981 | 16 | 16828 | 49 |
NTM,FGFR3,SHROOM3,CACHD1,NTRK2,ATP1A2,BMPR1B,FMN2,MACF1,NPAS3,SLC4A4,MSI2,GLI3,ADCY2,SPARCL1,HIF3A |
8.301e-03 | -4.79 | basal_(triple-negative)_carcinoma | COSMIC cancer mutations | basal_(triple-negative)_carcinoma | 2981 | 16 | 16828 | 49 |
GLI3,MSI2,HIF3A,ADCY2,SPARCL1,ATP1A2,NTRK2,CACHD1,MACF1,BMPR1B,FMN2,SHROOM3,FGFR3,NTM,NPAS3,SLC4A4 |
8.363e-03 | -4.78 | organic acid transport | biological process | GO:0015849 | 298 | 4 | 18204 | 49 |
SFXN5,SLC1A2,SLC1A3,NTRK2 |
8.446e-03 | -4.77 | CATATPASE | prints domains | PR00119 | 35 | 2 | 5227 | 21 |
ATP13A4,ATP1A2 |
8.525e-03 | -4.76 | retina development in camera-type eye | biological process | GO:0060041 | 156 | 3 | 18204 | 49 |
GPM6A,BMPR1B,NTRK2 |
8.675e-03 | -4.75 | regulation of osteoblast differentiation | biological process | GO:0045667 | 157 | 3 | 18204 | 49 |
GLI3,RANBP3L,BMPR1B |
8.711e-03 | -4.74 | skin-forearm-lentigo | COSMIC cancer mutations | skin-forearm-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-lentigo | COSMIC cancer mutations | skin-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-hand-lentigo | COSMIC cancer mutations | skin-hand-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-face-lentigo | COSMIC cancer mutations | skin-face-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-leg-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-leg-other-seborrhoeic_keratosis | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | urinary_tract-bladder-papilloma | COSMIC cancer mutations | urinary_tract-bladder-papilloma | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-trunk-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-trunk-other-seborrhoeic_keratosis | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-trunk-lentigo | COSMIC cancer mutations | skin-trunk-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-leg-lentigo | COSMIC cancer mutations | skin-leg-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | lentigo | COSMIC cancer mutations | lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.712e-03 | -4.74 | ATPase-coupled monoatomic cation transmembrane transporter activity | molecular function | GO:0019829 | 53 | 2 | 18094 | 48 |
ATP13A4,ATP1A2 |
8.726e-03 | -4.74 | GLI proteins bind promoters of Hh responsive genes to promote transcription | REACTOME pathways | R-HSA-5635851 | 3 | 1 | 10285 | 30 |
GLI3 |
8.748e-03 | -4.74 | ZYX (zyxin) | protein interactions | 7791 | 316 | 4 | 19454 | 50 |
MACF1,SORBS1,ABLIM1,SHROOM3 |
8.869e-03 | -4.73 | mannosyl-glycoprotein N-acetylglucosaminyltransferases | BIOCYC pathways | META_PWY-7426 | 8 | 1 | 902 | 1 |
MGAT4C |
8.962e-03 | -4.71 | neutral amino acid transport | biological process | GO:0015804 | 53 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
9.053e-03 | -4.70 | CTNNB1 (catenin beta 1) | protein interactions | 1499 | 926 | 7 | 19454 | 50 |
CTNND2,DTNA,PARD3B,NHSL1,CTNNA2,SORBS1,SHROOM3 |
9.087e-03 | -4.70 | metal ion binding | molecular function | GO:0046872 | 4239 | 19 | 18094 | 48 |
ABLIM1,GNA14,GLIS3,MGAT4C,RYR3,RORA,SPARCL1,SLC1A2,GLI3,SLC1A3,BMPR1B,MACF1,ADCY2,ATP1A2,DTNA,PAMR1,CPE,ATP13A4,ZNRF3 |
9.095e-03 | -4.70 | - | gene3d domains | 1.10.490.160 | 3 | 1 | 14470 | 44 |
RYR3 |
9.095e-03 | -4.70 | - | gene3d domains | 6.10.250.2510 | 3 | 1 | 14470 | 44 |
CTNNA2 |
9.147e-03 | -4.69 | presynaptic membrane | cellular component | GO:0042734 | 168 | 3 | 19108 | 49 |
GPM6A,SLC1A2,GABRB1 |
9.156e-03 | -4.69 | ear | COSMIC cancer mutations | ear | 624 | 6 | 16828 | 49 |
GABRB1,FGFR3,SPARCL1,STON2,MGAT4C,NPAS3 |
9.191e-03 | -4.69 | EF-hand | gene3d domains | 1.10.238.10 | 272 | 4 | 14470 | 44 |
SPARCL1,MACF1,DTNA,RYR3 |
9.212e-03 | -4.69 | oesophagus-carcinoma-adenocarcinoma | COSMIC cancer mutations | oesophagus-carcinoma-adenocarcinoma | 13112 | 45 | 16828 | 49 |
ATP13A4,RYR3,GLIS3,FMN2,GNA14,SHROOM3,PARD3B,ADCY2,AQP4,NPAS3,ATP1A2,BMPR1B,RANBP3L,PAMR1,SLC1A3,GPM6A,STON2,CTNND2,SORBS1,CPE,NTRK2,FGFR3,HIF3A,NHSL1,MGAT4C,LSAMP,SFXN5,GLUD1,FBXL7,TNIK,GPC5,SLC4A4,CACHD1,NKAIN3,MACF1,SOX5,NTM,SPARCL1,ZNRF3,PREX2,SLC1A2,RORA,GLI3,GABRB1,RFX4 |
9.290e-03 | -4.68 | inorganic anion transport | biological process | GO:0015698 | 161 | 3 | 18204 | 49 |
GABRB1,SLC1A3,SLC4A4 |
9.475e-03 | -4.66 | serous_carcinoma | COSMIC cancer mutations | serous_carcinoma | 10987 | 40 | 16828 | 49 |
SLC1A2,SLC1A3,PREX2,PAMR1,ZNRF3,GABRB1,GLI3,DTNA,RORA,NPAS3,SLC4A4,GPC5,RANBP3L,NTM,SOX5,MACF1,BMPR1B,ATP1A2,CACHD1,LSAMP,MGAT4C,NHSL1,ADCY2,MSI2,TNIK,FBXL7,GLUD1,SFXN5,SORBS1,CTNND2,RYR3,ATP13A4,PARD3B,SHROOM3,FGFR3,GNA14,FMN2,GLIS3,NTRK2,CPE |
9.564e-03 | -4.65 | side of membrane | cellular component | GO:0098552 | 715 | 6 | 19108 | 49 |
GPC5,AQP4,GNA14,LSAMP,NTM,DTNA |
9.597e-03 | -4.65 | Neurotransmitter Release Cycle | REACTOME pathways | R-HSA-112310 | 51 | 2 | 10285 | 30 |
SLC1A2,SLC1A3 |
9.625e-03 | -4.64 | response to cocaine | biological process | GO:0042220 | 55 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
9.634e-03 | -4.64 | biliary_tract | COSMIC cancer mutations | biliary_tract | 15309 | 49 | 16828 | 49 |
NTRK2,CPE,ABLIM1,FGFR3,STON2,SORBS1,CTNND2,FBXL7,GLUD1,SFXN5,MSI2,TNIK,HIF3A,MGAT4C,NHSL1,LSAMP,CACHD1,SOX5,MACF1,NKAIN3,NTM,GPC5,SLC4A4,GLI3,DTNA,RORA,GABRB1,RFX4,ZNRF3,SPARCL1,PREX2,SLC1A2,GLIS3,FMN2,GNA14,PARD3B,SHROOM3,ATP13A4,RYR3,ADCY2,PITPNC1,AQP4,ATP1A2,BMPR1B,RANBP3L,NPAS3,GPM6A,SLC1A3,PAMR1 |
9.634e-03 | -4.64 | LAMTOR1 (late endosomal/lysosomal adaptor, MAPK and MTOR activator 1) | protein interactions | 55004 | 714 | 6 | 19454 | 50 |
CACHD1,TNIK,DTNA,STON2,SLC1A3,FMN2 |
9.751e-03 | -4.63 | dendritic spine | cellular component | GO:0043197 | 172 | 3 | 19108 | 49 |
ATP1A2,GPM6A,NTRK2 |
9.929e-03 | -4.61 | import across plasma membrane | biological process | GO:0098739 | 165 | 3 | 18204 | 49 |
SLC1A2,SLC1A3,ATP1A2 |
9.950e-03 | -4.61 | CAV1 (caveolin 1) | protein interactions | 857 | 719 | 6 | 19454 | 50 |
DTNA,MACF1,TNIK,CACHD1,FMN2,SLC1A3 |
9.963e-03 | -4.61 | Aquaporin-mediated transport | REACTOME pathways | R-HSA-445717 | 52 | 2 | 10285 | 30 |
AQP4,ADCY2 |
1.006e-02 | -4.60 | neuron spine | cellular component | GO:0044309 | 174 | 3 | 19108 | 49 |
NTRK2,GPM6A,ATP1A2 |
1.008e-02 | -4.60 | cellular homeostasis | biological process | GO:0019725 | 689 | 6 | 18204 | 49 |
RYR3,SLC1A3,AQP4,ATP1A2,ATP13A4,SLC4A4 |
1.022e-02 | -4.58 | extrinsic component of membrane | cellular component | GO:0019898 | 175 | 3 | 19108 | 49 |
GNA14,CTNNA2,DTNA |
1.022e-02 | -4.58 | GLI-SUFU complex | cellular component | GO:1990788 | 4 | 1 | 19108 | 49 |
GLI3 |
1.024e-02 | -4.58 | Cdk14 (cyclin dependent kinase 14) | protein interactions | 18647 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Nkiras1 (NFKB inhibitor interacting Ras-like protein 1) | protein interactions | 69721 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | CCDC126 (coiled-coil domain containing 126) | protein interactions | 90693 | 4 | 1 | 19454 | 50 |
GPM6A |
1.024e-02 | -4.58 | Dnaja1 (DnaJ heat shock protein family (Hsp40) member A1) | protein interactions | 15502 | 4 | 1 | 19454 | 50 |
GLIS3 |
1.024e-02 | -4.58 | Ilkap (integrin-linked kinase-associated serine/threonine phosphatase 2C) | protein interactions | 67444 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Arhgef6 (Rac/Cdc42 guanine nucleotide exchange factor 6) | protein interactions | 73341 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Rhebl1 (Ras homolog enriched in brain like 1) | protein interactions | 69159 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Naa20 (N(alpha)-acetyltransferase 20, NatB catalytic subunit) | protein interactions | 67877 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Nme2 (NME/NM23 nucleoside diphosphate kinase 2) | protein interactions | 18103 | 4 | 1 | 19454 | 50 |
RORA |
1.024e-02 | -4.58 | Srgap1 (SLIT-ROBO Rho GTPase activating protein 1) | protein interactions | 117600 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Sufu (SUFU negative regulator of hedgehog signaling) | protein interactions | 24069 | 4 | 1 | 19454 | 50 |
GLI3 |
1.027e-02 | -4.58 | IGc2 | smart domains | SM00408 | 239 | 4 | 9717 | 35 |
FGFR3,NTRK2,LSAMP,NTM |
1.031e-02 | -4.57 | visual behavior | biological process | GO:0007632 | 57 | 2 | 18204 | 49 |
ATP1A2,SLC1A2 |
1.031e-02 | -4.57 | neuroblast proliferation | biological process | GO:0007405 | 57 | 2 | 18204 | 49 |
SOX5,GLI3 |
1.034e-02 | -4.57 | channel activity | molecular function | GO:0015267 | 502 | 5 | 18094 | 48 |
AQP4,RYR3,CACHD1,GABRB1,GPM6A |
1.041e-02 | -4.56 | - | gene3d domains | 2.30.42.10 | 149 | 3 | 14470 | 44 |
PREX2,SHROOM3,PARD3B |
1.042e-02 | -4.56 | SNTB1 (syntrophin beta 1) | protein interactions | 6641 | 60 | 2 | 19454 | 50 |
FGFR3,DTNA |
1.042e-02 | -4.56 | passive transmembrane transporter activity | molecular function | GO:0022803 | 503 | 5 | 18094 | 48 |
AQP4,GPM6A,GABRB1,RYR3,CACHD1 |
1.057e-02 | -4.55 | mediator complex binding | molecular function | GO:0036033 | 4 | 1 | 18094 | 48 |
GLI3 |
1.057e-02 | -4.55 | brain-derived neurotrophic factor binding | molecular function | GO:0048403 | 4 | 1 | 18094 | 48 |
NTRK2 |
1.057e-02 | -4.55 | ryanodine-sensitive calcium-release channel activity | molecular function | GO:0005219 | 4 | 1 | 18094 | 48 |
RYR3 |
1.057e-02 | -4.55 | tricarboxylic acid transmembrane transporter activity | molecular function | GO:0015142 | 4 | 1 | 18094 | 48 |
SFXN5 |
1.057e-02 | -4.55 | citrate transmembrane transporter activity | molecular function | GO:0015137 | 4 | 1 | 18094 | 48 |
SFXN5 |
1.065e-02 | -4.54 | ovary-other-neoplasm | COSMIC cancer mutations | ovary-other-neoplasm | 12717 | 44 | 16828 | 49 |
SLC1A2,SPARCL1,PREX2,GABRB1,RFX4,GLI3,RORA,GPC5,SLC4A4,NTM,CACHD1,SOX5,MACF1,NKAIN3,LSAMP,MGAT4C,NHSL1,MSI2,TNIK,FBXL7,GLUD1,SFXN5,SORBS1,CTNND2,STON2,ABLIM1,FGFR3,NTRK2,CPE,SLC1A3,PAMR1,GPM6A,RANBP3L,ATP1A2,BMPR1B,ADCY2,AQP4,RYR3,ATP13A4,GNA14,SHROOM3,PARD3B,GLIS3,FMN2 |
1.070e-02 | -4.54 | chemical homeostasis | biological process | GO:0048878 | 914 | 7 | 18204 | 49 |
AQP4,RORA,ATP1A2,RYR3,SLC1A3,SLC4A4,ATP13A4 |
1.072e-02 | -4.54 | smoothened signaling pathway involved in dorsal/ventral neural tube patterning | biological process | GO:0060831 | 4 | 1 | 18204 | 49 |
GLI3 |
1.072e-02 | -4.54 | regulation of glutamate uptake involved in transmission of nerve impulse | biological process | GO:0051946 | 4 | 1 | 18204 | 49 |
ATP1A2 |
1.072e-02 | -4.54 | glutamate biosynthetic process | biological process | GO:0006537 | 4 | 1 | 18204 | 49 |
GLUD1 |
1.072e-02 | -4.54 | protein localization to secretory granule | biological process | GO:0033366 | 4 | 1 | 18204 | 49 |
CPE |
1.072e-02 | -4.54 | regulation of amino acid uptake involved in synaptic transmission | biological process | GO:0051941 | 4 | 1 | 18204 | 49 |
ATP1A2 |
1.072e-02 | -4.54 | brain-derived neurotrophic factor receptor signaling pathway | biological process | GO:0031547 | 4 | 1 | 18204 | 49 |
NTRK2 |
1.072e-02 | -4.54 | trans-synaptic signaling by BDNF | biological process | GO:0099191 | 4 | 1 | 18204 | 49 |
NTRK2 |
1.072e-02 | -4.54 | ovarian cumulus expansion | biological process | GO:0001550 | 4 | 1 | 18204 | 49 |
BMPR1B |
1.072e-02 | -4.54 | positive regulation of mesenchymal stem cell differentiation | biological process | GO:2000741 | 4 | 1 | 18204 | 49 |
SOX5 |
1.072e-02 | -4.54 | frontal suture morphogenesis | biological process | GO:0060364 | 4 | 1 | 18204 | 49 |
GLI3 |
1.072e-02 | -4.54 | response to glycoside | biological process | GO:1903416 | 4 | 1 | 18204 | 49 |
ATP1A2 |
1.076e-02 | -4.53 | P5A-ATPase_N | interpro domains | IPR047819 | 4 | 1 | 18521 | 50 |
ATP13A4 |
1.076e-02 | -4.53 | Na/K-Atpase_Interacting | interpro domains | IPR008516 | 4 | 1 | 18521 | 50 |
NKAIN3 |
1.076e-02 | -4.53 | Shroom_fam | interpro domains | IPR027685 | 4 | 1 | 18521 | 50 |
SHROOM3 |
1.076e-02 | -4.53 | P5B-type_ATPase | interpro domains | IPR047821 | 4 | 1 | 18521 | 50 |
ATP13A4 |
1.076e-02 | -4.53 | Gprotein_alpha_Q | interpro domains | IPR000654 | 4 | 1 | 18521 | 50 |
GNA14 |
1.076e-02 | -4.53 | Glyco_transf_54 | interpro domains | IPR006759 | 4 | 1 | 18521 | 50 |
MGAT4C |
1.076e-02 | -4.53 | Desmoplakin_Spectrin-like | interpro domains | IPR041573 | 4 | 1 | 18521 | 50 |
MACF1 |
1.076e-02 | -4.53 | PCN-like_spectrin-like_rpt | interpro domains | IPR049538 | 4 | 1 | 18521 | 50 |
MACF1 |
1.076e-02 | -4.53 | NHS-like | interpro domains | IPR024845 | 4 | 1 | 18521 | 50 |
NHSL1 |
1.076e-02 | -4.53 | AbLIM_anchor | interpro domains | IPR032402 | 4 | 1 | 18521 | 50 |
ABLIM1 |
1.076e-02 | -4.53 | Alpha_catenin | interpro domains | IPR001033 | 4 | 1 | 18521 | 50 |
CTNNA2 |
1.076e-02 | -4.53 | FGF_rcpt_fam | interpro domains | IPR016248 | 4 | 1 | 18521 | 50 |
FGFR3 |
1.076e-02 | -4.53 | ASD2_dom | interpro domains | IPR014799 | 4 | 1 | 18521 | 50 |
SHROOM3 |
1.076e-02 | -4.53 | response to organonitrogen compound | biological process | GO:0010243 | 915 | 7 | 18204 | 49 |
GNA14,GABRB1,SLC1A3,RYR3,SORBS1,SLC1A2,TNIK |
1.077e-02 | -4.53 | Sorb | smart domains | SM00459 | 3 | 1 | 9717 | 35 |
SORBS1 |
1.077e-02 | -4.53 | PLP | smart domains | SM00002 | 3 | 1 | 9717 | 35 |
GPM6A |
1.079e-02 | -4.53 | MYELIN_PLP_1 | prosite domains | PS00575 | 3 | 1 | 12186 | 44 |
GPM6A |
1.079e-02 | -4.53 | SHD | prosite domains | PS51070 | 3 | 1 | 12186 | 44 |
STON2 |
1.079e-02 | -4.53 | VINCULIN_1 | prosite domains | PS00663 | 3 | 1 | 12186 | 44 |
CTNNA2 |
1.079e-02 | -4.53 | SOHO | prosite domains | PS50831 | 3 | 1 | 12186 | 44 |
SORBS1 |
1.079e-02 | -4.53 | ASD1 | prosite domains | PS51306 | 3 | 1 | 12186 | 44 |
SHROOM3 |
1.079e-02 | -4.53 | MYELIN_PLP_2 | prosite domains | PS01004 | 3 | 1 | 12186 | 44 |
GPM6A |
1.080e-02 | -4.53 | ACTB (actin beta) | protein interactions | 60 | 958 | 7 | 19454 | 50 |
SORBS1,SFXN5,NHSL1,FMN2,MACF1,ABLIM1,DTNA |
1.082e-02 | -4.53 | skeletal system development | biological process | GO:0001501 | 500 | 5 | 18204 | 49 |
RANBP3L,FGFR3,GLI3,SOX5,BMPR1B |
1.092e-02 | -4.52 | upper_aerodigestive_tract | COSMIC cancer mutations | upper_aerodigestive_tract | 13181 | 45 | 16828 | 49 |
NTM,NKAIN3,SOX5,MACF1,CACHD1,SLC4A4,GPC5,RFX4,GABRB1,RORA,GLI3,DTNA,SLC1A2,PREX2,ZNRF3,FGFR3,ABLIM1,NTRK2,CTNND2,SORBS1,STON2,TNIK,MSI2,SFXN5,FBXL7,LSAMP,NHSL1,MGAT4C,HIF3A,RANBP3L,BMPR1B,ATP1A2,NPAS3,GPM6A,PAMR1,SLC1A3,SHROOM3,PARD3B,GNA14,FMN2,GLIS3,RYR3,ATP13A4,PITPNC1,ADCY2 |
1.097e-02 | -4.51 | AbLIM_anchor | pfam domains | PF16182 | 4 | 1 | 17795 | 49 |
ABLIM1 |
1.097e-02 | -4.51 | Spectrin_4 | pfam domains | PF21020 | 4 | 1 | 17795 | 49 |
MACF1 |
1.097e-02 | -4.51 | NHS | pfam domains | PF15273 | 4 | 1 | 17795 | 49 |
NHSL1 |
1.097e-02 | -4.51 | ASD2 | pfam domains | PF08687 | 4 | 1 | 17795 | 49 |
SHROOM3 |
1.097e-02 | -4.51 | NKAIN | pfam domains | PF05640 | 4 | 1 | 17795 | 49 |
NKAIN3 |
1.097e-02 | -4.51 | Spectrin_3 | pfam domains | PF21019 | 4 | 1 | 17795 | 49 |
MACF1 |
1.097e-02 | -4.51 | Glyco_transf_54 | pfam domains | PF04666 | 4 | 1 | 17795 | 49 |
MGAT4C |
1.097e-02 | -4.51 | Spectrin_2 | pfam domains | PF18373 | 4 | 1 | 17795 | 49 |
MACF1 |
1.097e-02 | -4.51 | P5-ATPase | pfam domains | PF12409 | 4 | 1 | 17795 | 49 |
ATP13A4 |
1.098e-02 | -4.51 | primitive_neuroectodermal_tumour-medulloblastoma | COSMIC cancer mutations | primitive_neuroectodermal_tumour-medulloblastoma | 15350 | 49 | 16828 | 49 |
ADCY2,AQP4,PITPNC1,GLIS3,FMN2,GNA14,SHROOM3,PARD3B,ATP13A4,RYR3,GPM6A,PAMR1,SLC1A3,ATP1A2,BMPR1B,RANBP3L,NPAS3,SFXN5,FBXL7,GLUD1,TNIK,MSI2,HIF3A,NHSL1,MGAT4C,LSAMP,CPE,NTRK2,ABLIM1,FGFR3,STON2,CTNND2,SORBS1,RORA,DTNA,GLI3,GABRB1,RFX4,SPARCL1,ZNRF3,PREX2,SLC1A2,CACHD1,NKAIN3,MACF1,SOX5,NTM,GPC5,SLC4A4 |
1.101e-02 | -4.51 | endochondral bone morphogenesis | biological process | GO:0060350 | 59 | 2 | 18204 | 49 |
BMPR1B,FGFR3 |
1.103e-02 | -4.51 | skin-upper_leg-malignant_melanoma | COSMIC cancer mutations | skin-upper_leg-malignant_melanoma | 850 | 7 | 16828 | 49 |
STON2,PAMR1,PREX2,HIF3A,SHROOM3,FMN2,GLIS3 |
1.104e-02 | -4.51 | EZR (ezrin) | protein interactions | 7430 | 526 | 5 | 19454 | 50 |
MACF1,TNIK,SORBS1,ABLIM1,DTNA |
1.118e-02 | -4.49 | parathyroid-carcinoma | COSMIC cancer mutations | parathyroid-carcinoma | 300 | 4 | 16828 | 49 |
GPC5,PAMR1,MACF1,RYR3 |
1.126e-02 | -4.49 | monoatomic cation homeostasis | biological process | GO:0055080 | 505 | 5 | 18204 | 49 |
SLC4A4,ATP13A4,ATP1A2,RYR3,SLC1A3 |
1.137e-02 | -4.48 | regulation of glucose import | biological process | GO:0046324 | 60 | 2 | 18204 | 49 |
SLC1A2,SORBS1 |
1.137e-02 | -4.48 | export across plasma membrane | biological process | GO:0140115 | 60 | 2 | 18204 | 49 |
ATP1A2,SLC4A4 |
1.137e-02 | -4.48 | transmission of nerve impulse | biological process | GO:0019226 | 60 | 2 | 18204 | 49 |
ATP1A2,NTRK2 |
1.137e-02 | -4.48 | protein homotetramerization | biological process | GO:0051289 | 60 | 2 | 18204 | 49 |
RYR3,AQP4 |
1.138e-02 | -4.48 | head_neck | COSMIC cancer mutations | head_neck | 15361 | 49 | 16828 | 49 |
GPM6A,SLC1A3,PAMR1,RANBP3L,BMPR1B,ATP1A2,NPAS3,PITPNC1,AQP4,ADCY2,PARD3B,SHROOM3,GNA14,FMN2,GLIS3,RYR3,ATP13A4,RFX4,GABRB1,GLI3,DTNA,RORA,SLC1A2,PREX2,SPARCL1,ZNRF3,NTM,MACF1,SOX5,NKAIN3,CACHD1,SLC4A4,GPC5,MSI2,TNIK,FBXL7,GLUD1,SFXN5,LSAMP,MGAT4C,NHSL1,HIF3A,FGFR3,ABLIM1,NTRK2,CPE,SORBS1,CTNND2,STON2 |
1.143e-02 | -4.47 | human chr4q34.2 | chromosome location | human chr4q34.2 | 6 | 1 | 26134 | 50 |
GPM6A |
1.143e-02 | -4.47 | human chr14q13.1 | chromosome location | human chr14q13.1 | 6 | 1 | 26134 | 50 |
NPAS3 |
1.145e-02 | -4.47 | YWHAG (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein gamma) | protein interactions | 7532 | 1211 | 8 | 19454 | 50 |
FMN2,NHSL1,PARD3B,SHROOM3,PITPNC1,SORBS1,ABLIM1,MACF1 |
1.148e-02 | -4.47 | adrenal_cortical_adenoma | COSMIC cancer mutations | adrenal_cortical_adenoma | 161 | 3 | 16828 | 49 |
FMN2,CACHD1,ADCY2 |
1.149e-02 | -4.47 | GABA receptor activation | REACTOME pathways | R-HSA-977443 | 56 | 2 | 10285 | 30 |
GABRB1,ADCY2 |
1.149e-02 | -4.47 | Ion homeostasis | REACTOME pathways | R-HSA-5578775 | 56 | 2 | 10285 | 30 |
RYR3,ATP1A2 |
1.160e-02 | -4.46 | skin-benign_melanocytic_nevus-junctional | COSMIC cancer mutations | skin-benign_melanocytic_nevus-junctional | 4 | 1 | 16828 | 49 |
FGFR3 |
1.160e-02 | -4.46 | skin-lower_leg-malignant_melanoma-nodular | COSMIC cancer mutations | skin-lower_leg-malignant_melanoma-nodular | 4 | 1 | 16828 | 49 |
PREX2 |
1.160e-02 | -4.46 | inverted | COSMIC cancer mutations | inverted | 4 | 1 | 16828 | 49 |
FGFR3 |
1.160e-02 | -4.46 | urinary_tract-bladder-other-normal | COSMIC cancer mutations | urinary_tract-bladder-other-normal | 4 | 1 | 16828 | 49 |
FGFR3 |
1.160e-02 | -4.46 | skin-face-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-face-malignant_melanoma-superficial_spreading | 4 | 1 | 16828 | 49 |
PREX2 |
1.160e-02 | -4.46 | urinary_tract-bladder-papilloma-inverted | COSMIC cancer mutations | urinary_tract-bladder-papilloma-inverted | 4 | 1 | 16828 | 49 |
FGFR3 |
1.160e-02 | -4.46 | Ectoderm Differentiation | WikiPathways | WP2858 | 143 | 3 | 5310 | 18 |
GLI3,CTNND2,CTNNA2 |
1.166e-02 | -4.45 | ion binding | molecular function | GO:0043167 | 6007 | 24 | 18094 | 48 |
FGFR3,ATP13A4,PAMR1,GLUD1,BMPR1B,SLC1A2,SPARCL1,MGAT4C,GNA14,ABLIM1,NTRK2,PITPNC1,ZNRF3,CPE,TNIK,DTNA,ATP1A2,MACF1,ADCY2,SLC1A3,GLI3,RORA,RYR3,GLIS3 |
1.169e-02 | -4.45 | postsynaptic specialization | cellular component | GO:0099572 | 345 | 4 | 19108 | 49 |
GABRB1,NTRK2,CTNND2,TNIK |
1.178e-02 | -4.44 | transmembrane receptor protein tyrosine kinase activity | molecular function | GO:0004714 | 62 | 2 | 18094 | 48 |
FGFR3,NTRK2 |
1.201e-02 | -4.42 | RYANODINER | prints domains | PR00795 | 3 | 1 | 5227 | 21 |
RYR3 |
1.201e-02 | -4.42 | NTKRECEPTOR | prints domains | PR01939 | 3 | 1 | 5227 | 21 |
NTRK2 |
1.201e-02 | -4.42 | GABAARBETA | prints domains | PR01160 | 3 | 1 | 5227 | 21 |
GABRB1 |
1.201e-02 | -4.42 | RORNUCRECPTR | prints domains | PR01293 | 3 | 1 | 5227 | 21 |
RORA |
1.201e-02 | -4.42 | MYELINPLP | prints domains | PR00214 | 3 | 1 | 5227 | 21 |
GPM6A |
1.205e-02 | -4.42 | Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 7434 | 30 | 16828 | 49 |
SPARCL1,PREX2,SLC1A3,PAMR1,DTNA,GLI3,RORA,NPAS3,SLC4A4,ATP1A2,CACHD1,SOX5,MACF1,NKAIN3,HIF3A,ADCY2,TNIK,RYR3,SORBS1,CTNND2,ATP13A4,STON2,GNA14,ABLIM1,PARD3B,SHROOM3,FGFR3,NTRK2,GLIS3,FMN2 |
1.209e-02 | -4.42 | kidney | COSMIC cancer mutations | kidney | 15380 | 49 | 16828 | 49 |
CTNND2,SORBS1,STON2,FGFR3,ABLIM1,CPE,NTRK2,LSAMP,NHSL1,MGAT4C,HIF3A,TNIK,MSI2,SFXN5,GLUD1,FBXL7,SLC4A4,GPC5,NTM,NKAIN3,SOX5,MACF1,CACHD1,SLC1A2,PREX2,SPARCL1,ZNRF3,RFX4,GABRB1,RORA,GLI3,DTNA,RYR3,ATP13A4,SHROOM3,PARD3B,GNA14,FMN2,GLIS3,AQP4,PITPNC1,ADCY2,NPAS3,RANBP3L,BMPR1B,ATP1A2,PAMR1,SLC1A3,GPM6A |
1.211e-02 | -4.41 | - | gene3d domains | 6.10.250.3120 | 4 | 1 | 14470 | 44 |
SHROOM3 |
1.211e-02 | -4.41 | - | gene3d domains | 1.20.58.1060 | 4 | 1 | 14470 | 44 |
MACF1 |
1.216e-02 | -4.41 | parathyroid | COSMIC cancer mutations | parathyroid | 476 | 5 | 16828 | 49 |
PAMR1,MACF1,GPM6A,GPC5,RYR3 |
1.218e-02 | -4.41 | monoatomic ion homeostasis | biological process | GO:0050801 | 515 | 5 | 18204 | 49 |
SLC4A4,ATP13A4,ATP1A2,RYR3,SLC1A3 |
1.223e-02 | -4.40 | astrocytoma_Grade_III | COSMIC cancer mutations | astrocytoma_Grade_III | 1544 | 10 | 16828 | 49 |
GNA14,GABRB1,SHROOM3,FGFR3,CACHD1,RYR3,GPC5,ADCY2,STON2,PAMR1 |
1.223e-02 | -4.40 | D-Glutamine and D-glutamate metabolism | KEGG pathways | hsa00471 | 4 | 1 | 7161 | 22 |
GLUD1 |
1.223e-02 | -4.40 | D-Glutamine and D-glutamate metabolism | KEGG pathways | ko00471 | 4 | 1 | 7161 | 22 |
GLUD1 |
1.229e-02 | -4.40 | Ion transport by P-type ATPases | REACTOME pathways | R-HSA-936837 | 58 | 2 | 10285 | 30 |
ATP13A4,ATP1A2 |
1.245e-02 | -4.39 | camera-type eye development | biological process | GO:0043010 | 335 | 4 | 18204 | 49 |
BMPR1B,NTRK2,GPM6A,GLI3 |
1.249e-02 | -4.38 | back | COSMIC cancer mutations | back | 310 | 4 | 16828 | 49 |
PREX2,ATP1A2,TNIK,FGFR3 |
1.250e-02 | -4.38 | cell adhesion | biological process | GO:0007155 | 942 | 7 | 18204 | 49 |
CTNND2,LSAMP,SORBS1,NTM,CTNNA2,SPARCL1,PARD3B |
1.279e-02 | -4.36 | Rab38 (RAB38, member RAS oncogene family) | protein interactions | 72433 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | Rhoj (ras homolog family member J) | protein interactions | 80837 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | SLC10A3 (solute carrier family 10 member 3) | protein interactions | 8273 | 5 | 1 | 19454 | 50 |
SORBS1 |
1.279e-02 | -4.36 | Rhobtb1 (Rho-related BTB domain containing 1) | protein interactions | 69288 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | Rras2 (related RAS viral (r-ras) oncogene 2) | protein interactions | 66922 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | Rab6b (RAB6B, member RAS oncogene family) | protein interactions | 270192 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | Wwp2 (WW domain containing E3 ubiquitin protein ligase 2) | protein interactions | 66894 | 5 | 1 | 19454 | 50 |
GLIS3 |
1.279e-02 | -4.36 | RFX4 (regulatory factor X4) | protein interactions | 5992 | 5 | 1 | 19454 | 50 |
RFX4 |
1.279e-02 | -4.36 | TRH (thyrotropin releasing hormone) | protein interactions | 7200 | 5 | 1 | 19454 | 50 |
CPE |
1.279e-02 | -4.36 | Cdk4 (cyclin dependent kinase 4) | protein interactions | 12567 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.287e-02 | -4.35 | cranial nerve development | biological process | GO:0021545 | 64 | 2 | 18204 | 49 |
GLI3,SLC1A3 |
1.287e-02 | -4.35 | actin filament bundle assembly | biological process | GO:0051017 | 64 | 2 | 18204 | 49 |
FMN2,SORBS1 |
1.302e-02 | -4.34 | Synaptic Vesicle Pathway | WikiPathways | WP2267 | 52 | 2 | 5310 | 18 |
SLC1A3,ATP1A2 |
1.302e-02 | -4.34 | pancreas-carcinoma | COSMIC cancer mutations | pancreas-carcinoma | 14770 | 48 | 16828 | 49 |
ATP13A4,STON2,RYR3,SORBS1,CTNND2,GLIS3,NTRK2,CPE,FMN2,ABLIM1,GNA14,PARD3B,SHROOM3,FGFR3,HIF3A,ADCY2,PITPNC1,MGAT4C,NHSL1,AQP4,LSAMP,GLUD1,FBXL7,SFXN5,MSI2,TNIK,GPC5,NPAS3,SLC4A4,ATP1A2,CACHD1,MACF1,SOX5,BMPR1B,NKAIN3,RANBP3L,NTM,SPARCL1,ZNRF3,SLC1A3,PREX2,PAMR1,SLC1A2,GPM6A,GLI3,RORA,GABRB1,RFX4 |
1.312e-02 | -4.33 | regulation of carbohydrate metabolic process | biological process | GO:0006109 | 183 | 3 | 18204 | 49 |
SORBS1,RORA,SLC4A4 |
1.317e-02 | -4.33 | carboxylic acid transmembrane transporter activity | molecular function | GO:0046943 | 186 | 3 | 18094 | 48 |
SFXN5,SLC1A3,SLC1A2 |
1.320e-02 | -4.33 | fibroblast growth factor receptor activity | molecular function | GO:0005007 | 5 | 1 | 18094 | 48 |
FGFR3 |
1.320e-02 | -4.33 | transforming growth factor beta receptor activity, type I | molecular function | GO:0005025 | 5 | 1 | 18094 | 48 |
BMPR1B |
1.320e-02 | -4.33 | neurotrophin receptor activity | molecular function | GO:0005030 | 5 | 1 | 18094 | 48 |
NTRK2 |
1.327e-02 | -4.32 | L-amino acid transmembrane transporter activity | molecular function | GO:0015179 | 66 | 2 | 18094 | 48 |
SLC1A2,SLC1A3 |
1.328e-02 | -4.32 | signal transduction | biological process | GO:0007165 | 4637 | 20 | 18204 | 49 |
FGFR3,TNIK,ADCY2,SPARCL1,GLI3,GNA14,FMN2,RORA,CPE,ATP1A2,ZNRF3,SORBS1,RYR3,PREX2,PITPNC1,NTRK2,BMPR1B,CTNND2,MACF1,DTNA |
1.330e-02 | -4.32 | cellular response to stimulus | biological process | GO:0051716 | 6307 | 25 | 18204 | 49 |
GNA14,AQP4,CPE,ADCY2,TNIK,MACF1,DTNA,SHROOM3,SLC1A2,RYR3,ATP1A2,NTRK2,PITPNC1,GLI3,GABRB1,RORA,FMN2,FGFR3,SLC1A3,SPARCL1,CTNND2,SORBS1,ZNRF3,PREX2,BMPR1B |
1.332e-02 | -4.32 | testis-germ_cell_tumour-non_seminoma | COSMIC cancer mutations | testis-germ_cell_tumour-non_seminoma | 487 | 5 | 16828 | 49 |
TNIK,FGFR3,NTRK2,BMPR1B,MACF1 |
1.332e-02 | -4.32 | human chr8q13.2 | chromosome location | human chr8q13.2 | 7 | 1 | 26134 | 50 |
PREX2 |
1.336e-02 | -4.32 | organic acid transmembrane transporter activity | molecular function | GO:0005342 | 187 | 3 | 18094 | 48 |
SLC1A3,SFXN5,SLC1A2 |
1.339e-02 | -4.31 | citrate transport | biological process | GO:0015746 | 5 | 1 | 18204 | 49 |
SFXN5 |
1.339e-02 | -4.31 | synaptic signaling via neuropeptide | biological process | GO:0099538 | 5 | 1 | 18204 | 49 |
NTRK2 |
1.339e-02 | -4.31 | polar body extrusion after meiotic divisions | biological process | GO:0040038 | 5 | 1 | 18204 | 49 |
FMN2 |
1.339e-02 | -4.31 | tricarboxylic acid transport | biological process | GO:0006842 | 5 | 1 | 18204 | 49 |
SFXN5 |
1.339e-02 | -4.31 | amygdala development | biological process | GO:0021764 | 5 | 1 | 18204 | 49 |
ATP1A2 |
1.339e-02 | -4.31 | negative regulation of chondrocyte proliferation | biological process | GO:1902731 | 5 | 1 | 18204 | 49 |
BMPR1B |
1.342e-02 | -4.31 | salivary_gland-carcinoma-adenoid_cystic_carcinoma | COSMIC cancer mutations | salivary_gland-carcinoma-adenoid_cystic_carcinoma | 488 | 5 | 16828 | 49 |
MGAT4C,RORA,RYR3,GABRB1,CTNND2 |
1.343e-02 | -4.31 | Mtc | interpro domains | IPR004686 | 5 | 1 | 18521 | 50 |
SFXN5 |
1.343e-02 | -4.31 | P-type_TPase_V | interpro domains | IPR006544 | 5 | 1 | 18521 | 50 |
ATP13A4 |
1.343e-02 | -4.31 | Vinculin/catenin | interpro domains | IPR006077 | 5 | 1 | 18521 | 50 |
CTNNA2 |
1.343e-02 | -4.31 | PI_transfer | interpro domains | IPR001666 | 5 | 1 | 18521 | 50 |
PITPNC1 |
1.343e-02 | -4.31 | Follistatin/Osteonectin_EGF | interpro domains | IPR015369 | 5 | 1 | 18521 | 50 |
SPARCL1 |
1.343e-02 | -4.31 | Na/HCO3_transpt | interpro domains | IPR003024 | 5 | 1 | 18521 | 50 |
SLC4A4 |
1.356e-02 | -4.30 | arm | COSMIC cancer mutations | arm | 1331 | 9 | 16828 | 49 |
FGFR3,NTM,PARD3B,SHROOM3,MACF1,ATP1A2,SORBS1,NPAS3,SLC4A4 |
1.364e-02 | -4.29 | L-alpha-amino acid transmembrane transport | biological process | GO:1902475 | 66 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
1.367e-02 | -4.29 | neoplasm | COSMIC cancer mutations | neoplasm | 14787 | 48 | 16828 | 49 |
NTM,CACHD1,SOX5,MACF1,NKAIN3,GPC5,SLC4A4,GABRB1,RFX4,GLI3,DTNA,RORA,SLC1A2,SPARCL1,ZNRF3,PREX2,ABLIM1,FGFR3,NTRK2,CPE,SORBS1,CTNND2,STON2,MSI2,TNIK,GLUD1,FBXL7,SFXN5,LSAMP,HIF3A,MGAT4C,NHSL1,RANBP3L,ATP1A2,BMPR1B,NPAS3,GPM6A,SLC1A3,PAMR1,GNA14,SHROOM3,PARD3B,GLIS3,FMN2,RYR3,ATP13A4,ADCY2,AQP4 |
1.369e-02 | -4.29 | Vinculin | pfam domains | PF01044 | 5 | 1 | 17795 | 49 |
CTNNA2 |
1.369e-02 | -4.29 | IP_trans | pfam domains | PF02121 | 5 | 1 | 17795 | 49 |
PITPNC1 |
1.369e-02 | -4.29 | SFXNs | pfam domains | PF03820 | 5 | 1 | 17795 | 49 |
SFXN5 |
1.369e-02 | -4.29 | FOLN | pfam domains | PF09289 | 5 | 1 | 17795 | 49 |
SPARCL1 |
1.387e-02 | -4.28 | non_seminoma | COSMIC cancer mutations | non_seminoma | 492 | 5 | 16828 | 49 |
FGFR3,TNIK,NTRK2,MACF1,BMPR1B |
1.392e-02 | -4.27 | calcium channel complex | cellular component | GO:0034704 | 70 | 2 | 19108 | 49 |
CACHD1,RYR3 |
1.399e-02 | -4.27 | PCDH20 (protocadherin 20) | protein interactions | 64881 | 70 | 2 | 19454 | 50 |
CTNNA2,MGAT4C |
1.404e-02 | -4.27 | virilizing_syndrome_producing | COSMIC cancer mutations | virilizing_syndrome_producing | 321 | 4 | 16828 | 49 |
CACHD1,ATP1A2,FMN2,CTNND2 |
1.407e-02 | -4.26 | RAB35 (RAB35, member RAS oncogene family) | protein interactions | 11021 | 559 | 5 | 19454 | 50 |
DTNA,MACF1,CACHD1,FMN2,SLC1A3 |
1.418e-02 | -4.26 | hepatocellular_carcinoma | COSMIC cancer mutations | hepatocellular_carcinoma | 14800 | 48 | 16828 | 49 |
NPAS3,RANBP3L,BMPR1B,ATP1A2,SLC1A3,PAMR1,GPM6A,RYR3,ATP13A4,SHROOM3,PARD3B,GNA14,FMN2,GLIS3,PITPNC1,AQP4,ADCY2,SLC4A4,GPC5,NTM,SOX5,MACF1,NKAIN3,CACHD1,SLC1A2,PREX2,ZNRF3,SPARCL1,RFX4,GABRB1,DTNA,GLI3,RORA,SORBS1,CTNND2,STON2,FGFR3,ABLIM1,NTRK2,CPE,LSAMP,MGAT4C,NHSL1,HIF3A,TNIK,GLUD1,FBXL7,SFXN5 |
1.418e-02 | -4.26 | liver-carcinoma-hepatocellular_carcinoma | COSMIC cancer mutations | liver-carcinoma-hepatocellular_carcinoma | 14800 | 48 | 16828 | 49 |
FGFR3,ABLIM1,NTRK2,CPE,SORBS1,CTNND2,STON2,TNIK,GLUD1,FBXL7,SFXN5,LSAMP,MGAT4C,NHSL1,HIF3A,NTM,SOX5,MACF1,NKAIN3,CACHD1,SLC4A4,GPC5,RFX4,GABRB1,GLI3,DTNA,RORA,SLC1A2,PREX2,SPARCL1,ZNRF3,PARD3B,SHROOM3,GNA14,FMN2,GLIS3,RYR3,ATP13A4,PITPNC1,AQP4,ADCY2,RANBP3L,BMPR1B,ATP1A2,NPAS3,GPM6A,SLC1A3,PAMR1 |
1.429e-02 | -4.25 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_leukaemia | 2081 | 12 | 16828 | 49 |
BMPR1B,DTNA,SOX5,GLI3,CACHD1,NTRK2,ATP1A2,FGFR3,TNIK,SLC4A4,PREX2,ADCY2 |
1.433e-02 | -4.25 | haematopoietic_and_lymphoid_tissue-spleen-lymphoid_neoplasm-marginal_zone_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-spleen-lymphoid_neoplasm-marginal_zone_lymphoma | 323 | 4 | 16828 | 49 |
ADCY2,PARD3B,SORBS1,NTM |
1.437e-02 | -4.24 | ASD2 | prosite domains | PS51307 | 4 | 1 | 12186 | 44 |
SHROOM3 |
1.437e-02 | -4.24 | ANK2 (ankyrin 2) | protein interactions | 287 | 71 | 2 | 19454 | 50 |
TNIK,GPM6A |
1.444e-02 | -4.24 | actin filament bundle organization | biological process | GO:0061572 | 68 | 2 | 18204 | 49 |
SORBS1,FMN2 |
1.448e-02 | -4.24 | lichenoid_keratosis | COSMIC cancer mutations | lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-upper_arm-other-lichenoid_keratosis | COSMIC cancer mutations | skin-upper_arm-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-shoulder-other-nevus_sebaceous | COSMIC cancer mutations | skin-shoulder-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-upper_leg-other-lichenoid_keratosis | COSMIC cancer mutations | skin-upper_leg-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-shoulder-other-lichenoid_keratosis | COSMIC cancer mutations | skin-shoulder-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-flank-other-lichenoid_keratosis | COSMIC cancer mutations | skin-flank-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-face-other-lichenoid_keratosis | COSMIC cancer mutations | skin-face-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-lower_leg-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-lower_leg-malignant_melanoma-superficial_spreading | 5 | 1 | 16828 | 49 |
PREX2 |
1.448e-02 | -4.24 | skin-neck-other-nevus_sebaceous | COSMIC cancer mutations | skin-neck-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | syringocystadenoma_papilliferum | COSMIC cancer mutations | syringocystadenoma_papilliferum | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-arm-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-arm-other-seborrhoeic_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-hip-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-hip-other-seborrhoeic_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-neck-other-lichenoid_keratosis | COSMIC cancer mutations | skin-neck-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-other-lichenoid_keratosis | COSMIC cancer mutations | skin-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-forearm-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-forearm-other-seborrhoeic_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-chest-other-lichenoid_keratosis | COSMIC cancer mutations | skin-chest-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-lower_back-other-nevus_sebaceous | COSMIC cancer mutations | skin-lower_back-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-forearm-other-lichenoid_keratosis | COSMIC cancer mutations | skin-forearm-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-hand-other-lichenoid_keratosis | COSMIC cancer mutations | skin-hand-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-monoclonal_gammopathy_of_undetermined_significance | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-monoclonal_gammopathy_of_undetermined_significance | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | monoclonal_gammopathy_of_undetermined_significance | COSMIC cancer mutations | monoclonal_gammopathy_of_undetermined_significance | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-face-other-nevus_sebaceous | COSMIC cancer mutations | skin-face-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-breast-other-lichenoid_keratosis | COSMIC cancer mutations | skin-breast-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-lower_back-other-lichenoid_keratosis | COSMIC cancer mutations | skin-lower_back-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-lower_leg-other-lichenoid_keratosis | COSMIC cancer mutations | skin-lower_leg-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-scalp-other-nevus_sebaceous | COSMIC cancer mutations | skin-scalp-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-upper_back-other-lichenoid_keratosis | COSMIC cancer mutations | skin-upper_back-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-ear-other-nevus_sebaceous | COSMIC cancer mutations | skin-ear-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-adnexal_tumour-syringocystadenoma_papilliferum | COSMIC cancer mutations | skin-adnexal_tumour-syringocystadenoma_papilliferum | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-breast-other-nevus_sebaceous | COSMIC cancer mutations | skin-breast-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.23 | PDZ | smart domains | SM00228 | 143 | 3 | 9717 | 35 |
PARD3B,PREX2,SHROOM3 |
1.450e-02 | -4.23 | NGF-independant TRKA activation | REACTOME pathways | R-HSA-187024 | 5 | 1 | 10285 | 30 |
NTRK2 |
1.451e-02 | -4.23 | NTRK3 (neurotrophic receptor tyrosine kinase 3) | protein interactions | 4916 | 367 | 4 | 19454 | 50 |
ABLIM1,GLUD1,TNIK,NTRK2 |
1.462e-02 | -4.23 | cellular response to organic substance | biological process | GO:0071310 | 1716 | 10 | 18204 | 49 |
RORA,AQP4,GNA14,GABRB1,RYR3,SORBS1,SLC1A3,ATP1A2,ADCY2,SLC1A2 |
1.475e-02 | -4.22 | PDZ | prosite domains | PS50106 | 143 | 3 | 12186 | 44 |
PREX2,SHROOM3,PARD3B |
1.476e-02 | -4.22 | Ppp1cb (protein phosphatase 1 catalytic subunit beta) | protein interactions | 19046 | 72 | 2 | 19454 | 50 |
STON2,ABLIM1 |
1.476e-02 | -4.22 | PPP3CC (protein phosphatase 3 catalytic subunit gamma) | protein interactions | 5533 | 72 | 2 | 19454 | 50 |
BMPR1B,PARD3B |
1.476e-02 | -4.22 | DPYSL3 (dihydropyrimidinase like 3) | protein interactions | 1809 | 72 | 2 | 19454 | 50 |
TNIK,GPM6A |
1.499e-02 | -4.20 | ARF6 (ADP ribosylation factor 6) | protein interactions | 382 | 568 | 5 | 19454 | 50 |
GLUD1,CACHD1,TNIK,FMN2,SLC1A3 |
1.500e-02 | -4.20 | adenoid_cystic_carcinoma | COSMIC cancer mutations | adenoid_cystic_carcinoma | 1123 | 8 | 16828 | 49 |
NTRK2,MGAT4C,RORA,RYR3,GABRB1,CTNND2,FGFR3,TNIK |
1.508e-02 | -4.19 | upper_back | COSMIC cancer mutations | upper_back | 328 | 4 | 16828 | 49 |
FGFR3,PARD3B,MACF1,GPC5 |
1.520e-02 | -4.19 | skin-scalp-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-scalp-carcinoma-squamous_cell_carcinoma | 1596 | 10 | 16828 | 49 |
FGFR3,SHROOM3,RORA,MACF1,SOX5,ATP1A2,LSAMP,SLC4A4,ATP13A4,GPC5 |
1.526e-02 | -4.18 | ovulation cycle | biological process | GO:0042698 | 70 | 2 | 18204 | 49 |
GABRB1,BMPR1B |
1.532e-02 | -4.18 | ADCY1 (adenylate cyclase 1) | protein interactions | 107 | 6 | 1 | 19454 | 50 |
ADCY2 |
1.532e-02 | -4.18 | GDF6 (growth differentiation factor 6) | protein interactions | 392255 | 6 | 1 | 19454 | 50 |
BMPR1B |
1.532e-02 | -4.18 | RSPO3 (R-spondin 3) | protein interactions | 84870 | 6 | 1 | 19454 | 50 |
ZNRF3 |
1.532e-02 | -4.18 | SOX11 (SRY-box transcription factor 11) | protein interactions | 6664 | 6 | 1 | 19454 | 50 |
SOX5 |
1.532e-02 | -4.18 | Zbtb2 (zinc finger and BTB domain containing 2) | protein interactions | 381990 | 6 | 1 | 19454 | 50 |
SORBS1 |
1.532e-02 | -4.18 | Map2k3 (mitogen-activated protein kinase kinase 3) | protein interactions | 26397 | 6 | 1 | 19454 | 50 |
BMPR1B |
1.532e-02 | -4.18 | Rhod (ras homolog family member D) | protein interactions | 11854 | 6 | 1 | 19454 | 50 |
BMPR1B |
1.532e-02 | -4.18 | Tiam2 (T cell lymphoma invasion and metastasis 2) | protein interactions | 24001 | 6 | 1 | 19454 | 50 |
DTNA |
1.532e-02 | -4.18 | Fancl (Fanconi anemia, complementation group L) | protein interactions | 67030 | 6 | 1 | 19454 | 50 |
BMPR1B |
1.532e-02 | -4.18 | SOX1 (SRY-box transcription factor 1) | protein interactions | 6656 | 6 | 1 | 19454 | 50 |
SOX5 |
1.532e-02 | -4.18 | FGF6 (fibroblast growth factor 6) | protein interactions | 2251 | 6 | 1 | 19454 | 50 |
FGFR3 |
1.532e-02 | -4.18 | SLC12A5 (solute carrier family 12 member 5) | protein interactions | 57468 | 6 | 1 | 19454 | 50 |
GPM6A |
1.532e-02 | -4.18 | Klhl22 (kelch-like 22) | protein interactions | 224023 | 6 | 1 | 19454 | 50 |
GLUD1 |
1.532e-02 | -4.18 | CYRIA (CYFIP related Rac1 interactor A) | protein interactions | 81553 | 6 | 1 | 19454 | 50 |
GPM6A |
1.532e-02 | -4.18 | FGF18 (fibroblast growth factor 18) | protein interactions | 8817 | 6 | 1 | 19454 | 50 |
FGFR3 |
1.532e-02 | -4.18 | Itch (itchy, E3 ubiquitin protein ligase) | protein interactions | 16396 | 6 | 1 | 19454 | 50 |
GLIS3 |
1.532e-02 | -4.18 | FGF23 (fibroblast growth factor 23) | protein interactions | 8074 | 6 | 1 | 19454 | 50 |
FGFR3 |
1.532e-02 | -4.18 | DRP2 (dystrophin related protein 2) | protein interactions | 1821 | 6 | 1 | 19454 | 50 |
DTNA |
1.533e-02 | -4.18 | protein homooligomerization | biological process | GO:0051260 | 194 | 3 | 18204 | 49 |
AQP4,RYR3,SLC1A2 |
1.549e-02 | -4.17 | skin-ear-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-ear-carcinoma-squamous_cell_carcinoma | 506 | 5 | 16828 | 49 |
NPAS3,MGAT4C,SPARCL1,FGFR3,GABRB1 |
1.552e-02 | -4.17 | CASK (calcium/calmodulin dependent serine protein kinase) | protein interactions | 8573 | 204 | 3 | 19454 | 50 |
DTNA,ABLIM1,PARD3B |
1.555e-02 | -4.16 | marginal_zone_lymphoma | COSMIC cancer mutations | marginal_zone_lymphoma | 331 | 4 | 16828 | 49 |
NTM,SORBS1,PARD3B,ADCY2 |
1.581e-02 | -4.15 | calcium-induced calcium release activity | molecular function | GO:0048763 | 6 | 1 | 18094 | 48 |
RYR3 |
1.581e-02 | -4.15 | steroid hormone binding | molecular function | GO:1990239 | 6 | 1 | 18094 | 48 |
ATP1A2 |
1.581e-02 | -4.15 | sodium:bicarbonate symporter activity | molecular function | GO:0008510 | 6 | 1 | 18094 | 48 |
SLC4A4 |
1.598e-02 | -4.14 | GPROTEINAQ | prints domains | PR00442 | 4 | 1 | 5227 | 21 |
GNA14 |
1.598e-02 | -4.14 | ALPHACATENIN | prints domains | PR00805 | 4 | 1 | 5227 | 21 |
CTNNA2 |
1.600e-02 | -4.13 | other | COSMIC cancer mutations | other | 14843 | 48 | 16828 | 49 |
SFXN5,FBXL7,GLUD1,TNIK,MSI2,HIF3A,NHSL1,MGAT4C,LSAMP,CPE,NTRK2,ABLIM1,FGFR3,STON2,CTNND2,SORBS1,RORA,DTNA,GLI3,GABRB1,RFX4,SPARCL1,ZNRF3,PREX2,SLC1A2,CACHD1,NKAIN3,SOX5,MACF1,NTM,GPC5,SLC4A4,ADCY2,AQP4,GLIS3,FMN2,GNA14,SHROOM3,PARD3B,ATP13A4,RYR3,GPM6A,PAMR1,SLC1A3,ATP1A2,BMPR1B,RANBP3L,NPAS3 |
1.604e-02 | -4.13 | gamma-aminobutyric acid biosynthetic process | biological process | GO:0009449 | 6 | 1 | 18204 | 49 |
SLC1A3 |
1.604e-02 | -4.13 | intracellular water homeostasis | biological process | GO:0009992 | 6 | 1 | 18204 | 49 |
AQP4 |
1.604e-02 | -4.13 | cellular response to histamine | biological process | GO:0071420 | 6 | 1 | 18204 | 49 |
GABRB1 |
1.604e-02 | -4.13 | fused antrum stage | biological process | GO:0048165 | 6 | 1 | 18204 | 49 |
BMPR1B |
1.604e-02 | -4.13 | mammary gland formation | biological process | GO:0060592 | 6 | 1 | 18204 | 49 |
GLI3 |
1.604e-02 | -4.13 | asymmetric neuroblast division | biological process | GO:0055059 | 6 | 1 | 18204 | 49 |
SOX5 |
1.604e-02 | -4.13 | establishment of meiotic spindle localization | biological process | GO:0051295 | 6 | 1 | 18204 | 49 |
FMN2 |
1.604e-02 | -4.13 | optic nerve morphogenesis | biological process | GO:0021631 | 6 | 1 | 18204 | 49 |
GLI3 |
1.609e-02 | -4.13 | G3BP1 (G3BP stress granule assembly factor 1) | protein interactions | 10146 | 799 | 6 | 19454 | 50 |
SOX5,MACF1,GLUD1,MSI2,CTNNA2,SORBS1 |
1.609e-02 | -4.13 | RIH_dom | interpro domains | IPR000699 | 6 | 1 | 18521 | 50 |
RYR3 |
1.609e-02 | -4.13 | Adcy_conserved_dom | interpro domains | IPR009398 | 6 | 1 | 18521 | 50 |
ADCY2 |
1.609e-02 | -4.13 | RIH_assoc-dom | interpro domains | IPR013662 | 6 | 1 | 18521 | 50 |
RYR3 |
1.609e-02 | -4.13 | Ins145_P3_rcpt | interpro domains | IPR014821 | 6 | 1 | 18521 | 50 |
RYR3 |
1.609e-02 | -4.13 | EF-hand_dom_typ2 | interpro domains | IPR015154 | 6 | 1 | 18521 | 50 |
DTNA |
1.609e-02 | -4.13 | GAR_dom_sf | interpro domains | IPR036534 | 6 | 1 | 18521 | 50 |
MACF1 |
1.609e-02 | -4.13 | EF-hand_dom_typ1 | interpro domains | IPR015153 | 6 | 1 | 18521 | 50 |
DTNA |
1.609e-02 | -4.13 | GAR_dom | interpro domains | IPR003108 | 6 | 1 | 18521 | 50 |
MACF1 |
1.609e-02 | -4.13 | Ryanodine_IP3_receptor | interpro domains | IPR015925 | 6 | 1 | 18521 | 50 |
RYR3 |
1.609e-02 | -4.13 | Desmoplakin_SH3 | interpro domains | IPR041615 | 6 | 1 | 18521 | 50 |
MACF1 |
1.609e-02 | -4.13 | RyR/IP3R_RIH_dom_sf | interpro domains | IPR035910 | 6 | 1 | 18521 | 50 |
RYR3 |
1.609e-02 | -4.13 | P-type_ATPase_IIC | interpro domains | IPR005775 | 6 | 1 | 18521 | 50 |
ATP1A2 |
1.609e-02 | -4.13 | Glypican_CS | interpro domains | IPR019803 | 6 | 1 | 18521 | 50 |
GPC5 |
1.609e-02 | -4.13 | Glypican | interpro domains | IPR001863 | 6 | 1 | 18521 | 50 |
GPC5 |
1.609e-02 | -4.13 | stem cell proliferation | biological process | GO:0072089 | 72 | 2 | 18204 | 49 |
GLI3,ZNRF3 |
1.622e-02 | -4.12 | salivary_gland | COSMIC cancer mutations | salivary_gland | 1139 | 8 | 16828 | 49 |
FGFR3,CTNND2,TNIK,RYR3,GABRB1,MGAT4C,RORA,NTRK2 |
1.629e-02 | -4.12 | MKRN2 (makorin ring finger protein 2) | protein interactions | 23609 | 380 | 4 | 19454 | 50 |
BMPR1B,MACF1,GLI3,FGFR3 |
1.641e-02 | -4.11 | Ins145_P3_rec | pfam domains | PF08709 | 6 | 1 | 17795 | 49 |
RYR3 |
1.641e-02 | -4.11 | Glypican | pfam domains | PF01153 | 6 | 1 | 17795 | 49 |
GPC5 |
1.641e-02 | -4.11 | RYDR_ITPR | pfam domains | PF01365 | 6 | 1 | 17795 | 49 |
RYR3 |
1.641e-02 | -4.11 | EF-hand_2 | pfam domains | PF09068 | 6 | 1 | 17795 | 49 |
DTNA |
1.641e-02 | -4.11 | SH3_10 | pfam domains | PF17902 | 6 | 1 | 17795 | 49 |
MACF1 |
1.641e-02 | -4.11 | Plectin | pfam domains | PF00681 | 6 | 1 | 17795 | 49 |
MACF1 |
1.641e-02 | -4.11 | Adcy_cons_dom | pfam domains | PF06327 | 6 | 1 | 17795 | 49 |
ADCY2 |
1.641e-02 | -4.11 | EF-hand_3 | pfam domains | PF09069 | 6 | 1 | 17795 | 49 |
DTNA |
1.641e-02 | -4.11 | GAS2 | pfam domains | PF02187 | 6 | 1 | 17795 | 49 |
MACF1 |
1.641e-02 | -4.11 | RIH_assoc | pfam domains | PF08454 | 6 | 1 | 17795 | 49 |
RYR3 |
1.652e-02 | -4.10 | peptide metabolic process | biological process | GO:0006518 | 73 | 2 | 18204 | 49 |
SLC1A2,CPE |
1.675e-02 | -4.09 | ABI1 (abl interactor 1) | protein interactions | 10006 | 210 | 3 | 19454 | 50 |
SLC1A3,NHSL1,SORBS1 |
1.696e-02 | -4.08 | CDK6 (cyclin dependent kinase 6) | protein interactions | 1021 | 211 | 3 | 19454 | 50 |
SOX5,FGFR3,SORBS1 |
1.705e-02 | -4.07 | HAD_sf | interpro domains | IPR023214 | 74 | 2 | 18521 | 50 |
ATP13A4,ATP1A2 |
1.709e-02 | -4.07 | human chr4q22.3 | chromosome location | human chr4q22.3 | 9 | 1 | 26134 | 50 |
BMPR1B |
1.716e-02 | -4.07 | MARCKS (myristoylated alanine rich protein kinase C substrate) | protein interactions | 4082 | 588 | 5 | 19454 | 50 |
SLC1A3,ABLIM1,DTNA,MACF1,CACHD1 |
1.717e-02 | -4.06 | ANKRD40 (ankyrin repeat domain 40) | protein interactions | 91369 | 78 | 2 | 19454 | 50 |
SOX5,MSI2 |
1.717e-02 | -4.06 | Nedd4 (NEDD4 E3 ubiquitin protein ligase) | protein interactions | 25489 | 78 | 2 | 19454 | 50 |
NTRK2,BMPR1B |
1.718e-02 | -4.06 | Calcium signaling pathway | KEGG pathways | ko04020 | 181 | 3 | 7161 | 22 |
RYR3,ADCY2,GNA14 |
1.718e-02 | -4.06 | Calcium signaling pathway | KEGG pathways | hsa04020 | 181 | 3 | 7161 | 22 |
GNA14,ADCY2,RYR3 |
1.718e-02 | -4.06 | DNAJC2 (DnaJ heat shock protein family (Hsp40) member C2) | protein interactions | 27000 | 212 | 3 | 19454 | 50 |
GLUD1,MACF1,TNIK |
1.735e-02 | -4.05 | collecting_duct_carcinoma | COSMIC cancer mutations | collecting_duct_carcinoma | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-head_neck-epidermal_nevus | COSMIC cancer mutations | skin-head_neck-epidermal_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-arm-epidermal_nevus | COSMIC cancer mutations | skin-arm-epidermal_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | kidney-carcinoma-collecting_duct_carcinoma | COSMIC cancer mutations | kidney-carcinoma-collecting_duct_carcinoma | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-face-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-face-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-back-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-back-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-trunk-epidermal_nevus | COSMIC cancer mutations | skin-trunk-epidermal_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-in_situ_epithelial_neoplasm-Bowen_disease | COSMIC cancer mutations | skin-in_situ_epithelial_neoplasm-Bowen_disease | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | lentiginous_nevus | COSMIC cancer mutations | lentiginous_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-benign_melanocytic_nevus-lentiginous_nevus | COSMIC cancer mutations | skin-benign_melanocytic_nevus-lentiginous_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-abdomen-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-abdomen-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-lower_back-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-lower_back-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-lower_leg-epidermal_nevus | COSMIC cancer mutations | skin-lower_leg-epidermal_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-upper_leg-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-upper_leg-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-in_situ_epithelial_neoplasm-actinic_keratosis | COSMIC cancer mutations | skin-in_situ_epithelial_neoplasm-actinic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-forearm-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-forearm-malignant_melanoma-superficial_spreading | 6 | 1 | 16828 | 49 |
PREX2 |
1.735e-02 | -4.05 | autonomic_ganglia-paraganglioma-benign | COSMIC cancer mutations | autonomic_ganglia-paraganglioma-benign | 6 | 1 | 16828 | 49 |
NHSL1 |
1.735e-02 | -4.05 | skin-adnexal_tumour-trichoblastoma | COSMIC cancer mutations | skin-adnexal_tumour-trichoblastoma | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-epidermal_nevus | COSMIC cancer mutations | skin-epidermal_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-head_neck-malignant_melanoma | COSMIC cancer mutations | skin-head_neck-malignant_melanoma | 6 | 1 | 16828 | 49 |
PREX2 |
1.735e-02 | -4.05 | skin-flank-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-flank-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.738e-02 | -4.05 | Activation of TRKA receptors | REACTOME pathways | R-HSA-187015 | 6 | 1 | 10285 | 30 |
NTRK2 |
1.738e-02 | -4.05 | amino acid biosynthetic process | biological process | GO:0008652 | 75 | 2 | 18204 | 49 |
GLUD1,SLC1A3 |
1.747e-02 | -4.05 | small molecule binding | molecular function | GO:0036094 | 6197 | 24 | 18094 | 48 |
SLC1A2,SPARCL1,GNA14,MGAT4C,ABLIM1,ATP13A4,FGFR3,GLUD1,PAMR1,BMPR1B,GLI3,RORA,RYR3,GLIS3,NTRK2,ZNRF3,PITPNC1,TNIK,CPE,SLC1A3,ADCY2,ATP1A2,MACF1,DTNA |
1.751e-02 | -4.05 | presynaptic active zone | cellular component | GO:0048786 | 79 | 2 | 19108 | 49 |
GPM6A,GABRB1 |
1.759e-02 | -4.04 | FBXO45 (F-box protein 45) | protein interactions | 200933 | 79 | 2 | 19454 | 50 |
CTNNA2,SHROOM3 |
1.761e-02 | -4.04 | NCK1 (NCK adaptor protein 1) | protein interactions | 4690 | 214 | 3 | 19454 | 50 |
TNIK,NTRK2,NHSL1 |
1.765e-02 | -4.04 | cytoskeleton organization | biological process | GO:0007010 | 1251 | 8 | 18204 | 49 |
SORBS1,TNIK,CTNNA2,ABLIM1,PARD3B,FMN2,SHROOM3,MACF1 |
1.766e-02 | -4.04 | stomach-adenocarcinoma | COSMIC cancer mutations | stomach-adenocarcinoma | 4101 | 19 | 16828 | 49 |
GPC5,SLC4A4,ATP13A4,CTNND2,CACHD1,ATP1A2,FMN2,MACF1,ABLIM1,FGFR3,SHROOM3,PARD3B,PAMR1,PREX2,MGAT4C,SLC1A2,RORA,GLI3,RFX4 |
1.769e-02 | -4.03 | bone-tibia-chondrosarcoma | COSMIC cancer mutations | bone-tibia-chondrosarcoma | 70 | 2 | 16828 | 49 |
CPE,RANBP3L |
1.774e-02 | -4.03 | calcium ion transmembrane transport | biological process | GO:0070588 | 205 | 3 | 18204 | 49 |
GPM6A,CACHD1,RYR3 |
1.779e-02 | -4.03 | Neuronal System | REACTOME pathways | R-HSA-112316 | 349 | 4 | 10285 | 30 |
GABRB1,ADCY2,SLC1A3,SLC1A2 |
1.782e-02 | -4.03 | alpha-beta T cell differentiation | biological process | GO:0046632 | 76 | 2 | 18204 | 49 |
GLI3,RORA |
1.785e-02 | -4.03 | nitrogen compound transport | biological process | GO:0071705 | 1507 | 9 | 18204 | 49 |
NTRK2,ATP13A4,SLC1A2,SLC1A3,MACF1,CPE,GLI3,RANBP3L,FMN2 |
1.786e-02 | -4.03 | Smurf1 (SMAD specific E3 ubiquitin protein ligase 1) | protein interactions | 75788 | 7 | 1 | 19454 | 50 |
GLIS3 |
1.786e-02 | -4.03 | Smad7 (SMAD family member 7) | protein interactions | 17131 | 7 | 1 | 19454 | 50 |
BMPR1B |
1.786e-02 | -4.03 | Uhmk1 (U2AF homology motif (UHM) kinase 1) | protein interactions | 16589 | 7 | 1 | 19454 | 50 |
BMPR1B |
1.786e-02 | -4.03 | RGMB (repulsive guidance molecule BMP co-receptor b) | protein interactions | 285704 | 7 | 1 | 19454 | 50 |
BMPR1B |
1.786e-02 | -4.03 | FGF5 (fibroblast growth factor 5) | protein interactions | 2250 | 7 | 1 | 19454 | 50 |
FGFR3 |
1.786e-02 | -4.03 | SASH3 (SAM and SH3 domain containing 3) | protein interactions | 54440 | 7 | 1 | 19454 | 50 |
BMPR1B |
1.786e-02 | -4.03 | Fbxo3 (F-box protein 3) | protein interactions | 57443 | 7 | 1 | 19454 | 50 |
BMPR1B |
1.786e-02 | -4.03 | ABCC12 (ATP binding cassette subfamily C member 12) | protein interactions | 94160 | 7 | 1 | 19454 | 50 |
NPAS3 |
1.811e-02 | -4.01 | Leucine Dehydrogenase, chain A, domain 1 | gene3d domains | 3.40.50.10860 | 6 | 1 | 14470 | 44 |
GLUD1 |
1.811e-02 | -4.01 | Plakin repeat | gene3d domains | 3.90.1290.10 | 6 | 1 | 14470 | 44 |
MACF1 |
1.811e-02 | -4.01 | IP3 receptor type 1 binding core, RIH domain | gene3d domains | 1.25.10.30 | 6 | 1 | 14470 | 44 |
RYR3 |
1.811e-02 | -4.01 | Gas2-like domain | gene3d domains | 3.30.920.20 | 6 | 1 | 14470 | 44 |
MACF1 |
1.815e-02 | -4.01 | alveolar | COSMIC cancer mutations | alveolar | 2414 | 13 | 16828 | 49 |
MACF1,FMN2,PARD3B,FGFR3,NPAS3,SORBS1,RYR3,PREX2,SLC1A3,PAMR1,NHSL1,ZNRF3,SPARCL1 |
1.815e-02 | -4.01 | soft_tissue-striated_muscle-rhabdomyosarcoma-alveolar | COSMIC cancer mutations | soft_tissue-striated_muscle-rhabdomyosarcoma-alveolar | 2414 | 13 | 16828 | 49 |
NHSL1,PAMR1,PREX2,SLC1A3,SPARCL1,ZNRF3,NPAS3,SORBS1,RYR3,FMN2,MACF1,FGFR3,PARD3B |
1.815e-02 | -4.01 | Corticotropin Activation of Cortisol Production | SMPDB pathways | SMP0000310 | 5 | 1 | 1369 | 5 |
ADCY2 |
1.821e-02 | -4.01 | SMAD binding | molecular function | GO:0046332 | 78 | 2 | 18094 | 48 |
BMPR1B,RANBP3L |
1.826e-02 | -4.00 | GFAP (glial fibrillary acidic protein) | protein interactions | 2670 | 217 | 3 | 19454 | 50 |
ABLIM1,RORA,NKAIN3 |
1.827e-02 | -4.00 | neural retina development | biological process | GO:0003407 | 77 | 2 | 18204 | 49 |
NTRK2,GPM6A |
1.827e-02 | -4.00 | positive regulation of axonogenesis | biological process | GO:0050772 | 77 | 2 | 18204 | 49 |
NTRK2,MACF1 |
1.843e-02 | -3.99 | L-leucine binding | molecular function | GO:0070728 | 7 | 1 | 18094 | 48 |
GLUD1 |
1.843e-02 | -3.99 | P-type sodium:potassium-exchanging transporter activity | molecular function | GO:0005391 | 7 | 1 | 18094 | 48 |
ATP1A2 |
1.843e-02 | -3.99 | P-type sodium transporter activity | molecular function | GO:0008554 | 7 | 1 | 18094 | 48 |
ATP1A2 |
1.843e-02 | -3.99 | phosphatidic acid transfer activity | molecular function | GO:1990050 | 7 | 1 | 18094 | 48 |
PITPNC1 |
1.865e-02 | -3.98 | Protein_kinase_ATP_BS | interpro domains | IPR017441 | 377 | 4 | 18521 | 50 |
NTRK2,BMPR1B,TNIK,FGFR3 |
1.869e-02 | -3.98 | ventral spinal cord interneuron specification | biological process | GO:0021521 | 7 | 1 | 18204 | 49 |
GLI3 |
1.869e-02 | -3.98 | chromosome movement towards spindle pole | biological process | GO:0051305 | 7 | 1 | 18204 | 49 |
FMN2 |
1.869e-02 | -3.98 | forebrain dorsal/ventral pattern formation | biological process | GO:0021798 | 7 | 1 | 18204 | 49 |
GLI3 |
1.869e-02 | -3.98 | negative regulation of non-canonical Wnt signaling pathway | biological process | GO:2000051 | 7 | 1 | 18204 | 49 |
ZNRF3 |
1.869e-02 | -3.98 | cellular response to magnesium ion | biological process | GO:0071286 | 7 | 1 | 18204 | 49 |
RYR3 |
1.869e-02 | -3.98 | negative regulation of Arp2/3 complex-mediated actin nucleation | biological process | GO:0034316 | 7 | 1 | 18204 | 49 |
CTNNA2 |
1.869e-02 | -3.98 | hindgut morphogenesis | biological process | GO:0007442 | 7 | 1 | 18204 | 49 |
GLI3 |
1.869e-02 | -3.98 | parallel actin filament bundle assembly | biological process | GO:0030046 | 7 | 1 | 18204 | 49 |
FMN2 |
1.869e-02 | -3.98 | cell fate specification involved in pattern specification | biological process | GO:0060573 | 7 | 1 | 18204 | 49 |
GLI3 |
1.869e-02 | -3.98 | forebrain radial glial cell differentiation | biological process | GO:0021861 | 7 | 1 | 18204 | 49 |
GLI3 |
1.872e-02 | -3.98 | positive regulation of osteoblast differentiation | biological process | GO:0045669 | 78 | 2 | 18204 | 49 |
GLI3,BMPR1B |
1.872e-02 | -3.98 | regulation of glucose transmembrane transport | biological process | GO:0010827 | 78 | 2 | 18204 | 49 |
SLC1A2,SORBS1 |
1.872e-02 | -3.98 | positive regulation of carbohydrate metabolic process | biological process | GO:0045913 | 78 | 2 | 18204 | 49 |
SLC4A4,SORBS1 |
1.873e-02 | -3.98 | response to nitrogen compound | biological process | GO:1901698 | 1021 | 7 | 18204 | 49 |
GNA14,GABRB1,SLC1A3,RYR3,SORBS1,SLC1A2,TNIK |
1.875e-02 | -3.98 | SPARC/Testican_Ca-bd-dom | interpro domains | IPR019577 | 7 | 1 | 18521 | 50 |
SPARCL1 |
1.875e-02 | -3.98 | Plakin_repeat_sf | interpro domains | IPR035915 | 7 | 1 | 18521 | 50 |
MACF1 |
1.875e-02 | -3.98 | Alpha-catenin/vinculin-like_sf | interpro domains | IPR036723 | 7 | 1 | 18521 | 50 |
CTNNA2 |
1.875e-02 | -3.98 | Plakophilin/d_Catenin | interpro domains | IPR028435 | 7 | 1 | 18521 | 50 |
CTNND2 |
1.875e-02 | -3.98 | Aquaporin_transptr | interpro domains | IPR034294 | 7 | 1 | 18521 | 50 |
AQP4 |
1.875e-02 | -3.98 | Plectin_repeat | interpro domains | IPR001101 | 7 | 1 | 18521 | 50 |
MACF1 |
1.875e-02 | -3.98 | GS_dom | interpro domains | IPR003605 | 7 | 1 | 18521 | 50 |
BMPR1B |
1.882e-02 | -3.97 | HAD-like_sf | interpro domains | IPR036412 | 78 | 2 | 18521 | 50 |
ATP13A4,ATP1A2 |
1.897e-02 | -3.96 | human chr9q21.2 | chromosome location | human chr9q21.2 | 10 | 1 | 26134 | 50 |
GNA14 |
1.897e-02 | -3.96 | human chr9p24.2 | chromosome location | human chr9p24.2 | 10 | 1 | 26134 | 50 |
GLIS3 |
1.897e-02 | -3.96 | human chr14q31.1 | chromosome location | human chr14q31.1 | 10 | 1 | 26134 | 50 |
STON2 |
1.902e-02 | -3.96 | testis | COSMIC cancer mutations | testis | 733 | 6 | 16828 | 49 |
PREX2,TNIK,FGFR3,NTRK2,BMPR1B,MACF1 |
1.909e-02 | -3.96 | eye development | biological process | GO:0001654 | 381 | 4 | 18204 | 49 |
GLI3,NTRK2,BMPR1B,GPM6A |
1.912e-02 | -3.96 | SPARC_Ca_bdg | pfam domains | PF10591 | 7 | 1 | 17795 | 49 |
SPARCL1 |
1.912e-02 | -3.96 | TGF_beta_GS | pfam domains | PF08515 | 7 | 1 | 17795 | 49 |
BMPR1B |
1.914e-02 | -3.96 | central_nervous_system-brain-glioma-oligodendroglioma_Grade_II | COSMIC cancer mutations | central_nervous_system-brain-glioma-oligodendroglioma_Grade_II | 73 | 2 | 16828 | 49 |
FGFR3,MACF1 |
1.921e-02 | -3.95 | caveola | cellular component | GO:0005901 | 83 | 2 | 19108 | 49 |
ATP1A2,SORBS1 |
1.930e-02 | -3.95 | DNM3 (dynamin 3) | protein interactions | 26052 | 83 | 2 | 19454 | 50 |
GPM6A,FGFR3 |
1.930e-02 | -3.95 | SYT1 (synaptotagmin 1) | protein interactions | 6857 | 83 | 2 | 19454 | 50 |
STON2,GPM6A |
1.943e-02 | -3.94 | mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | COSMIC cancer mutations | mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | 951 | 7 | 16828 | 49 |
ATP13A4,PREX2,GPC5,SLC1A2,MACF1,GLI3,FMN2 |
1.943e-02 | -3.94 | stomach-carcinoma-mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | COSMIC cancer mutations | stomach-carcinoma-mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | 951 | 7 | 16828 | 49 |
FMN2,MACF1,GLI3,ATP13A4,PREX2,GPC5,SLC1A2 |
1.964e-02 | -3.93 | oligodendroglioma_Grade_II | COSMIC cancer mutations | oligodendroglioma_Grade_II | 74 | 2 | 16828 | 49 |
FGFR3,MACF1 |
1.972e-02 | -3.93 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_T_cell_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_T_cell_leukaemia | 739 | 6 | 16828 | 49 |
GABRB1,SHROOM3,FGFR3,ZNRF3,PREX2,MGAT4C |
1.972e-02 | -3.93 | acute_lymphoblastic_T_cell_leukaemia | COSMIC cancer mutations | acute_lymphoblastic_T_cell_leukaemia | 739 | 6 | 16828 | 49 |
GABRB1,FGFR3,SHROOM3,ZNRF3,MGAT4C,PREX2 |
1.974e-02 | -3.93 | Tyr_kinase_cat_dom | interpro domains | IPR020635 | 80 | 2 | 18521 | 50 |
NTRK2,FGFR3 |
1.976e-02 | -3.92 | visual system development | biological process | GO:0150063 | 385 | 4 | 18204 | 49 |
GPM6A,NTRK2,BMPR1B,GLI3 |
1.985e-02 | -3.92 | MAPRE3 (microtubule associated protein RP/EB family member 3) | protein interactions | 22924 | 224 | 3 | 19454 | 50 |
GPM6A,MACF1,ABLIM1 |
1.989e-02 | -3.92 | central_nervous_system-brain-glioma-astrocytoma_Grade_III | COSMIC cancer mutations | central_nervous_system-brain-glioma-astrocytoma_Grade_III | 1419 | 9 | 16828 | 49 |
CACHD1,GNA14,GABRB1,FGFR3,SHROOM3,ADCY2,GPC5,PAMR1,RYR3 |
1.991e-02 | -3.92 | FGFR1 (fibroblast growth factor receptor 1) | protein interactions | 2260 | 611 | 5 | 19454 | 50 |
NHSL1,FGFR3,ABLIM1,DTNA,TNIK |
1.993e-02 | -3.92 | PITRANSFER | prints domains | PR00391 | 5 | 1 | 5227 | 21 |
PITPNC1 |
1.993e-02 | -3.92 | NAHCO3TRSPRT | prints domains | PR01232 | 5 | 1 | 5227 | 21 |
SLC4A4 |
1.996e-02 | -3.91 | rhabdomyosarcoma | COSMIC cancer mutations | rhabdomyosarcoma | 4150 | 19 | 16828 | 49 |
RYR3,SORBS1,CTNND2,NPAS3,PARD3B,FGFR3,GLIS3,MACF1,FMN2,ZNRF3,ADCY2,SPARCL1,SLC1A3,PREX2,PAMR1,NHSL1,AQP4,GLI3,RORA |
2.009e-02 | -3.91 | adult locomotory behavior | biological process | GO:0008344 | 81 | 2 | 18204 | 49 |
PREX2,ATP1A2 |
2.021e-02 | -3.90 | skin-benign_melanocytic_nevus-compound | COSMIC cancer mutations | skin-benign_melanocytic_nevus-compound | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-other-nevus_sebaceous | COSMIC cancer mutations | skin-other-nevus_sebaceous | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-benign_melanocytic_nevus-intradermal | COSMIC cancer mutations | skin-benign_melanocytic_nevus-intradermal | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-shoulder-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-shoulder-other-seborrhoeic_keratosis | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-upper_leg-malignant_melanoma-nodular | COSMIC cancer mutations | skin-upper_leg-malignant_melanoma-nodular | 7 | 1 | 16828 | 49 |
PREX2 |
2.021e-02 | -3.90 | skin-chest-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-chest-other-seborrhoeic_keratosis | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-face-malignant_melanoma-nodular | COSMIC cancer mutations | skin-face-malignant_melanoma-nodular | 7 | 1 | 16828 | 49 |
PREX2 |
2.021e-02 | -3.90 | trichilemmoma | COSMIC cancer mutations | trichilemmoma | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | nevus_sebaceous | COSMIC cancer mutations | nevus_sebaceous | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-neck-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-neck-other-seborrhoeic_keratosis | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-face-adnexal_tumour-malignant_adnexal_tumour | COSMIC cancer mutations | skin-face-adnexal_tumour-malignant_adnexal_tumour | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | urinary_tract-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-carcinoma-transitional_cell_carcinoma | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-adnexal_tumour-trichilemmoma | COSMIC cancer mutations | skin-adnexal_tumour-trichilemmoma | 7 | 1 | 16828 | 49 |
FGFR3 |
2.023e-02 | -3.90 | Adherens junction | KEGG pathways | ko04520 | 72 | 2 | 7161 | 22 |
SORBS1,CTNNA2 |
2.023e-02 | -3.90 | Adherens junction | KEGG pathways | hsa04520 | 72 | 2 | 7161 | 22 |
SORBS1,CTNNA2 |
2.025e-02 | -3.90 | FGFR3b ligand binding and activation | REACTOME pathways | R-HSA-190371 | 7 | 1 | 10285 | 30 |
FGFR3 |
2.034e-02 | -3.90 | zonula adherens | cellular component | GO:0005915 | 8 | 1 | 19108 | 49 |
SORBS1 |
2.034e-02 | -3.90 | HFE-transferrin receptor complex | cellular component | GO:1990712 | 8 | 1 | 19108 | 49 |
BMPR1B |
2.038e-02 | -3.89 | Rps27a (ribosomal protein S27A) | protein interactions | 78294 | 8 | 1 | 19454 | 50 |
BMPR1B |
2.038e-02 | -3.89 | Rasd2 (RASD family, member 2) | protein interactions | 75141 | 8 | 1 | 19454 | 50 |
BMPR1B |
2.038e-02 | -3.89 | LHB (luteinizing hormone subunit beta) | protein interactions | 3972 | 8 | 1 | 19454 | 50 |
NTM |
2.038e-02 | -3.89 | CCK (cholecystokinin) | protein interactions | 885 | 8 | 1 | 19454 | 50 |
CPE |
2.038e-02 | -3.89 | INSM1 (INSM transcriptional repressor 1) | protein interactions | 3642 | 8 | 1 | 19454 | 50 |
SORBS1 |
2.038e-02 | -3.89 | BMP15 (bone morphogenetic protein 15) | protein interactions | 9210 | 8 | 1 | 19454 | 50 |
BMPR1B |
2.044e-02 | -3.89 | bone-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 6023 | 25 | 16828 | 49 |
SPARCL1,PAMR1,PREX2,SLC1A3,RORA,DTNA,GLI3,SLC4A4,NPAS3,CACHD1,ATP1A2,NKAIN3,MACF1,SOX5,ADCY2,RYR3,CTNND2,STON2,ATP13A4,GNA14,ABLIM1,FGFR3,SHROOM3,NTRK2,GLIS3 |
2.053e-02 | -3.89 | contractile actin filament bundle | cellular component | GO:0097517 | 86 | 2 | 19108 | 49 |
SORBS1,ABLIM1 |
2.053e-02 | -3.89 | stress fiber | cellular component | GO:0001725 | 86 | 2 | 19108 | 49 |
SORBS1,ABLIM1 |
2.055e-02 | -3.88 | receptor complex | cellular component | GO:0043235 | 409 | 4 | 19108 | 49 |
NTRK2,GABRB1,BMPR1B,FGFR3 |
2.063e-02 | -3.88 | EGLN1 (egl-9 family hypoxia inducible factor 1) | protein interactions | 54583 | 86 | 2 | 19454 | 50 |
HIF3A,FGFR3 |
2.063e-02 | -3.88 | SYNJ1 (synaptojanin 1) | protein interactions | 8867 | 86 | 2 | 19454 | 50 |
SORBS1,GPM6A |
2.067e-02 | -3.88 | kidney-Wilms_tumour | COSMIC cancer mutations | kidney-Wilms_tumour | 545 | 5 | 16828 | 49 |
TNIK,FGFR3,BMPR1B,FMN2,NTRK2 |
2.075e-02 | -3.88 | response to oxygen-containing compound | biological process | GO:1901700 | 1546 | 9 | 18204 | 49 |
SLC1A2,ADCY2,RYR3,SLC1A3,SORBS1,ATP1A2,GNA14,GABRB1,RORA |
2.078e-02 | -3.87 | sensory system development | biological process | GO:0048880 | 391 | 4 | 18204 | 49 |
GPM6A,BMPR1B,NTRK2,GLI3 |
2.082e-02 | -3.87 | Wilms_tumour | COSMIC cancer mutations | Wilms_tumour | 546 | 5 | 16828 | 49 |
TNIK,FGFR3,BMPR1B,FMN2,NTRK2 |
2.101e-02 | -3.86 | EF_hand_dom | interpro domains | IPR002048 | 218 | 3 | 18521 | 50 |
MACF1,SPARCL1,RYR3 |
2.103e-02 | -3.86 | BMP receptor activity | molecular function | GO:0098821 | 8 | 1 | 18094 | 48 |
BMPR1B |
2.103e-02 | -3.86 | sodium ion binding | molecular function | GO:0031402 | 8 | 1 | 18094 | 48 |
ATP1A2 |
2.103e-02 | -3.86 | glutamate binding | molecular function | GO:0016595 | 8 | 1 | 18094 | 48 |
SLC1A3 |
2.103e-02 | -3.86 | P-type potassium transmembrane transporter activity | molecular function | GO:0008556 | 8 | 1 | 18094 | 48 |
ATP1A2 |
2.105e-02 | -3.86 | glutamatergic synapse | cellular component | GO:0098978 | 412 | 4 | 19108 | 49 |
SLC1A2,GPM6A,SPARCL1,TNIK |
2.106e-02 | -3.86 | Muscle contraction | REACTOME pathways | R-HSA-397014 | 204 | 3 | 10285 | 30 |
RYR3,SORBS1,ATP1A2 |
2.119e-02 | -3.85 | cellular response to oxygen-containing compound | biological process | GO:1901701 | 1047 | 7 | 18204 | 49 |
SLC1A3,SORBS1,RYR3,ADCY2,SLC1A2,RORA,GNA14 |
2.125e-02 | -3.85 | HAD superfamily/HAD-like | gene3d domains | 3.40.50.1000 | 74 | 2 | 14470 | 44 |
ATP13A4,ATP1A2 |
2.127e-02 | -3.85 | BICD1 (BICD cargo adaptor 1) | protein interactions | 636 | 230 | 3 | 19454 | 50 |
SHROOM3,SORBS1,TNIK |
2.127e-02 | -3.85 | DST (dystonin) | protein interactions | 667 | 230 | 3 | 19454 | 50 |
TNIK,ATP1A2,NTRK2 |
2.129e-02 | -3.85 | Thyroid hormone synthesis | KEGG pathways | hsa04918 | 74 | 2 | 7161 | 22 |
ATP1A2,ADCY2 |
2.129e-02 | -3.85 | Thyroid hormone synthesis | KEGG pathways | ko04918 | 74 | 2 | 7161 | 22 |
ATP1A2,ADCY2 |
2.130e-02 | -3.85 | leg | COSMIC cancer mutations | leg | 969 | 7 | 16828 | 49 |
SHROOM3,FGFR3,NTM,FMN2,HIF3A,ATP13A4,SLC4A4 |
2.134e-02 | -3.85 | insulin processing | biological process | GO:0030070 | 8 | 1 | 18204 | 49 |
CPE |
2.134e-02 | -3.85 | cell proliferation in hindbrain | biological process | GO:0021534 | 8 | 1 | 18204 | 49 |
RORA |
2.134e-02 | -3.85 | regulation of L-glutamate import across plasma membrane | biological process | GO:0002036 | 8 | 1 | 18204 | 49 |
ATP1A2 |
2.134e-02 | -3.85 | glutamate catabolic process | biological process | GO:0006538 | 8 | 1 | 18204 | 49 |
GLUD1 |
2.134e-02 | -3.85 | cell proliferation in external granule layer | biological process | GO:0021924 | 8 | 1 | 18204 | 49 |
RORA |
2.134e-02 | -3.85 | regulation of synapse structural plasticity | biological process | GO:0051823 | 8 | 1 | 18204 | 49 |
CTNNA2 |
2.134e-02 | -3.85 | hindgut development | biological process | GO:0061525 | 8 | 1 | 18204 | 49 |
GLI3 |
2.134e-02 | -3.85 | gamma-aminobutyric acid metabolic process | biological process | GO:0009448 | 8 | 1 | 18204 | 49 |
SLC1A3 |
2.134e-02 | -3.85 | cerebellar granule cell precursor proliferation | biological process | GO:0021930 | 8 | 1 | 18204 | 49 |
RORA |
2.134e-02 | -3.85 | meiotic cytokinesis | biological process | GO:0033206 | 8 | 1 | 18204 | 49 |
FMN2 |
2.140e-02 | -3.84 | Villin_headpiece | interpro domains | IPR003128 | 8 | 1 | 18521 | 50 |
ABLIM1 |
2.140e-02 | -3.84 | RFX-like | interpro domains | IPR039779 | 8 | 1 | 18521 | 50 |
RFX4 |
2.140e-02 | -3.84 | Villin_headpiece_dom_sf | interpro domains | IPR036886 | 8 | 1 | 18521 | 50 |
ABLIM1 |
2.140e-02 | -3.84 | AC_N | interpro domains | IPR032628 | 8 | 1 | 18521 | 50 |
ADCY2 |
2.140e-02 | -3.84 | Adcy | interpro domains | IPR030672 | 8 | 1 | 18521 | 50 |
ADCY2 |
2.140e-02 | -3.84 | Plakin | interpro domains | IPR043197 | 8 | 1 | 18521 | 50 |
MACF1 |
2.142e-02 | -3.84 | GAS2 | smart domains | SM00243 | 6 | 1 | 9717 | 35 |
MACF1 |
2.147e-02 | -3.84 | GLYPICAN | prosite domains | PS01207 | 6 | 1 | 12186 | 44 |
GPC5 |
2.147e-02 | -3.84 | GAR | prosite domains | PS51460 | 6 | 1 | 12186 | 44 |
MACF1 |
2.151e-02 | -3.84 | L-amino acid transport | biological process | GO:0015807 | 84 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
2.151e-02 | -3.84 | regulation of sodium ion transport | biological process | GO:0002028 | 84 | 2 | 18204 | 49 |
NKAIN3,ATP1A2 |
2.153e-02 | -3.84 | RAP2A (RAP2A, member of RAS oncogene family) | protein interactions | 5911 | 88 | 2 | 19454 | 50 |
BMPR1B,TNIK |
2.153e-02 | -3.84 | HSPG2 (heparan sulfate proteoglycan 2) | protein interactions | 3339 | 88 | 2 | 19454 | 50 |
GLI3,GPC5 |
2.153e-02 | -3.84 | Ig_sub | interpro domains | IPR003599 | 394 | 4 | 18521 | 50 |
FGFR3,NTRK2,NTM,LSAMP |
2.175e-02 | -3.83 | Intracellular Signalling Through PGD2 receptor and Prostaglandin D2 | SMPDB pathways | SMP0000343 | 6 | 1 | 1369 | 5 |
ADCY2 |
2.175e-02 | -3.83 | Dopamine Activation of Neurological Reward System | SMPDB pathways | SMP0000308 | 6 | 1 | 1369 | 5 |
ADCY2 |
2.177e-02 | -3.83 | cAMP signaling pathway | KEGG pathways | ko04024 | 198 | 3 | 7161 | 22 |
GLI3,ADCY2,ATP1A2 |
2.177e-02 | -3.83 | cAMP signaling pathway | KEGG pathways | hsa04024 | 198 | 3 | 7161 | 22 |
ADCY2,GLI3,ATP1A2 |
2.182e-02 | -3.82 | VHP | pfam domains | PF02209 | 8 | 1 | 17795 | 49 |
ABLIM1 |
2.182e-02 | -3.82 | AC_N | pfam domains | PF16214 | 8 | 1 | 17795 | 49 |
ADCY2 |
2.184e-02 | -3.82 | Gastric acid secretion | KEGG pathways | ko04971 | 75 | 2 | 7161 | 22 |
ATP1A2,ADCY2 |
2.184e-02 | -3.82 | Gastric acid secretion | KEGG pathways | hsa04971 | 75 | 2 | 7161 | 22 |
ADCY2,ATP1A2 |
2.186e-02 | -3.82 | skin-upper_arm-malignant_melanoma | COSMIC cancer mutations | skin-upper_arm-malignant_melanoma | 553 | 5 | 16828 | 49 |
PARD3B,STON2,FMN2,SLC4A4,PREX2 |
2.199e-02 | -3.82 | oligodendrocyte differentiation | biological process | GO:0048709 | 85 | 2 | 18204 | 49 |
NTRK2,GLI3 |
2.199e-02 | -3.82 | regulation of smoothened signaling pathway | biological process | GO:0008589 | 85 | 2 | 18204 | 49 |
GLI3,RORA |
2.212e-02 | -3.81 | RHOJ (ras homolog family member J) | protein interactions | 57381 | 628 | 5 | 19454 | 50 |
BMPR1B,MACF1,CACHD1,SLC1A3,STON2 |
2.246e-02 | -3.80 | Tmod3 (tropomodulin 3) | protein interactions | 50875 | 90 | 2 | 19454 | 50 |
STON2,ABLIM1 |
2.247e-02 | -3.80 | central nervous system neuron development | biological process | GO:0021954 | 86 | 2 | 18204 | 49 |
GABRB1,NTRK2 |
2.249e-02 | -3.79 | MARK3 (microtubule affinity regulating kinase 3) | protein interactions | 4140 | 235 | 3 | 19454 | 50 |
MACF1,DTNA,NTRK2 |
2.285e-02 | -3.78 | astrocyte end-foot | cellular component | GO:0097450 | 9 | 1 | 19108 | 49 |
AQP4 |
2.285e-02 | -3.78 | flotillin complex | cellular component | GO:0016600 | 9 | 1 | 19108 | 49 |
SORBS1 |
2.290e-02 | -3.78 | VEPH1 (ventricular zone expressed PH domain containing 1) | protein interactions | 79674 | 9 | 1 | 19454 | 50 |
BMPR1B |
2.290e-02 | -3.78 | NRXN2 (neurexin 2) | protein interactions | 9379 | 9 | 1 | 19454 | 50 |
MACF1 |
2.290e-02 | -3.78 | Tyw3 (tRNA-yW synthesizing protein 3 homolog (S. cerevisiae)) | protein interactions | 209584 | 9 | 1 | 19454 | 50 |
CTNNA2 |
2.290e-02 | -3.78 | GUSBP1 (GUSB pseudogene 1) | protein interactions | 728411 | 9 | 1 | 19454 | 50 |
FGFR3 |
2.290e-02 | -3.78 | KLB (klotho beta) | protein interactions | 152831 | 9 | 1 | 19454 | 50 |
FGFR3 |
2.292e-02 | -3.78 | SOS1 (SOS Ras/Rac guanine nucleotide exchange factor 1) | protein interactions | 6654 | 91 | 2 | 19454 | 50 |
TNIK,SORBS1 |
2.292e-02 | -3.78 | DGUOK (deoxyguanosine kinase) | protein interactions | 1716 | 91 | 2 | 19454 | 50 |
GPM6A,NTM |
2.296e-02 | -3.77 | dorsal/ventral pattern formation | biological process | GO:0009953 | 87 | 2 | 18204 | 49 |
GLI3,BMPR1B |
2.306e-02 | -3.77 | cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_I | COSMIC cancer mutations | cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_I | 8 | 1 | 16828 | 49 |
FGFR3 |
2.306e-02 | -3.77 | urinary_tract-ureter-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-ureter-carcinoma-transitional_cell_carcinoma | 8 | 1 | 16828 | 49 |
FGFR3 |
2.306e-02 | -3.77 | skin-chest-malignant_melanoma-nodular | COSMIC cancer mutations | skin-chest-malignant_melanoma-nodular | 8 | 1 | 16828 | 49 |
PREX2 |
2.306e-02 | -3.77 | junctional | COSMIC cancer mutations | junctional | 8 | 1 | 16828 | 49 |
FGFR3 |
2.306e-02 | -3.77 | actinic_keratosis | COSMIC cancer mutations | actinic_keratosis | 8 | 1 | 16828 | 49 |
FGFR3 |
2.306e-02 | -3.77 | cervical_intraepithelial_neoplasia_Grade_I | COSMIC cancer mutations | cervical_intraepithelial_neoplasia_Grade_I | 8 | 1 | 16828 | 49 |
FGFR3 |
2.306e-02 | -3.77 | trichoblastoma | COSMIC cancer mutations | trichoblastoma | 8 | 1 | 16828 | 49 |
FGFR3 |
2.311e-02 | -3.77 | Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | REACTOME pathways | R-HSA-434316 | 8 | 1 | 10285 | 30 |
GNA14 |
2.311e-02 | -3.77 | Free fatty acids regulate insulin secretion | REACTOME pathways | R-HSA-400451 | 8 | 1 | 10285 | 30 |
GNA14 |
2.311e-02 | -3.77 | Release of Hh-Np from the secreting cell | REACTOME pathways | R-HSA-5362798 | 8 | 1 | 10285 | 30 |
GPC5 |
2.318e-02 | -3.76 | skin-leg-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-leg-malignant_melanoma-superficial_spreading | 210 | 3 | 16828 | 49 |
SLC4A4,ATP13A4,NTM |
2.325e-02 | -3.76 | forearm | COSMIC cancer mutations | forearm | 81 | 2 | 16828 | 49 |
PREX2,FGFR3 |
2.329e-02 | -3.76 | actomyosin | cellular component | GO:0042641 | 92 | 2 | 19108 | 49 |
ABLIM1,SORBS1 |
2.339e-02 | -3.76 | POTEI (POTE ankyrin domain family member I) | protein interactions | 653269 | 92 | 2 | 19454 | 50 |
FGFR3,DTNA |
2.339e-02 | -3.76 | FNTA (farnesyltransferase, CAAX box, subunit alpha) | protein interactions | 2339 | 92 | 2 | 19454 | 50 |
FGFR3,TNIK |
2.356e-02 | -3.75 | cellular response to chemical stimulus | biological process | GO:0070887 | 2411 | 12 | 18204 | 49 |
NTRK2,RYR3,SORBS1,ATP1A2,SLC1A2,SLC1A3,ADCY2,AQP4,RORA,FMN2,GNA14,GABRB1 |
2.387e-02 | -3.74 | ARHGEF6 (Rac/Cdc42 guanine nucleotide exchange factor 6) | protein interactions | 9459 | 93 | 2 | 19454 | 50 |
BMPR1B,ABLIM1 |
2.388e-02 | -3.73 | ACTIVIN2R | prints domains | PR00653 | 6 | 1 | 5227 | 21 |
BMPR1B |
2.388e-02 | -3.73 | hand | COSMIC cancer mutations | hand | 566 | 5 | 16828 | 49 |
HIF3A,SLC4A4,PREX2,FGFR3,SHROOM3 |
2.397e-02 | -3.73 | semicircular canal development | biological process | GO:0060872 | 9 | 1 | 18204 | 49 |
GLI3 |
2.397e-02 | -3.73 | negative regulation of striated muscle contraction | biological process | GO:0045988 | 9 | 1 | 18204 | 49 |
ATP1A2 |
2.397e-02 | -3.73 | hindbrain radial glia guided cell migration | biological process | GO:0021932 | 9 | 1 | 18204 | 49 |
CTNNA2 |
2.397e-02 | -3.73 | cranial suture morphogenesis | biological process | GO:0060363 | 9 | 1 | 18204 | 49 |
GLI3 |
2.397e-02 | -3.73 | phospholipase C-activating dopamine receptor signaling pathway | biological process | GO:0060158 | 9 | 1 | 18204 | 49 |
GNA14 |
2.397e-02 | -3.73 | embryonic neurocranium morphogenesis | biological process | GO:0048702 | 9 | 1 | 18204 | 49 |
GLI3 |
2.397e-02 | -3.73 | negative regulation of actin nucleation | biological process | GO:0051126 | 9 | 1 | 18204 | 49 |
CTNNA2 |
2.397e-02 | -3.73 | polyamine transmembrane transport | biological process | GO:1902047 | 9 | 1 | 18204 | 49 |
ATP13A4 |
2.397e-02 | -3.73 | release of sequestered calcium ion into cytosol by sarcoplasmic reticulum | biological process | GO:0014808 | 9 | 1 | 18204 | 49 |
RYR3 |
2.404e-02 | -3.73 | Fol_N | interpro domains | IPR003645 | 9 | 1 | 18521 | 50 |
SPARCL1 |
2.404e-02 | -3.73 | Band3_cytoplasmic_dom | interpro domains | IPR013769 | 9 | 1 | 18521 | 50 |
SLC4A4 |
2.404e-02 | -3.73 | Aminoacid_DH-like_N_sf | interpro domains | IPR046346 | 9 | 1 | 18521 | 50 |
GLUD1 |
2.404e-02 | -3.73 | Activin_recp | interpro domains | IPR000472 | 9 | 1 | 18521 | 50 |
BMPR1B |
2.404e-02 | -3.73 | DNA-bd_RFX | interpro domains | IPR003150 | 9 | 1 | 18521 | 50 |
RFX4 |
2.405e-02 | -3.73 | central_nervous_system-brain-atypical_teratoid-rhabdoid_tumour | COSMIC cancer mutations | central_nervous_system-brain-atypical_teratoid-rhabdoid_tumour | 213 | 3 | 16828 | 49 |
FGFR3,GABRB1,FMN2 |
2.405e-02 | -3.73 | atypical_teratoid-rhabdoid_tumour | COSMIC cancer mutations | atypical_teratoid-rhabdoid_tumour | 213 | 3 | 16828 | 49 |
GABRB1,FGFR3,FMN2 |
2.407e-02 | -3.73 | Villin headpiece domain | gene3d domains | 1.10.950.10 | 8 | 1 | 14470 | 44 |
ABLIM1 |
2.411e-02 | -3.73 | intracellular signaling cassette | biological process | GO:0141124 | 837 | 6 | 18204 | 49 |
RYR3,ATP1A2,ADCY2,TNIK,FGFR3,PREX2 |
2.412e-02 | -3.72 | striated_muscle | COSMIC cancer mutations | striated_muscle | 4228 | 19 | 16828 | 49 |
FGFR3,PARD3B,GLIS3,FMN2,MACF1,RYR3,CTNND2,SORBS1,NPAS3,RORA,GLI3,ADCY2,SPARCL1,ZNRF3,AQP4,PAMR1,NHSL1,SLC1A3,PREX2 |
2.430e-02 | -3.72 | protein binding | molecular function | GO:0005515 | 13983 | 43 | 18094 | 48 |
GPC5,NTRK2,FMN2,ZNRF3,PITPNC1,SOX5,TNIK,CPE,SLC1A3,AQP4,MACF1,ATP1A2,ADCY2,DTNA,GLI3,SFXN5,RORA,RFX4,HIF3A,FBXL7,GABRB1,GLIS3,RYR3,SORBS1,PARD3B,LSAMP,NTM,FGFR3,STON2,GLUD1,BMPR1B,SLC1A2,RANBP3L,SPARCL1,MSI2,GNA14,GPM6A,CTNNA2,NPAS3,SHROOM3,CTNND2,ABLIM1,SLC4A4 |
2.435e-02 | -3.72 | GRIN1 (glutamate ionotropic receptor NMDA type subunit 1) | protein interactions | 2902 | 94 | 2 | 19454 | 50 |
FGFR3,NTRK2 |
2.435e-02 | -3.72 | WWC1 (WW and C2 domain containing 1) | protein interactions | 23286 | 94 | 2 | 19454 | 50 |
TNIK,ABLIM1 |
2.452e-02 | -3.71 | Activin_recp | pfam domains | PF01064 | 9 | 1 | 17795 | 49 |
BMPR1B |
2.452e-02 | -3.71 | RFX_DNA_binding | pfam domains | PF02257 | 9 | 1 | 17795 | 49 |
RFX4 |
2.452e-02 | -3.71 | Band_3_cyto | pfam domains | PF07565 | 9 | 1 | 17795 | 49 |
SLC4A4 |
2.459e-02 | -3.71 | human chr5p15.1 | chromosome location | human chr5p15.1 | 13 | 1 | 26134 | 50 |
FBXL7 |
2.469e-02 | -3.70 | neck | COSMIC cancer mutations | neck | 1231 | 8 | 16828 | 49 |
PREX2,ATP13A4,ADCY2,GPC5,CTNND2,ATP1A2,FGFR3,SHROOM3 |
2.490e-02 | -3.69 | transmembrane transporter complex | cellular component | GO:1902495 | 434 | 4 | 19108 | 49 |
ATP1A2,RYR3,GABRB1,CACHD1 |
2.495e-02 | -3.69 | GS | smart domains | SM00467 | 7 | 1 | 9717 | 35 |
BMPR1B |
2.495e-02 | -3.69 | PLEC | smart domains | SM00250 | 7 | 1 | 9717 | 35 |
MACF1 |
2.495e-02 | -3.69 | axon | cellular component | GO:0030424 | 650 | 5 | 19108 | 49 |
GPM6A,NTRK2,SLC1A2,CTNNA2,DTNA |
2.501e-02 | -3.69 | GS | prosite domains | PS51256 | 7 | 1 | 12186 | 44 |
BMPR1B |
2.519e-02 | -3.68 | chemical synaptic transmission | biological process | GO:0007268 | 415 | 4 | 18204 | 49 |
SLC1A2,GABRB1,SLC1A3,DTNA |
2.519e-02 | -3.68 | anterograde trans-synaptic signaling | biological process | GO:0098916 | 415 | 4 | 18204 | 49 |
DTNA,SLC1A2,GABRB1,SLC1A3 |
2.521e-02 | -3.68 | actin filament bundle | cellular component | GO:0032432 | 96 | 2 | 19108 | 49 |
ABLIM1,SORBS1 |
2.523e-02 | -3.68 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-NK-T_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-NK-T_cell_lymphoma | 217 | 3 | 16828 | 49 |
MGAT4C,DTNA,RFX4 |
2.534e-02 | -3.68 | Vasopressin Regulation of Water Homeostasis | SMPDB pathways | SMP0000322 | 7 | 1 | 1369 | 5 |
ADCY2 |
2.541e-02 | -3.67 | Vbp1 (von Hippel-Lindau binding protein 1) | protein interactions | 22327 | 10 | 1 | 19454 | 50 |
ABLIM1 |
2.541e-02 | -3.67 | CALB2 (calbindin 2) | protein interactions | 794 | 10 | 1 | 19454 | 50 |
GPM6A |
2.541e-02 | -3.67 | SLC8A2 (solute carrier family 8 member A2) | protein interactions | 6543 | 10 | 1 | 19454 | 50 |
GPM6A |
2.541e-02 | -3.67 | SERPINB11 (serpin family B member 11) | protein interactions | 89778 | 10 | 1 | 19454 | 50 |
CPE |
2.541e-02 | -3.67 | Smurf2 (SMAD specific E3 ubiquitin protein ligase 2) | protein interactions | 66313 | 10 | 1 | 19454 | 50 |
GLIS3 |
2.541e-02 | -3.67 | GSG1 (germ cell associated 1) | protein interactions | 83445 | 10 | 1 | 19454 | 50 |
PITPNC1 |
2.547e-02 | -3.67 | YWHAZ (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta) | protein interactions | 7534 | 1138 | 7 | 19454 | 50 |
MACF1,SORBS1,PITPNC1,ABLIM1,SHROOM3,PARD3B,NHSL1 |
2.548e-02 | -3.67 | protein tetramerization | biological process | GO:0051262 | 92 | 2 | 18204 | 49 |
AQP4,RYR3 |
2.581e-02 | -3.66 | Tpm1 (tropomyosin 1, alpha) | protein interactions | 22003 | 97 | 2 | 19454 | 50 |
STON2,ABLIM1 |
2.585e-02 | -3.66 | ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) | protein interactions | 25 | 248 | 3 | 19454 | 50 |
CTNND2,STON2,SORBS1 |
2.589e-02 | -3.65 | shoulder | COSMIC cancer mutations | shoulder | 387 | 4 | 16828 | 49 |
FGFR3,CPE,PREX2,MACF1 |
2.591e-02 | -3.65 | in_situ_epithelial_neoplasm | COSMIC cancer mutations | in_situ_epithelial_neoplasm | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | epidermal_nevus | COSMIC cancer mutations | epidermal_nevus | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | Bowen_disease | COSMIC cancer mutations | Bowen_disease | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | skin-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-other-seborrhoeic_keratosis | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | skin-chest-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-chest-malignant_melanoma-superficial_spreading | 9 | 1 | 16828 | 49 |
PREX2 |
2.591e-02 | -3.65 | compound | COSMIC cancer mutations | compound | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | skin-upper_leg-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-upper_leg-malignant_melanoma-superficial_spreading | 9 | 1 | 16828 | 49 |
PREX2 |
2.591e-02 | -3.65 | ovary-low_malignant_potential_(borderline)_tumour-Brenner_tumour | COSMIC cancer mutations | ovary-low_malignant_potential_(borderline)_tumour-Brenner_tumour | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | skin-benign_melanocytic_nevus-congenital | COSMIC cancer mutations | skin-benign_melanocytic_nevus-congenital | 9 | 1 | 16828 | 49 |
FGFR3 |
2.616e-02 | -3.64 | muscle contraction | biological process | GO:0006936 | 238 | 3 | 18204 | 49 |
DTNA,ATP1A2,RYR3 |
2.622e-02 | -3.64 | phosphatidylinositol transfer activity | molecular function | GO:0008526 | 10 | 1 | 18094 | 48 |
PITPNC1 |
2.622e-02 | -3.64 | polyamine transmembrane transporter activity | molecular function | GO:0015203 | 10 | 1 | 18094 | 48 |
ATP13A4 |
2.622e-02 | -3.64 | neurotrophin binding | molecular function | GO:0043121 | 10 | 1 | 18094 | 48 |
NTRK2 |
2.631e-02 | -3.64 | DNAAF2 (dynein axonemal assembly factor 2) | protein interactions | 55172 | 98 | 2 | 19454 | 50 |
GPM6A,LSAMP |
2.646e-02 | -3.63 | human chr2p13.2 | chromosome location | human chr2p13.2 | 14 | 1 | 26134 | 50 |
SFXN5 |
2.648e-02 | -3.63 | LPA receptor mediated events | Pathway Interaction DB | lysophospholipid_pathway | 65 | 2 | 2226 | 9 |
GNA14,ADCY2 |
2.660e-02 | -3.63 | regulation of mesenchymal stem cell differentiation | biological process | GO:2000739 | 10 | 1 | 18204 | 49 |
SOX5 |
2.660e-02 | -3.63 | retinal rod cell development | biological process | GO:0046548 | 10 | 1 | 18204 | 49 |
NTRK2 |
2.660e-02 | -3.63 | cellular response to brain-derived neurotrophic factor stimulus | biological process | GO:1990416 | 10 | 1 | 18204 | 49 |
NTRK2 |
2.660e-02 | -3.63 | response to histamine | biological process | GO:0034776 | 10 | 1 | 18204 | 49 |
GABRB1 |
2.660e-02 | -3.63 | spinal cord motor neuron cell fate specification | biological process | GO:0021520 | 10 | 1 | 18204 | 49 |
GLI3 |
2.660e-02 | -3.63 | establishment of centrosome localization | biological process | GO:0051660 | 10 | 1 | 18204 | 49 |
PARD3B |
2.660e-02 | -3.63 | release of sequestered calcium ion into cytosol by endoplasmic reticulum | biological process | GO:1903514 | 10 | 1 | 18204 | 49 |
RYR3 |
2.660e-02 | -3.63 | regulation of bone development | biological process | GO:1903010 | 10 | 1 | 18204 | 49 |
GLI3 |
2.660e-02 | -3.63 | trans-synaptic signaling, modulating synaptic transmission | biological process | GO:0099550 | 10 | 1 | 18204 | 49 |
NTRK2 |
2.660e-02 | -3.63 | cAMP biosynthetic process | biological process | GO:0006171 | 10 | 1 | 18204 | 49 |
ADCY2 |
2.668e-02 | -3.62 | PAS_fold_3 | interpro domains | IPR013655 | 10 | 1 | 18521 | 50 |
NPAS3 |
2.668e-02 | -3.62 | HCO3_transpt_euk | interpro domains | IPR003020 | 10 | 1 | 18521 | 50 |
SLC4A4 |
2.668e-02 | -3.62 | MIR_motif | interpro domains | IPR016093 | 10 | 1 | 18521 | 50 |
RYR3 |
2.668e-02 | -3.62 | MIP_CS | interpro domains | IPR022357 | 10 | 1 | 18521 | 50 |
AQP4 |
2.668e-02 | -3.62 | PTrfase/Anion_transptr | interpro domains | IPR016152 | 10 | 1 | 18521 | 50 |
SLC4A4 |
2.668e-02 | -3.62 | HCO3_transpt-like_TM_dom | interpro domains | IPR011531 | 10 | 1 | 18521 | 50 |
SLC4A4 |
2.668e-02 | -3.62 | MIR_dom_sf | interpro domains | IPR036300 | 10 | 1 | 18521 | 50 |
RYR3 |
2.683e-02 | -3.62 | ATPase-coupled transmembrane transporter activity | molecular function | GO:0042626 | 96 | 2 | 18094 | 48 |
ATP13A4,ATP1A2 |
2.698e-02 | -3.61 | growth | biological process | GO:0040007 | 424 | 4 | 18204 | 49 |
GLI3,FGFR3,SLC1A2,BMPR1B |
2.698e-02 | -3.61 | developmental growth | biological process | GO:0048589 | 424 | 4 | 18204 | 49 |
BMPR1B,FGFR3,GLI3,SLC1A2 |
2.719e-02 | -3.60 | Tyr_kinase_AS | interpro domains | IPR008266 | 95 | 2 | 18521 | 50 |
FGFR3,NTRK2 |
2.720e-02 | -3.60 | MIR | pfam domains | PF02815 | 10 | 1 | 17795 | 49 |
RYR3 |
2.720e-02 | -3.60 | HCO3_cotransp | pfam domains | PF00955 | 10 | 1 | 17795 | 49 |
SLC4A4 |
2.720e-02 | -3.60 | PAS_3 | pfam domains | PF08447 | 10 | 1 | 17795 | 49 |
NPAS3 |
2.731e-02 | -3.60 | ATP4A (ATPase H+/K+ transporting subunit alpha) | protein interactions | 495 | 100 | 2 | 19454 | 50 |
GPM6A,ATP1A2 |
2.731e-02 | -3.60 | SUFU (SUFU negative regulator of hedgehog signaling) | protein interactions | 51684 | 100 | 2 | 19454 | 50 |
GLIS3,GLI3 |
2.735e-02 | -3.60 | RHOG (ras homolog family member G) | protein interactions | 391 | 902 | 6 | 19454 | 50 |
MACF1,GLUD1,DTNA,STON2,PREX2,FMN2 |
2.758e-02 | -3.59 | Insulin secretion | KEGG pathways | hsa04911 | 85 | 2 | 7161 | 22 |
ATP1A2,ADCY2 |
2.769e-02 | -3.59 | NK-T_cell_lymphoma | COSMIC cancer mutations | NK-T_cell_lymphoma | 225 | 3 | 16828 | 49 |
RFX4,MGAT4C,DTNA |
2.781e-02 | -3.58 | CLEC4A (C-type lectin domain family 4 member A) | protein interactions | 50856 | 101 | 2 | 19454 | 50 |
FGFR3,CTNNA2 |
2.786e-02 | -3.58 | clathrin coat of endocytic vesicle | cellular component | GO:0030128 | 11 | 1 | 19108 | 49 |
STON2 |
2.786e-02 | -3.58 | AP-2 adaptor complex | cellular component | GO:0030122 | 11 | 1 | 19108 | 49 |
STON2 |
2.792e-02 | -3.58 | Cobll1 (Cobl-like 1) | protein interactions | 319876 | 11 | 1 | 19454 | 50 |
ABLIM1 |
2.792e-02 | -3.58 | CCDC17 (coiled-coil domain containing 17) | protein interactions | 149483 | 11 | 1 | 19454 | 50 |
FGFR3 |
2.792e-02 | -3.58 | NEUROD4 (neuronal differentiation 4) | protein interactions | 58158 | 11 | 1 | 19454 | 50 |
GABRB1 |
2.792e-02 | -3.58 | Wipi2 (WD repeat domain, phosphoinositide interacting 2) | protein interactions | 74781 | 11 | 1 | 19454 | 50 |
MACF1 |
2.792e-02 | -3.58 | SYN3 (synapsin III) | protein interactions | 8224 | 11 | 1 | 19454 | 50 |
GPM6A |
2.792e-02 | -3.58 | NTS (neurotensin) | protein interactions | 4922 | 11 | 1 | 19454 | 50 |
CPE |
2.792e-02 | -3.58 | AQP5 (aquaporin 5) | protein interactions | 362 | 11 | 1 | 19454 | 50 |
ATP1A2 |
2.792e-02 | -3.58 | ADCY5 (adenylate cyclase 5) | protein interactions | 111 | 11 | 1 | 19454 | 50 |
ADCY2 |
2.792e-02 | -3.58 | Batf3 (basic leucine zipper transcription factor, ATF-like 3) | protein interactions | 381319 | 11 | 1 | 19454 | 50 |
MACF1 |
2.792e-02 | -3.58 | Gtf2e2 (general transcription factor II E, polypeptide 2 (beta subunit)) | protein interactions | 68153 | 11 | 1 | 19454 | 50 |
NHSL1 |
2.810e-02 | -3.57 | nerve development | biological process | GO:0021675 | 97 | 2 | 18204 | 49 |
SLC1A3,GLI3 |
2.810e-02 | -3.57 | amino acid transmembrane transport | biological process | GO:0003333 | 97 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
2.832e-02 | -3.56 | human chr8q12.3 | chromosome location | human chr8q12.3 | 15 | 1 | 26134 | 50 |
NKAIN3 |
2.846e-02 | -3.56 | VHP | smart domains | SM00153 | 8 | 1 | 9717 | 35 |
ABLIM1 |
2.847e-02 | -3.56 | regulation of synapse organization | biological process | GO:0050807 | 246 | 3 | 18204 | 49 |
CTNNA2,NTRK2,GPM6A |
2.847e-02 | -3.56 | positive regulation of neurogenesis | biological process | GO:0050769 | 246 | 3 | 18204 | 49 |
NTRK2,MACF1,GLI3 |
2.853e-02 | -3.56 | HP | prosite domains | PS51089 | 8 | 1 | 12186 | 44 |
ABLIM1 |
2.865e-02 | -3.55 | urinary_tract-bladder-carcinoma | COSMIC cancer mutations | urinary_tract-bladder-carcinoma | 14050 | 46 | 16828 | 49 |
TNIK,MSI2,SFXN5,GLUD1,FBXL7,LSAMP,HIF3A,MGAT4C,ABLIM1,FGFR3,CPE,NTRK2,CTNND2,SORBS1,STON2,GABRB1,RFX4,RORA,GLI3,DTNA,SLC1A2,SPARCL1,ZNRF3,PREX2,NTM,CACHD1,SOX5,MACF1,GPC5,SLC4A4,ADCY2,PITPNC1,GNA14,SHROOM3,PARD3B,GLIS3,FMN2,RYR3,ATP13A4,GPM6A,PAMR1,SLC1A3,RANBP3L,ATP1A2,BMPR1B,NPAS3 |
2.875e-02 | -3.55 | cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_III | COSMIC cancer mutations | cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_III | 10 | 1 | 16828 | 49 |
FGFR3 |
2.875e-02 | -3.55 | renal_cell_carcinoma_unclassified | COSMIC cancer mutations | renal_cell_carcinoma_unclassified | 10 | 1 | 16828 | 49 |
FGFR3 |
2.875e-02 | -3.55 | intradermal | COSMIC cancer mutations | intradermal | 10 | 1 | 16828 | 49 |
FGFR3 |
2.875e-02 | -3.55 | lung-carcinoma-pleomorphic_carcinoma | COSMIC cancer mutations | lung-carcinoma-pleomorphic_carcinoma | 10 | 1 | 16828 | 49 |
FGFR3 |
2.875e-02 | -3.55 | cervical_intraepithelial_neoplasia_Grade_III | COSMIC cancer mutations | cervical_intraepithelial_neoplasia_Grade_III | 10 | 1 | 16828 | 49 |
FGFR3 |
2.875e-02 | -3.55 | kidney-carcinoma-renal_cell_carcinoma_unclassified | COSMIC cancer mutations | kidney-carcinoma-renal_cell_carcinoma_unclassified | 10 | 1 | 16828 | 49 |
FGFR3 |
2.875e-02 | -3.55 | skin-back-malignant_melanoma-nodular | COSMIC cancer mutations | skin-back-malignant_melanoma-nodular | 10 | 1 | 16828 | 49 |
PREX2 |
2.880e-02 | -3.55 | Bicarbonate transporters | REACTOME pathways | R-HSA-425381 | 10 | 1 | 10285 | 30 |
SLC4A4 |
2.880e-02 | -3.55 | Acetylcholine regulates insulin secretion | REACTOME pathways | R-HSA-399997 | 10 | 1 | 10285 | 30 |
GNA14 |
2.880e-02 | -3.55 | Adenylate cyclase activating pathway | REACTOME pathways | R-HSA-170660 | 10 | 1 | 10285 | 30 |
ADCY2 |
2.880e-02 | -3.55 | Signaling by FGFR3 fusions in cancer | REACTOME pathways | R-HSA-8853334 | 10 | 1 | 10285 | 30 |
FGFR3 |
2.880e-02 | -3.55 | sulfur amino acid transmembrane transporter activity | molecular function | GO:0000099 | 11 | 1 | 18094 | 48 |
SLC1A2 |
2.881e-02 | -3.55 | upper_aerodigestive_tract-head_neck-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-head_neck-carcinoma-squamous_cell_carcinoma | 9263 | 34 | 16828 | 49 |
ATP1A2,CACHD1,MACF1,SOX5,NKAIN3,BMPR1B,RANBP3L,GPC5,SLC4A4,GLI3,RORA,GABRB1,PREX2,PAMR1,NTRK2,GLIS3,FMN2,GNA14,SHROOM3,PARD3B,FGFR3,STON2,RYR3,SORBS1,CTNND2,FBXL7,MSI2,TNIK,HIF3A,ADCY2,MGAT4C,PITPNC1,NHSL1,LSAMP |
2.884e-02 | -3.55 | RAB6B (RAB6B, member RAS oncogene family) | protein interactions | 51560 | 103 | 2 | 19454 | 50 |
BMPR1B,GPM6A |
2.885e-02 | -3.55 | inorganic ion homeostasis | biological process | GO:0098771 | 433 | 4 | 18204 | 49 |
ATP13A4,RYR3,SLC1A3,ATP1A2 |
2.892e-02 | -3.54 | Glucose-Alanine Cycle | SMPDB pathways | SMP0000127 | 8 | 1 | 1369 | 5 |
GLUD1 |
2.892e-02 | -3.54 | Intracellular Signalling Through Prostacyclin Receptor and Prostacyclin | SMPDB pathways | SMP0000354 | 8 | 1 | 1369 | 5 |
ADCY2 |
2.892e-02 | -3.54 | Bile Acid Indirect Signalling Pathway | SMPDB pathways | SMP0086851 | 8 | 1 | 1369 | 5 |
FGFR3 |
2.893e-02 | -3.54 | amino acid transmembrane transporter activity | molecular function | GO:0015171 | 100 | 2 | 18094 | 48 |
SLC1A2,SLC1A3 |
2.894e-02 | -3.54 | Ig-like_dom | interpro domains | IPR007110 | 432 | 4 | 18521 | 50 |
FGFR3,NTM,LSAMP,NTRK2 |
2.916e-02 | -3.54 | monoatomic ion channel activity | molecular function | GO:0005216 | 441 | 4 | 18094 | 48 |
GPM6A,GABRB1,CACHD1,RYR3 |
2.917e-02 | -3.53 | NS-malignant_melanoma | COSMIC cancer mutations | NS-malignant_melanoma | 3420 | 16 | 16828 | 49 |
FMN2,MACF1,GLIS3,ATP1A2,FGFR3,SHROOM3,STON2,ATP13A4,GPC5,CTNND2,RFX4,GABRB1,MGAT4C,PITPNC1,PREX2,ADCY2 |
2.920e-02 | -3.53 | LCK (LCK proto-oncogene, Src family tyrosine kinase) | protein interactions | 3932 | 455 | 4 | 19454 | 50 |
MACF1,DTNA,FMN2,CTNND2 |
2.920e-02 | -3.53 | FGFR4 (fibroblast growth factor receptor 4) | protein interactions | 2264 | 455 | 4 | 19454 | 50 |
SORBS1,TNIK,GLUD1,ABLIM1 |
2.922e-02 | -3.53 | cell fate commitment involved in pattern specification | biological process | GO:0060581 | 11 | 1 | 18204 | 49 |
GLI3 |
2.922e-02 | -3.53 | glutamate secretion | biological process | GO:0014047 | 11 | 1 | 18204 | 49 |
NTRK2 |
2.922e-02 | -3.53 | L-ascorbic acid metabolic process | biological process | GO:0019852 | 11 | 1 | 18204 | 49 |
ATP1A2 |
2.922e-02 | -3.53 | ventral spinal cord interneuron fate commitment | biological process | GO:0060579 | 11 | 1 | 18204 | 49 |
GLI3 |
2.922e-02 | -3.53 | establishment or maintenance of transmembrane electrochemical gradient | biological process | GO:0010248 | 11 | 1 | 18204 | 49 |
ATP1A2 |
2.922e-02 | -3.53 | lactone metabolic process | biological process | GO:1901334 | 11 | 1 | 18204 | 49 |
ATP1A2 |
2.922e-02 | -3.53 | antral ovarian follicle growth | biological process | GO:0001547 | 11 | 1 | 18204 | 49 |
BMPR1B |
2.922e-02 | -3.53 | polyamine transport | biological process | GO:0015846 | 11 | 1 | 18204 | 49 |
ATP13A4 |
2.922e-02 | -3.53 | thymocyte apoptotic process | biological process | GO:0070242 | 11 | 1 | 18204 | 49 |
GLI3 |
2.922e-02 | -3.53 | cellular response to caffeine | biological process | GO:0071313 | 11 | 1 | 18204 | 49 |
RYR3 |
2.927e-02 | -3.53 | Post-translational modification: synthesis of GPI-anchored proteins | REACTOME pathways | R-HSA-163125 | 92 | 2 | 10285 | 30 |
LSAMP,NTM |
2.931e-02 | -3.53 | Ran_bind_dom | interpro domains | IPR000156 | 11 | 1 | 18521 | 50 |
RANBP3L |
2.931e-02 | -3.53 | RanBP1-like | interpro domains | IPR045255 | 11 | 1 | 18521 | 50 |
RANBP3L |
2.931e-02 | -3.53 | Tyr_kinase_rcpt_2_CS | interpro domains | IPR002011 | 11 | 1 | 18521 | 50 |
NTRK2 |
2.941e-02 | -3.53 | GABAergic synapse | KEGG pathways | ko04727 | 88 | 2 | 7161 | 22 |
ADCY2,GABRB1 |
2.941e-02 | -3.53 | GABAergic synapse | KEGG pathways | hsa04727 | 88 | 2 | 7161 | 22 |
ADCY2,GABRB1 |
2.988e-02 | -3.51 | Adap_comp_sub | pfam domains | PF00928 | 11 | 1 | 17795 | 49 |
STON2 |
2.988e-02 | -3.51 | PAS_11 | pfam domains | PF14598 | 11 | 1 | 17795 | 49 |
HIF3A |
2.988e-02 | -3.51 | Ran_BP1 | pfam domains | PF00638 | 11 | 1 | 17795 | 49 |
RANBP3L |
2.997e-02 | -3.51 | calcium ion transport | biological process | GO:0006816 | 251 | 3 | 18204 | 49 |
GPM6A,CACHD1,RYR3 |
3.000e-02 | -3.51 | Helical hairpin bin | gene3d domains | 1.10.287.570 | 10 | 1 | 14470 | 44 |
SLC4A4 |
3.012e-02 | -3.50 | Tgif disruption of Shh signaling | WikiPathways | WP3674 | 9 | 1 | 5310 | 18 |
GLI3 |
3.018e-02 | -3.50 | transporter complex | cellular component | GO:1990351 | 461 | 4 | 19108 | 49 |
CACHD1,ATP1A2,RYR3,GABRB1 |
3.021e-02 | -3.50 | response to organic substance | biological process | GO:0010033 | 2498 | 12 | 18204 | 49 |
NTRK2,RYR3,SORBS1,ATP1A2,SLC1A2,AQP4,RORA,GNA14,GABRB1,SLC1A3,ADCY2,TNIK |
3.026e-02 | -3.50 | Pathways in cancer | KEGG pathways | hsa05200 | 395 | 4 | 7161 | 22 |
FGFR3,ADCY2,CTNNA2,GLI3 |
3.027e-02 | -3.50 | regulation of glucose metabolic process | biological process | GO:0010906 | 101 | 2 | 18204 | 49 |
SORBS1,RORA |
3.027e-02 | -3.50 | regulation of synapse structure or activity | biological process | GO:0050803 | 252 | 3 | 18204 | 49 |
GPM6A,NTRK2,CTNNA2 |
3.035e-02 | -3.49 | sodium:potassium-exchanging ATPase complex | cellular component | GO:0005890 | 12 | 1 | 19108 | 49 |
ATP1A2 |
3.036e-02 | -3.49 | NRAS (NRAS proto-oncogene, GTPase) | protein interactions | 4893 | 683 | 5 | 19454 | 50 |
MACF1,CACHD1,TNIK,SLC1A3,FMN2 |
3.039e-02 | -3.49 | skin-hand-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-hand-carcinoma-squamous_cell_carcinoma | 407 | 4 | 16828 | 49 |
HIF3A,SLC4A4,FGFR3,SHROOM3 |
3.042e-02 | -3.49 | SSTR2 (somatostatin receptor 2) | protein interactions | 6752 | 12 | 1 | 19454 | 50 |
GNA14 |
3.042e-02 | -3.49 | CA4 (carbonic anhydrase 4) | protein interactions | 762 | 12 | 1 | 19454 | 50 |
SLC4A4 |
3.042e-02 | -3.49 | LGR5 (leucine rich repeat containing G protein-coupled receptor 5) | protein interactions | 8549 | 12 | 1 | 19454 | 50 |
ZNRF3 |
3.042e-02 | -3.49 | NTF4 (neurotrophin 4) | protein interactions | 4909 | 12 | 1 | 19454 | 50 |
NTRK2 |
3.042e-02 | -3.49 | LMP-1 (latent membrane protein LMP-1) | protein interactions | 3783750 | 12 | 1 | 19454 | 50 |
TNIK |
3.042e-02 | -3.49 | BAMBI (BMP and activin membrane bound inhibitor) | protein interactions | 25805 | 12 | 1 | 19454 | 50 |
BMPR1B |
3.042e-02 | -3.49 | PROK2 (prokineticin 2) | protein interactions | 60675 | 12 | 1 | 19454 | 50 |
CPE |
3.042e-02 | -3.49 | ART4 (ADP-ribosyltransferase 4 (inactive) (Dombrock blood group)) | protein interactions | 420 | 12 | 1 | 19454 | 50 |
GPM6A |
3.067e-02 | -3.48 | PROKAR_LIPOPROTEIN | prosite domains | PS51257 | 76 | 2 | 12186 | 44 |
CPE,GLIS3 |
3.082e-02 | -3.48 | alpha-beta T cell activation | biological process | GO:0046631 | 102 | 2 | 18204 | 49 |
GLI3,RORA |
3.083e-02 | -3.48 | response to stimulus | biological process | GO:0050896 | 7803 | 28 | 18204 | 49 |
SOX5,GABRB1,GLI3,RORA,FMN2,SPARCL1,FGFR3,SLC1A3,CTNND2,PREX2,BMPR1B,CTNNA2,ZNRF3,SORBS1,CPE,GNA14,AQP4,ADCY2,TNIK,MACF1,DTNA,SHROOM3,GPM6A,NTRK2,PITPNC1,SLC1A2,RYR3,ATP1A2 |
3.100e-02 | -3.47 | RHOA (ras homolog family member A) | protein interactions | 387 | 1186 | 7 | 19454 | 50 |
FMN2,CTNNA2,PARD3B,PREX2,STON2,GLUD1,MACF1 |
3.101e-02 | -3.47 | regulation of neuron projection development | biological process | GO:0010975 | 443 | 4 | 18204 | 49 |
TNIK,MACF1,CTNNA2,NTRK2 |
3.125e-02 | -3.47 | regulation of biological process | biological process | GO:0050789 | 12079 | 39 | 18204 | 49 |
CTNND2,GPC5,RANBP3L,PREX2,CTNNA2,BMPR1B,MSI2,NKAIN3,NPAS3,SORBS1,ZNRF3,GLI3,GABRB1,SOX5,FMN2,RORA,GLUD1,SPARCL1,FGFR3,SLC1A3,MACF1,DTNA,SHROOM3,STON2,HIF3A,GPM6A,SLC4A4,GLIS3,PITPNC1,NTRK2,SLC1A2,ATP1A2,RYR3,CPE,GNA14,RFX4,TNIK,ADCY2,SFXN5 |
3.129e-02 | -3.46 | Morphine addiction | KEGG pathways | ko05032 | 91 | 2 | 7161 | 22 |
GABRB1,ADCY2 |
3.129e-02 | -3.46 | Morphine addiction | KEGG pathways | hsa05032 | 91 | 2 | 7161 | 22 |
GABRB1,ADCY2 |
3.131e-02 | -3.46 | biological regulation | biological process | GO:0065007 | 12501 | 40 | 18204 | 49 |
SPARCL1,SLC1A3,FGFR3,GLUD1,RORA,FMN2,SOX5,GLI3,GABRB1,BMPR1B,CTNNA2,PREX2,ZNRF3,SORBS1,NPAS3,MSI2,NKAIN3,RANBP3L,CTNND2,GPC5,RFX4,ADCY2,SFXN5,TNIK,CPE,AQP4,GNA14,NTRK2,GLIS3,PITPNC1,SLC4A4,GPM6A,HIF3A,RYR3,ATP1A2,SLC1A2,SHROOM3,DTNA,MACF1,STON2 |
3.138e-02 | -3.46 | G protein-coupled neurotransmitter receptor activity | molecular function | GO:0099528 | 12 | 1 | 18094 | 48 |
GABRB1 |
3.138e-02 | -3.46 | adenylate cyclase binding | molecular function | GO:0008179 | 12 | 1 | 18094 | 48 |
ADCY2 |
3.147e-02 | -3.46 | FKBP1A (FKBP prolyl isomerase 1A) | protein interactions | 2280 | 108 | 2 | 19454 | 50 |
RYR3,MSI2 |
3.149e-02 | -3.46 | PFN1 (profilin 1) | protein interactions | 5216 | 466 | 4 | 19454 | 50 |
FMN2,NHSL1,ABLIM1,MACF1 |
3.151e-02 | -3.46 | protein complex oligomerization | biological process | GO:0051259 | 256 | 3 | 18204 | 49 |
AQP4,RYR3,SLC1A2 |
3.158e-02 | -3.46 | skin-back-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-back-malignant_melanoma-superficial_spreading | 11 | 1 | 16828 | 49 |
PREX2 |
3.158e-02 | -3.46 | congenital | COSMIC cancer mutations | congenital | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | oncocytoma | COSMIC cancer mutations | oncocytoma | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | prostate-hyperplasia | COSMIC cancer mutations | prostate-hyperplasia | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | seborrhoeic_keratosis | COSMIC cancer mutations | seborrhoeic_keratosis | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | skin-hand-malignant_melanoma-acral_lentiginous | COSMIC cancer mutations | skin-hand-malignant_melanoma-acral_lentiginous | 11 | 1 | 16828 | 49 |
PREX2 |
3.158e-02 | -3.46 | skin-neck-carcinoma-basal_cell_carcinoma | COSMIC cancer mutations | skin-neck-carcinoma-basal_cell_carcinoma | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | skin-scalp-carcinoma-basal_cell_carcinoma | COSMIC cancer mutations | skin-scalp-carcinoma-basal_cell_carcinoma | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | pleomorphic_carcinoma | COSMIC cancer mutations | pleomorphic_carcinoma | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | kidney-other-oncocytoma | COSMIC cancer mutations | kidney-other-oncocytoma | 11 | 1 | 16828 | 49 |
FGFR3 |
3.184e-02 | -3.45 | pigment accumulation | biological process | GO:0043476 | 12 | 1 | 18204 | 49 |
SHROOM3 |
3.184e-02 | -3.45 | sulfur amino acid transport | biological process | GO:0000101 | 12 | 1 | 18204 | 49 |
SLC1A2 |
3.184e-02 | -3.45 | auditory behavior | biological process | GO:0031223 | 12 | 1 | 18204 | 49 |
SLC1A3 |
3.184e-02 | -3.45 | negative thymic T cell selection | biological process | GO:0045060 | 12 | 1 | 18204 | 49 |
GLI3 |
3.184e-02 | -3.45 | positive regulation of extrinsic apoptotic signaling pathway via death domain receptors | biological process | GO:1902043 | 12 | 1 | 18204 | 49 |
BMPR1B |
3.184e-02 | -3.45 | cellular pigment accumulation | biological process | GO:0043482 | 12 | 1 | 18204 | 49 |
SHROOM3 |
3.184e-02 | -3.45 | dicarboxylic acid biosynthetic process | biological process | GO:0043650 | 12 | 1 | 18204 | 49 |
GLUD1 |
3.184e-02 | -3.45 | mammalian oogenesis stage | biological process | GO:0022605 | 12 | 1 | 18204 | 49 |
BMPR1B |
3.193e-02 | -3.44 | AP2_Mu_C_sf | interpro domains | IPR036168 | 12 | 1 | 18521 | 50 |
STON2 |
3.193e-02 | -3.44 | TGFB_receptor | interpro domains | IPR000333 | 12 | 1 | 18521 | 50 |
BMPR1B |
3.197e-02 | -3.44 | FOLN | smart domains | SM00274 | 9 | 1 | 9717 | 35 |
SPARCL1 |
3.200e-02 | -3.44 | CLSTN1 (calsyntenin 1) | protein interactions | 22883 | 109 | 2 | 19454 | 50 |
SLC1A3,MGAT4C |
3.204e-02 | -3.44 | human chr9q21.33 | chromosome location | human chr9q21.33 | 17 | 1 | 26134 | 50 |
NTRK2 |
3.204e-02 | -3.44 | RFX_DBD | prosite domains | PS51526 | 9 | 1 | 12186 | 44 |
RFX4 |
3.207e-02 | -3.44 | biliary_tract-bile_duct-carcinoma-adenocarcinoma | COSMIC cancer mutations | biliary_tract-bile_duct-carcinoma-adenocarcinoma | 15095 | 48 | 16828 | 49 |
GPC5,SLC4A4,CACHD1,MACF1,SOX5,NTM,ZNRF3,SPARCL1,PREX2,SLC1A2,RORA,DTNA,GLI3,GABRB1,RFX4,STON2,CTNND2,SORBS1,CPE,NTRK2,ABLIM1,FGFR3,HIF3A,NHSL1,MGAT4C,LSAMP,SFXN5,FBXL7,GLUD1,TNIK,MSI2,NPAS3,ATP1A2,BMPR1B,RANBP3L,PAMR1,SLC1A3,GPM6A,ATP13A4,RYR3,GLIS3,FMN2,GNA14,PARD3B,SHROOM3,ADCY2,AQP4,PITPNC1 |
3.207e-02 | -3.44 | bile_duct | COSMIC cancer mutations | bile_duct | 15095 | 48 | 16828 | 49 |
ATP13A4,RYR3,GLIS3,FMN2,GNA14,PARD3B,SHROOM3,ADCY2,AQP4,PITPNC1,NPAS3,ATP1A2,BMPR1B,RANBP3L,PAMR1,SLC1A3,GPM6A,STON2,CTNND2,SORBS1,CPE,NTRK2,ABLIM1,FGFR3,HIF3A,NHSL1,MGAT4C,LSAMP,SFXN5,FBXL7,GLUD1,TNIK,MSI2,GPC5,SLC4A4,CACHD1,SOX5,MACF1,NTM,ZNRF3,SPARCL1,PREX2,SLC1A2,RORA,GLI3,DTNA,GABRB1,RFX4 |
3.249e-02 | -3.43 | Excitatory Neural Signalling Through 5-HTR 6 and Serotonin | SMPDB pathways | SMP0000312 | 9 | 1 | 1369 | 5 |
ADCY2 |
3.249e-02 | -3.43 | Intracellular Signalling Through FSH Receptor and Follicle Stimulating Hormone | SMPDB pathways | SMP0000333 | 9 | 1 | 1369 | 5 |
ADCY2 |
3.249e-02 | -3.43 | Excitatory Neural Signalling Through 5-HTR 7 and Serotonin | SMPDB pathways | SMP0000311 | 9 | 1 | 1369 | 5 |
ADCY2 |
3.249e-02 | -3.43 | Intracellular Signalling Through Histamine H2 Receptor and Histamine | SMPDB pathways | SMP0000335 | 9 | 1 | 1369 | 5 |
ADCY2 |
3.249e-02 | -3.43 | Excitatory Neural Signalling Through 5-HTR 4 and Serotonin | SMPDB pathways | SMP0000309 | 9 | 1 | 1369 | 5 |
ADCY2 |
3.254e-02 | -3.43 | LZTR1 (leucine zipper like post translational regulator 1) | protein interactions | 8216 | 110 | 2 | 19454 | 50 |
PARD3B,BMPR1B |
3.256e-02 | -3.42 | CarboxypepD_reg | pfam domains | PF13620 | 12 | 1 | 17795 | 49 |
CPE |
3.271e-02 | -3.42 | RDX (radixin) | protein interactions | 5962 | 272 | 3 | 19454 | 50 |
FGFR3,MACF1,ABLIM1 |
3.275e-02 | -3.42 | regulation of plasma membrane bounded cell projection organization | biological process | GO:0120035 | 666 | 5 | 18204 | 49 |
TNIK,GPM6A,MACF1,NTRK2,CTNNA2 |
3.276e-02 | -3.42 | steroid binding | molecular function | GO:0005496 | 107 | 2 | 18094 | 48 |
ATP1A2,RORA |
3.291e-02 | -3.41 | PLPPR4 (phospholipid phosphatase related 4) | protein interactions | 9890 | 13 | 1 | 19454 | 50 |
ZNRF3 |
3.291e-02 | -3.41 | TBCC (tubulin folding cofactor C) | protein interactions | 6903 | 13 | 1 | 19454 | 50 |
NTM |
3.291e-02 | -3.41 | Pias1 (protein inhibitor of activated STAT 1) | protein interactions | 56469 | 13 | 1 | 19454 | 50 |
GLI3 |
3.291e-02 | -3.41 | RAB3C (RAB3C, member RAS oncogene family) | protein interactions | 115827 | 13 | 1 | 19454 | 50 |
GPM6A |
3.296e-02 | -3.41 | Carboxypeptidase-like, regulatory domain | gene3d domains | 2.60.40.1120 | 11 | 1 | 14470 | 44 |
CPE |
3.307e-02 | -3.41 | oogenesis | biological process | GO:0048477 | 106 | 2 | 18204 | 49 |
FMN2,BMPR1B |
3.307e-02 | -3.41 | pigmentation | biological process | GO:0043473 | 106 | 2 | 18204 | 49 |
SHROOM3,GLI3 |
3.310e-02 | -3.41 | bladder | COSMIC cancer mutations | bladder | 14112 | 46 | 16828 | 49 |
ATP13A4,RYR3,GLIS3,FMN2,GNA14,PARD3B,SHROOM3,ADCY2,PITPNC1,NPAS3,ATP1A2,BMPR1B,RANBP3L,SLC1A3,PAMR1,GPM6A,STON2,SORBS1,CTNND2,NTRK2,CPE,ABLIM1,FGFR3,HIF3A,MGAT4C,LSAMP,FBXL7,GLUD1,SFXN5,MSI2,TNIK,GPC5,SLC4A4,CACHD1,MACF1,SOX5,NTM,ZNRF3,SPARCL1,PREX2,SLC1A2,DTNA,GLI3,RORA,GABRB1,RFX4 |
3.310e-02 | -3.41 | urinary_tract | COSMIC cancer mutations | urinary_tract | 14112 | 46 | 16828 | 49 |
NPAS3,RANBP3L,ATP1A2,BMPR1B,SLC1A3,PAMR1,GPM6A,RYR3,ATP13A4,GNA14,PARD3B,SHROOM3,GLIS3,FMN2,ADCY2,PITPNC1,GPC5,SLC4A4,NTM,CACHD1,SOX5,MACF1,SLC1A2,ZNRF3,SPARCL1,PREX2,GABRB1,RFX4,DTNA,GLI3,RORA,SORBS1,CTNND2,STON2,ABLIM1,FGFR3,NTRK2,CPE,LSAMP,HIF3A,MGAT4C,MSI2,TNIK,FBXL7,GLUD1,SFXN5 |
3.330e-02 | -3.40 | Hedgehog signaling | KEGG pathways | hsa_M00678 | 11 | 1 | 7161 | 22 |
GLI3 |
3.330e-02 | -3.40 | Hedgehog signaling | KEGG pathways | M00678 | 11 | 1 | 7161 | 22 |
GLI3 |
3.342e-02 | -3.40 | TyrKc | smart domains | SM00219 | 80 | 2 | 9717 | 35 |
NTRK2,FGFR3 |
3.379e-02 | -3.39 | positive regulation of cell differentiation | biological process | GO:0045597 | 906 | 6 | 18204 | 49 |
SOX5,GLI3,RANBP3L,MACF1,BMPR1B,NTRK2 |
3.387e-02 | -3.39 | skin-arm-malignant_melanoma | COSMIC cancer mutations | skin-arm-malignant_melanoma | 1308 | 8 | 16828 | 49 |
SLC4A4,NPAS3,SORBS1,ATP1A2,MACF1,NTM,PARD3B,SHROOM3 |
3.389e-02 | -3.38 | human chr4p12 | chromosome location | human chr4p12 | 18 | 1 | 26134 | 50 |
GABRB1 |
3.395e-02 | -3.38 | transforming growth factor beta receptor activity | molecular function | GO:0005024 | 13 | 1 | 18094 | 48 |
BMPR1B |
3.395e-02 | -3.38 | monoatomic cation:bicarbonate symporter activity | molecular function | GO:0140410 | 13 | 1 | 18094 | 48 |
SLC4A4 |
3.395e-02 | -3.38 | GABA-gated chloride ion channel activity | molecular function | GO:0022851 | 13 | 1 | 18094 | 48 |
GABRB1 |
3.395e-02 | -3.38 | potassium ion binding | molecular function | GO:0030955 | 13 | 1 | 18094 | 48 |
ATP1A2 |
3.418e-02 | -3.38 | GFI1B (growth factor independent 1B transcriptional repressor) | protein interactions | 8328 | 113 | 2 | 19454 | 50 |
ZNRF3,DTNA |
3.427e-02 | -3.37 | adrenal_gland | COSMIC cancer mutations | adrenal_gland | 2628 | 13 | 16828 | 49 |
RFX4,GLI3,SLC1A2,NHSL1,ADCY2,ZNRF3,FGFR3,FMN2,SOX5,CACHD1,ATP1A2,NTRK2,CTNND2 |
3.440e-02 | -3.37 | cervix-carcinoma-mixed_adenosquamous_carcinoma | COSMIC cancer mutations | cervix-carcinoma-mixed_adenosquamous_carcinoma | 12 | 1 | 16828 | 49 |
FGFR3 |
3.440e-02 | -3.37 | skin-benign_melanocytic_nevus | COSMIC cancer mutations | skin-benign_melanocytic_nevus | 12 | 1 | 16828 | 49 |
FGFR3 |
3.440e-02 | -3.37 | skin-abdomen-malignant_melanoma-nodular | COSMIC cancer mutations | skin-abdomen-malignant_melanoma-nodular | 12 | 1 | 16828 | 49 |
PREX2 |
3.440e-02 | -3.37 | skin-face-carcinoma-basal_cell_carcinoma | COSMIC cancer mutations | skin-face-carcinoma-basal_cell_carcinoma | 12 | 1 | 16828 | 49 |
FGFR3 |
3.444e-02 | -3.37 | negative T cell selection | biological process | GO:0043383 | 13 | 1 | 18204 | 49 |
GLI3 |
3.444e-02 | -3.37 | ventral spinal cord interneuron differentiation | biological process | GO:0021514 | 13 | 1 | 18204 | 49 |
GLI3 |
3.444e-02 | -3.37 | negative regulation of cytosolic calcium ion concentration | biological process | GO:0051481 | 13 | 1 | 18204 | 49 |
ATP1A2 |
3.444e-02 | -3.37 | prepulse inhibition | biological process | GO:0060134 | 13 | 1 | 18204 | 49 |
CTNNA2 |
3.444e-02 | -3.37 | cerebellar Purkinje cell differentiation | biological process | GO:0021702 | 13 | 1 | 18204 | 49 |
RORA |
3.444e-02 | -3.37 | T-helper 17 cell differentiation | biological process | GO:0072539 | 13 | 1 | 18204 | 49 |
RORA |
3.444e-02 | -3.37 | regulation of respiratory gaseous exchange by nervous system process | biological process | GO:0002087 | 13 | 1 | 18204 | 49 |
ATP1A2 |
3.446e-02 | -3.37 | FGFR3 mutant receptor activation | REACTOME pathways | R-HSA-2033514 | 12 | 1 | 10285 | 30 |
FGFR3 |
3.446e-02 | -3.37 | Regulation of gene expression by Hypoxia-inducible Factor | REACTOME pathways | R-HSA-1234158 | 12 | 1 | 10285 | 30 |
HIF3A |
3.446e-02 | -3.37 | Defective EXT1 causes exostoses 1, TRPS2 and CHDS | REACTOME pathways | R-HSA-3656253 | 12 | 1 | 10285 | 30 |
GPC5 |
3.446e-02 | -3.37 | Signaling by activated point mutants of FGFR3 | REACTOME pathways | R-HSA-1839130 | 12 | 1 | 10285 | 30 |
FGFR3 |
3.446e-02 | -3.37 | Defective EXT2 causes exostoses 2 | REACTOME pathways | R-HSA-3656237 | 12 | 1 | 10285 | 30 |
GPC5 |
3.452e-02 | -3.37 | Circadian entrainment | KEGG pathways | hsa04713 | 96 | 2 | 7161 | 22 |
RYR3,ADCY2 |
3.452e-02 | -3.37 | Circadian entrainment | KEGG pathways | ko04713 | 96 | 2 | 7161 | 22 |
ADCY2,RYR3 |
3.459e-02 | -3.36 | plasma membrane raft | cellular component | GO:0044853 | 114 | 2 | 19108 | 49 |
SORBS1,ATP1A2 |
3.475e-02 | -3.36 | Hedgehog 'off' state | REACTOME pathways | R-HSA-5610787 | 101 | 2 | 10285 | 30 |
ADCY2,GLI3 |
3.530e-02 | -3.34 | SMAD7 (SMAD family member 7) | protein interactions | 4092 | 115 | 2 | 19454 | 50 |
BMPR1B,SOX5 |
3.539e-02 | -3.34 | chloride transmembrane transport | biological process | GO:1902476 | 110 | 2 | 18204 | 49 |
GABRB1,SLC1A3 |
3.540e-02 | -3.34 | Nedd4 (neural precursor cell expressed, developmentally down-regulated 4) | protein interactions | 17999 | 14 | 1 | 19454 | 50 |
GLIS3 |
3.540e-02 | -3.34 | Asap1 (ArfGAP with SH3 domain, ankyrin repeat and PH domain1) | protein interactions | 13196 | 14 | 1 | 19454 | 50 |
MACF1 |
3.540e-02 | -3.34 | FGF7 (fibroblast growth factor 7) | protein interactions | 2252 | 14 | 1 | 19454 | 50 |
FGFR3 |
3.540e-02 | -3.34 | BOD1L2 (biorientation of chromosomes in cell division 1 like 2) | protein interactions | 284257 | 14 | 1 | 19454 | 50 |
FMN2 |
3.540e-02 | -3.34 | RHEBL1 (RHEB like 1) | protein interactions | 121268 | 14 | 1 | 19454 | 50 |
BMPR1B |
3.540e-02 | -3.34 | PLXNA4 (plexin A4) | protein interactions | 91584 | 14 | 1 | 19454 | 50 |
GPM6A |
3.540e-02 | -3.34 | SLC1A2 (solute carrier family 1 member 2) | protein interactions | 6506 | 14 | 1 | 19454 | 50 |
SLC1A2 |
3.540e-02 | -3.34 | RSPO1 (R-spondin 1) | protein interactions | 284654 | 14 | 1 | 19454 | 50 |
ZNRF3 |
3.545e-02 | -3.34 | mast_cell_neoplasm | COSMIC cancer mutations | mast_cell_neoplasm | 248 | 3 | 16828 | 49 |
ADCY2,GPC5,NPAS3 |
3.545e-02 | -3.34 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-mast_cell_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-mast_cell_neoplasm | 248 | 3 | 16828 | 49 |
NPAS3,GPC5,ADCY2 |
3.546e-02 | -3.34 | MIR | smart domains | SM00472 | 10 | 1 | 9717 | 35 |
RYR3 |
3.554e-02 | -3.34 | MIP | prosite domains | PS00221 | 10 | 1 | 12186 | 44 |
AQP4 |
3.554e-02 | -3.34 | MIR | prosite domains | PS50919 | 10 | 1 | 12186 | 44 |
RYR3 |
3.574e-02 | -3.33 | human chr6q24.1 | chromosome location | human chr6q24.1 | 19 | 1 | 26134 | 50 |
NHSL1 |
3.574e-02 | -3.33 | human chr10q23.2 | chromosome location | human chr10q23.2 | 19 | 1 | 26134 | 50 |
GLUD1 |
3.574e-02 | -3.33 | human chr5p15.2 | chromosome location | human chr5p15.2 | 19 | 1 | 26134 | 50 |
CTNND2 |
3.574e-02 | -3.33 | human chr11q25 | chromosome location | human chr11q25 | 19 | 1 | 26134 | 50 |
NTM |
3.586e-02 | -3.33 | SKIL (SKI like proto-oncogene) | protein interactions | 6498 | 116 | 2 | 19454 | 50 |
MACF1,SPARCL1 |
3.590e-02 | -3.33 | Alpha-catenin/vinculin-like | gene3d domains | 1.20.120.230 | 12 | 1 | 14470 | 44 |
CTNNA2 |
3.590e-02 | -3.33 | Mu homology domain, subdomain B | gene3d domains | 2.60.40.1170 | 12 | 1 | 14470 | 44 |
STON2 |
3.593e-02 | -3.33 | regulation of cell projection organization | biological process | GO:0031344 | 683 | 5 | 18204 | 49 |
TNIK,CTNNA2,NTRK2,MACF1,GPM6A |
3.605e-02 | -3.32 | Intracellular Signalling Through LHCGR Receptor and Luteinizing Hormone/Choriogonadotropin | SMPDB pathways | SMP0000338 | 10 | 1 | 1369 | 5 |
ADCY2 |
3.612e-02 | -3.32 | chromophobe_renal_cell_carcinoma | COSMIC cancer mutations | chromophobe_renal_cell_carcinoma | 430 | 4 | 16828 | 49 |
TNIK,FGFR3,NTRK2,BMPR1B |
3.612e-02 | -3.32 | kidney-carcinoma-chromophobe_renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-chromophobe_renal_cell_carcinoma | 430 | 4 | 16828 | 49 |
TNIK,FGFR3,NTRK2,BMPR1B |
3.612e-02 | -3.32 | oesophagus-lower_third-carcinoma-adenocarcinoma | COSMIC cancer mutations | oesophagus-lower_third-carcinoma-adenocarcinoma | 6302 | 25 | 16828 | 49 |
ZNRF3,PAMR1,PREX2,RORA,GLI3,GPC5,NPAS3,RANBP3L,CACHD1,SOX5,MACF1,ADCY2,AQP4,MGAT4C,GLUD1,RYR3,CTNND2,SORBS1,STON2,ATP13A4,SHROOM3,PARD3B,CPE,NTRK2,FMN2 |
3.619e-02 | -3.32 | cell migration | biological process | GO:0016477 | 921 | 6 | 18204 | 49 |
CTNNA2,NTRK2,GPM6A,FMN2,GPC5,GLI3 |
3.652e-02 | -3.31 | microtubule minus-end binding | molecular function | GO:0051011 | 14 | 1 | 18094 | 48 |
MACF1 |
3.678e-02 | -3.30 | HLH_DNA-bd_sf | interpro domains | IPR036638 | 112 | 2 | 18521 | 50 |
HIF3A,NPAS3 |
3.678e-02 | -3.30 | bHLH_dom | interpro domains | IPR011598 | 112 | 2 | 18521 | 50 |
NPAS3,HIF3A |
3.704e-02 | -3.30 | cell surface receptor signaling pathway | biological process | GO:0007166 | 1992 | 10 | 18204 | 49 |
MACF1,CPE,GLI3,CTNND2,NTRK2,BMPR1B,TNIK,FGFR3,SORBS1,ZNRF3 |
3.704e-02 | -3.30 | cellular response to forskolin | biological process | GO:1904322 | 14 | 1 | 18204 | 49 |
ADCY2 |
3.704e-02 | -3.30 | mechanosensory behavior | biological process | GO:0007638 | 14 | 1 | 18204 | 49 |
SLC1A3 |
3.704e-02 | -3.30 | response to forskolin | biological process | GO:1904321 | 14 | 1 | 18204 | 49 |
ADCY2 |
3.704e-02 | -3.30 | relaxation of cardiac muscle | biological process | GO:0055119 | 14 | 1 | 18204 | 49 |
ATP1A2 |
3.704e-02 | -3.30 | glutathione biosynthetic process | biological process | GO:0006750 | 14 | 1 | 18204 | 49 |
SLC1A2 |
3.704e-02 | -3.30 | cerebrospinal fluid circulation | biological process | GO:0090660 | 14 | 1 | 18204 | 49 |
AQP4 |
3.704e-02 | -3.30 | radial glial cell differentiation | biological process | GO:0060019 | 14 | 1 | 18204 | 49 |
GLI3 |
3.704e-02 | -3.30 | negative regulation of sodium ion transmembrane transporter activity | biological process | GO:2000650 | 14 | 1 | 18204 | 49 |
ATP1A2 |
3.704e-02 | -3.30 | layer formation in cerebral cortex | biological process | GO:0021819 | 14 | 1 | 18204 | 49 |
GLI3 |
3.704e-02 | -3.30 | cellular response to purine-containing compound | biological process | GO:0071415 | 14 | 1 | 18204 | 49 |
RYR3 |
3.715e-02 | -3.29 | Aquaporin-like | interpro domains | IPR023271 | 14 | 1 | 18521 | 50 |
AQP4 |
3.715e-02 | -3.29 | MIP | interpro domains | IPR000425 | 14 | 1 | 18521 | 50 |
AQP4 |
3.715e-02 | -3.29 | MHD | interpro domains | IPR028565 | 14 | 1 | 18521 | 50 |
STON2 |
3.721e-02 | -3.29 | skin-back-carcinoma-basal_cell_carcinoma | COSMIC cancer mutations | skin-back-carcinoma-basal_cell_carcinoma | 13 | 1 | 16828 | 49 |
FGFR3 |
3.721e-02 | -3.29 | cervix-carcinoma-adenocarcinoma | COSMIC cancer mutations | cervix-carcinoma-adenocarcinoma | 13 | 1 | 16828 | 49 |
FGFR3 |
3.721e-02 | -3.29 | skin-shoulder-malignant_melanoma-nodular | COSMIC cancer mutations | skin-shoulder-malignant_melanoma-nodular | 13 | 1 | 16828 | 49 |
PREX2 |
3.721e-02 | -3.29 | adrenal_gland-adrenal_gland-adrenal_cortical_adenoma-virilizing_syndrome_producing | COSMIC cancer mutations | adrenal_gland-adrenal_gland-adrenal_cortical_adenoma-virilizing_syndrome_producing | 13 | 1 | 16828 | 49 |
CACHD1 |
3.721e-02 | -3.29 | endometrium-ovary-endometriosis | COSMIC cancer mutations | endometrium-ovary-endometriosis | 13 | 1 | 16828 | 49 |
FGFR3 |
3.721e-02 | -3.29 | Brenner_tumour | COSMIC cancer mutations | Brenner_tumour | 13 | 1 | 16828 | 49 |
FGFR3 |
3.721e-02 | -3.29 | skin-scalp-malignant_melanoma-nodular | COSMIC cancer mutations | skin-scalp-malignant_melanoma-nodular | 13 | 1 | 16828 | 49 |
PREX2 |
3.728e-02 | -3.29 | FGFR3c ligand binding and activation | REACTOME pathways | R-HSA-190372 | 13 | 1 | 10285 | 30 |
FGFR3 |
3.728e-02 | -3.29 | GABA A receptor activation | REACTOME pathways | R-HSA-977441 | 13 | 1 | 10285 | 30 |
GABRB1 |
3.728e-02 | -3.29 | Passive transport by Aquaporins | REACTOME pathways | R-HSA-432047 | 13 | 1 | 10285 | 30 |
AQP4 |
3.728e-02 | -3.29 | FGFR3 ligand binding and activation | REACTOME pathways | R-HSA-190239 | 13 | 1 | 10285 | 30 |
FGFR3 |
3.728e-02 | -3.29 | Phospholipase C-mediated cascade; FGFR3 | REACTOME pathways | R-HSA-5654227 | 13 | 1 | 10285 | 30 |
FGFR3 |
3.754e-02 | -3.28 | basal plasma membrane | cellular component | GO:0009925 | 288 | 3 | 19108 | 49 |
SLC1A3,SLC4A4,AQP4 |
3.768e-02 | -3.28 | ATP binding | molecular function | GO:0005524 | 1467 | 8 | 18094 | 48 |
GLUD1,TNIK,ADCY2,ATP1A2,BMPR1B,NTRK2,FGFR3,ATP13A4 |
3.780e-02 | -3.28 | axolemma | cellular component | GO:0030673 | 15 | 1 | 19108 | 49 |
SLC1A2 |
3.788e-02 | -3.27 | TIAM2 (TIAM Rac1 associated GEF 2) | protein interactions | 26230 | 15 | 1 | 19454 | 50 |
TNIK |
3.788e-02 | -3.27 | PCSK1N (proprotein convertase subtilisin/kexin type 1 inhibitor) | protein interactions | 27344 | 15 | 1 | 19454 | 50 |
MGAT4C |
3.788e-02 | -3.27 | FGF9 (fibroblast growth factor 9) | protein interactions | 2254 | 15 | 1 | 19454 | 50 |
FGFR3 |
3.788e-02 | -3.27 | IGSF1 (immunoglobulin superfamily member 1) | protein interactions | 3547 | 15 | 1 | 19454 | 50 |
BMPR1B |
3.788e-02 | -3.27 | RNASE13 (ribonuclease A family member 13 (inactive)) | protein interactions | 440163 | 15 | 1 | 19454 | 50 |
CPE |
3.788e-02 | -3.27 | Retrograde endocannabinoid signaling | KEGG pathways | ko04723 | 101 | 2 | 7161 | 22 |
GABRB1,ADCY2 |
3.788e-02 | -3.27 | Retrograde endocannabinoid signaling | KEGG pathways | hsa04723 | 101 | 2 | 7161 | 22 |
ADCY2,GABRB1 |
3.788e-02 | -3.27 | MIP | pfam domains | PF00230 | 14 | 1 | 17795 | 49 |
AQP4 |
3.810e-02 | -3.27 | CEP128 (centrosomal protein 128) | protein interactions | 145508 | 289 | 3 | 19454 | 50 |
SORBS1,GLUD1,ABLIM1 |
3.814e-02 | -3.27 | LRP6 (LDL receptor related protein 6) | protein interactions | 4040 | 120 | 2 | 19454 | 50 |
ZNRF3,MGAT4C |
3.822e-02 | -3.26 | oesophagus-middle_third-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | oesophagus-middle_third-carcinoma-squamous_cell_carcinoma | 3531 | 16 | 16828 | 49 |
TNIK,GPM6A,PREX2,PAMR1,NHSL1,ADCY2,SPARCL1,ABLIM1,MACF1,SOX5,FMN2,ATP1A2,CTNND2,RYR3,SLC4A4,GPC5 |
3.840e-02 | -3.26 | middle_third | COSMIC cancer mutations | middle_third | 3533 | 16 | 16828 | 49 |
GPM6A,TNIK,SPARCL1,ADCY2,PREX2,PAMR1,NHSL1,ATP1A2,MACF1,SOX5,FMN2,ABLIM1,GPC5,SLC4A4,RYR3,CTNND2 |
3.840e-02 | -3.26 | KIF14 (kinesin family member 14) | protein interactions | 9928 | 1803 | 9 | 19454 | 50 |
SOX5,STON2,GLUD1,ABLIM1,MACF1,MSI2,SLC1A3,SHROOM3,SORBS1 |
3.851e-02 | -3.26 | stomach-carcinoma | COSMIC cancer mutations | stomach-carcinoma | 439 | 4 | 16828 | 49 |
NTRK2,BMPR1B,TNIK,FGFR3 |
3.878e-02 | -3.25 | actin filament organization | biological process | GO:0007015 | 278 | 3 | 18204 | 49 |
SHROOM3,FMN2,SORBS1 |
3.881e-02 | -3.25 | bone-humerus-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-humerus-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 107 | 2 | 16828 | 49 |
HIF3A,PARD3B |
3.894e-02 | -3.25 | RanBD | smart domains | SM00160 | 11 | 1 | 9717 | 35 |
RANBP3L |
3.900e-02 | -3.24 | germ_cell_tumour | COSMIC cancer mutations | germ_cell_tumour | 867 | 6 | 16828 | 49 |
BMPR1B,MACF1,NTRK2,TNIK,FGFR3,PREX2 |
3.902e-02 | -3.24 | RANBD1 | prosite domains | PS50196 | 11 | 1 | 12186 | 44 |
RANBP3L |
3.902e-02 | -3.24 | RECEPTOR_TYR_KIN_II | prosite domains | PS00239 | 11 | 1 | 12186 | 44 |
NTRK2 |
3.908e-02 | -3.24 | neurexin family protein binding | molecular function | GO:0042043 | 15 | 1 | 18094 | 48 |
CPE |
3.908e-02 | -3.24 | phosphatidylglycerol binding | molecular function | GO:1901611 | 15 | 1 | 18094 | 48 |
PITPNC1 |
3.914e-02 | -3.24 | skin-leg-malignant_melanoma-nodular | COSMIC cancer mutations | skin-leg-malignant_melanoma-nodular | 258 | 3 | 16828 | 49 |
SLC4A4,ATP13A4,FMN2 |
3.930e-02 | -3.24 | BRK1 (BRICK1 subunit of SCAR/WAVE actin nucleating complex) | protein interactions | 55845 | 122 | 2 | 19454 | 50 |
DTNA,NHSL1 |
3.943e-02 | -3.23 | human chr4q32.3 | chromosome location | human chr4q32.3 | 21 | 1 | 26134 | 50 |
CPE |
3.943e-02 | -3.23 | human chr13q31.3 | chromosome location | human chr13q31.3 | 21 | 1 | 26134 | 50 |
GPC5 |
3.947e-02 | -3.23 | testis-germ_cell_tumour-seminoma | COSMIC cancer mutations | testis-germ_cell_tumour-seminoma | 648 | 5 | 16828 | 49 |
PREX2,BMPR1B,NTRK2,TNIK,FGFR3 |
3.949e-02 | -3.23 | HCO3TRNSPORT | prints domains | PR01231 | 10 | 1 | 5227 | 21 |
SLC4A4 |
3.959e-02 | -3.23 | Ammonia Recycling | SMPDB pathways | SMP0000009 | 11 | 1 | 1369 | 5 |
GLUD1 |
3.959e-02 | -3.23 | NAD+ Signalling and Aging | SMPDB pathways | SMP0084271 | 11 | 1 | 1369 | 5 |
RORA |
3.964e-02 | -3.23 | system process | biological process | GO:0003008 | 2015 | 10 | 18204 | 49 |
SLC1A2,SLC1A3,RYR3,ATP1A2,ABLIM1,NTRK2,SLC4A4,CTNNA2,AQP4,DTNA |
3.964e-02 | -3.23 | positive regulation of glycogen biosynthetic process | biological process | GO:0045725 | 15 | 1 | 18204 | 49 |
SORBS1 |
3.964e-02 | -3.23 | sarcoplasmic reticulum calcium ion transport | biological process | GO:0070296 | 15 | 1 | 18204 | 49 |
RYR3 |
3.964e-02 | -3.23 | chondrocyte proliferation | biological process | GO:0035988 | 15 | 1 | 18204 | 49 |
FGFR3 |
3.964e-02 | -3.23 | response to caffeine | biological process | GO:0031000 | 15 | 1 | 18204 | 49 |
RYR3 |
3.964e-02 | -3.23 | regulation of neuron projection arborization | biological process | GO:0150011 | 15 | 1 | 18204 | 49 |
MACF1 |
3.964e-02 | -3.23 | protein homotrimerization | biological process | GO:0070207 | 15 | 1 | 18204 | 49 |
SLC1A2 |
3.964e-02 | -3.23 | negative regulation of sodium ion transmembrane transport | biological process | GO:1902306 | 15 | 1 | 18204 | 49 |
ATP1A2 |
3.964e-02 | -3.23 | dorsal/ventral neural tube patterning | biological process | GO:0021904 | 15 | 1 | 18204 | 49 |
GLI3 |
3.964e-02 | -3.23 | apical protein localization | biological process | GO:0045176 | 15 | 1 | 18204 | 49 |
SHROOM3 |
3.964e-02 | -3.23 | peripheral nervous system neuron differentiation | biological process | GO:0048934 | 15 | 1 | 18204 | 49 |
NTRK2 |
3.964e-02 | -3.23 | neuroblast division | biological process | GO:0055057 | 15 | 1 | 18204 | 49 |
SOX5 |
3.964e-02 | -3.23 | peripheral nervous system neuron development | biological process | GO:0048935 | 15 | 1 | 18204 | 49 |
NTRK2 |
3.964e-02 | -3.23 | intracellular potassium ion homeostasis | biological process | GO:0030007 | 15 | 1 | 18204 | 49 |
ATP1A2 |
3.964e-02 | -3.23 | cerebellar Purkinje cell layer formation | biological process | GO:0021694 | 15 | 1 | 18204 | 49 |
RORA |
3.970e-02 | -3.23 | bone-tibia-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-tibia-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 649 | 5 | 16828 | 49 |
ABLIM1,FGFR3,TNIK,MACF1,PREX2 |
3.975e-02 | -3.23 | FH2_Formin | interpro domains | IPR015425 | 15 | 1 | 18521 | 50 |
FMN2 |
3.975e-02 | -3.23 | ATPase_P-typ_cation-transptr_C | interpro domains | IPR006068 | 15 | 1 | 18521 | 50 |
ATP1A2 |
3.975e-02 | -3.23 | CNH_dom | interpro domains | IPR001180 | 15 | 1 | 18521 | 50 |
TNIK |
3.975e-02 | -3.23 | FH2_Formin_sf | interpro domains | IPR042201 | 15 | 1 | 18521 | 50 |
FMN2 |
3.997e-02 | -3.22 | Bone Morphogenic Protein (BMP) Signalling and Regulation | WikiPathways | WP1425 | 12 | 1 | 5310 | 18 |
BMPR1B |
3.997e-02 | -3.22 | MFAP5-mediated ovarian cancer cell motility and invasiveness | WikiPathways | WP3301 | 12 | 1 | 5310 | 18 |
RYR3 |
4.002e-02 | -3.22 | endometriosis | COSMIC cancer mutations | endometriosis | 14 | 1 | 16828 | 49 |
FGFR3 |
4.002e-02 | -3.22 | urinary_tract-renal_pelvis-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-renal_pelvis-carcinoma-transitional_cell_carcinoma | 14 | 1 | 16828 | 49 |
FGFR3 |
4.002e-02 | -3.22 | in_situ_neoplasm | COSMIC cancer mutations | in_situ_neoplasm | 14 | 1 | 16828 | 49 |
FGFR3 |
4.002e-02 | -3.22 | small_round_cell_tumour | COSMIC cancer mutations | small_round_cell_tumour | 14 | 1 | 16828 | 49 |
FGFR3 |
4.002e-02 | -3.22 | soft_tissue-small_round_cell_tumour | COSMIC cancer mutations | soft_tissue-small_round_cell_tumour | 14 | 1 | 16828 | 49 |
FGFR3 |
4.010e-02 | -3.22 | DCC mediated attractive signaling | REACTOME pathways | R-HSA-418885 | 14 | 1 | 10285 | 30 |
ABLIM1 |
4.023e-02 | -3.21 | Prot_kinase_dom | interpro domains | IPR000719 | 480 | 4 | 18521 | 50 |
FGFR3,TNIK,BMPR1B,NTRK2 |
4.024e-02 | -3.21 | G Protein Signaling Pathways | WikiPathways | WP35 | 95 | 2 | 5310 | 18 |
ADCY2,GNA14 |
4.027e-02 | -3.21 | postsynaptic density, intracellular component | cellular component | GO:0099092 | 16 | 1 | 19108 | 49 |
TNIK |
4.035e-02 | -3.21 | CDH12 (cadherin 12) | protein interactions | 1010 | 16 | 1 | 19454 | 50 |
CTNNA2 |
4.035e-02 | -3.21 | CTSK (cathepsin K) | protein interactions | 1513 | 16 | 1 | 19454 | 50 |
FGFR3 |
4.035e-02 | -3.21 | AMMECR1L (AMMECR1 like) | protein interactions | 83607 | 16 | 1 | 19454 | 50 |
MACF1 |
4.035e-02 | -3.21 | GALNT13 (polypeptide N-acetylgalactosaminyltransferase 13) | protein interactions | 114805 | 16 | 1 | 19454 | 50 |
TNIK |
4.035e-02 | -3.21 | FZD4 (frizzled class receptor 4) | protein interactions | 8322 | 16 | 1 | 19454 | 50 |
ZNRF3 |
4.035e-02 | -3.21 | SAPCD1 (suppressor APC domain containing 1) | protein interactions | 401251 | 16 | 1 | 19454 | 50 |
CTNNA2 |
4.035e-02 | -3.21 | FNDC8 (fibronectin type III domain containing 8) | protein interactions | 54752 | 16 | 1 | 19454 | 50 |
SPARCL1 |
4.035e-02 | -3.21 | HLA-H (major histocompatibility complex, class I, H (pseudogene)) | protein interactions | 3136 | 16 | 1 | 19454 | 50 |
FGFR3 |
4.053e-02 | -3.21 | Cation_ATPase_C | pfam domains | PF00689 | 15 | 1 | 17795 | 49 |
ATP1A2 |
4.053e-02 | -3.21 | FH2 | pfam domains | PF02181 | 15 | 1 | 17795 | 49 |
FMN2 |
4.053e-02 | -3.21 | CNH | pfam domains | PF00780 | 15 | 1 | 17795 | 49 |
TNIK |
4.092e-02 | -3.20 | regulation of signaling | biological process | GO:0023051 | 3534 | 15 | 18204 | 49 |
CTNND2,GPC5,MACF1,ATP1A2,ZNRF3,SORBS1,BMPR1B,NTRK2,PREX2,RORA,GLUD1,GLI3,SLC1A3,TNIK,FGFR3 |
4.101e-02 | -3.19 | Ig-like_dom_sf | interpro domains | IPR036179 | 483 | 4 | 18521 | 50 |
FGFR3,NTRK2,LSAMP,NTM |
4.106e-02 | -3.19 | SLAMF1 (signaling lymphocytic activation molecule family member 1) | protein interactions | 6504 | 125 | 2 | 19454 | 50 |
CACHD1,CPE |
4.106e-02 | -3.19 | SCGB1D1 (secretoglobin family 1D member 1) | protein interactions | 10648 | 125 | 2 | 19454 | 50 |
CPE,CACHD1 |
4.112e-02 | -3.19 | export from cell | biological process | GO:0140352 | 485 | 4 | 18204 | 49 |
ATP1A2,NTRK2,CPE,SLC4A4 |
4.117e-02 | -3.19 | secondary active transmembrane transporter activity | molecular function | GO:0015291 | 289 | 3 | 18094 | 48 |
SLC1A3,SLC4A4,SLC1A2 |
4.126e-02 | -3.19 | Integration of energy metabolism | REACTOME pathways | R-HSA-163685 | 111 | 2 | 10285 | 30 |
GNA14,ADCY2 |
4.127e-02 | -3.19 | human chr3q13.31 | chromosome location | human chr3q13.31 | 22 | 1 | 26134 | 50 |
LSAMP |
4.156e-02 | -3.18 | regulation of cell communication | biological process | GO:0010646 | 3541 | 15 | 18204 | 49 |
RORA,GLUD1,GLI3,SLC1A3,TNIK,FGFR3,MACF1,GPC5,CTNND2,BMPR1B,NTRK2,PREX2,ATP1A2,ZNRF3,SORBS1 |
4.163e-02 | -3.18 | water channel activity | molecular function | GO:0015250 | 16 | 1 | 18094 | 48 |
AQP4 |
4.163e-02 | -3.18 | adenylate cyclase activity | molecular function | GO:0004016 | 16 | 1 | 18094 | 48 |
ADCY2 |
4.163e-02 | -3.18 | oxysterol binding | molecular function | GO:0008142 | 16 | 1 | 18094 | 48 |
RORA |
4.163e-02 | -3.18 | ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential | molecular function | GO:0099507 | 16 | 1 | 18094 | 48 |
GABRB1 |
4.166e-02 | -3.18 | SYP (synaptophysin) | protein interactions | 6855 | 126 | 2 | 19454 | 50 |
PITPNC1,GPM6A |
4.176e-02 | -3.18 | Glycerol uptake facilitator protein | gene3d domains | 1.20.1080.10 | 14 | 1 | 14470 | 44 |
AQP4 |
4.198e-02 | -3.17 | ossification | biological process | GO:0001503 | 287 | 3 | 18204 | 49 |
GLI3,FGFR3,BMPR1B |
4.207e-02 | -3.17 | chloride transport | biological process | GO:0006821 | 121 | 2 | 18204 | 49 |
SLC1A3,GABRB1 |
4.223e-02 | -3.16 | cardiac left ventricle morphogenesis | biological process | GO:0003214 | 16 | 1 | 18204 | 49 |
CPE |
4.223e-02 | -3.16 | asymmetric cell division | biological process | GO:0008356 | 16 | 1 | 18204 | 49 |
SOX5 |
4.223e-02 | -3.16 | glutamine family amino acid biosynthetic process | biological process | GO:0009084 | 16 | 1 | 18204 | 49 |
GLUD1 |
4.223e-02 | -3.16 | locomotory exploration behavior | biological process | GO:0035641 | 16 | 1 | 18204 | 49 |
ATP1A2 |
4.223e-02 | -3.16 | regulation of respiratory system process | biological process | GO:0044065 | 16 | 1 | 18204 | 49 |
ATP1A2 |
4.223e-02 | -3.16 | regulation of amino acid transmembrane transport | biological process | GO:1903789 | 16 | 1 | 18204 | 49 |
ATP1A2 |
4.223e-02 | -3.16 | tricarboxylic acid metabolic process | biological process | GO:0072350 | 16 | 1 | 18204 | 49 |
GLUD1 |
4.223e-02 | -3.16 | non-proteinogenic amino acid biosynthetic process | biological process | GO:0170043 | 16 | 1 | 18204 | 49 |
SLC1A3 |
4.223e-02 | -3.16 | nonribosomal peptide biosynthetic process | biological process | GO:0019184 | 16 | 1 | 18204 | 49 |
SLC1A2 |
4.223e-02 | -3.16 | spinal cord dorsal/ventral patterning | biological process | GO:0021513 | 16 | 1 | 18204 | 49 |
GLI3 |
4.223e-02 | -3.16 | regulation of Wnt signaling pathway, planar cell polarity pathway | biological process | GO:2000095 | 16 | 1 | 18204 | 49 |
ZNRF3 |
4.223e-02 | -3.16 | nose development | biological process | GO:0043584 | 16 | 1 | 18204 | 49 |
GLI3 |
4.223e-02 | -3.16 | insulin metabolic process | biological process | GO:1901142 | 16 | 1 | 18204 | 49 |
CPE |
4.223e-02 | -3.16 | regulation of amino acid import across plasma membrane | biological process | GO:0010958 | 16 | 1 | 18204 | 49 |
ATP1A2 |
4.223e-02 | -3.16 | large_intestine-adenoma | COSMIC cancer mutations | large_intestine-adenoma | 266 | 3 | 16828 | 49 |
RYR3,SOX5,GLI3 |
4.225e-02 | -3.16 | EF_HAND_2 | prosite domains | PS50222 | 215 | 3 | 12186 | 44 |
RYR3,MACF1,SPARCL1 |
4.235e-02 | -3.16 | GproteinA_insert | interpro domains | IPR011025 | 16 | 1 | 18521 | 50 |
GNA14 |
4.235e-02 | -3.16 | CarboxyPept-like_regulatory | interpro domains | IPR008969 | 16 | 1 | 18521 | 50 |
CPE |
4.235e-02 | -3.16 | Gprotein_alpha_su | interpro domains | IPR001019 | 16 | 1 | 18521 | 50 |
GNA14 |
4.267e-02 | -3.15 | neuron projection terminus | cellular component | GO:0044306 | 128 | 2 | 19108 | 49 |
SLC1A2,NTRK2 |
4.282e-02 | -3.15 | ureter | COSMIC cancer mutations | ureter | 15 | 1 | 16828 | 49 |
FGFR3 |
4.282e-02 | -3.15 | CCDC32 (coiled-coil domain containing 32) | protein interactions | 90416 | 17 | 1 | 19454 | 50 |
STON2 |
4.282e-02 | -3.15 | SEPSECS (Sep (O-phosphoserine) tRNA:Sec (selenocysteine) tRNA synthase) | protein interactions | 51091 | 17 | 1 | 19454 | 50 |
ABLIM1 |
4.282e-02 | -3.15 | TAGAP (T cell activation RhoGTPase activating protein) | protein interactions | 117289 | 17 | 1 | 19454 | 50 |
DTNA |
4.282e-02 | -3.15 | Sqstm1 (sequestosome 1) | protein interactions | 18412 | 17 | 1 | 19454 | 50 |
BMPR1B |
4.282e-02 | -3.15 | MSANTD2 (Myb/SANT DNA binding domain containing 2) | protein interactions | 79684 | 17 | 1 | 19454 | 50 |
SOX5 |
4.282e-02 | -3.15 | PAX4 (paired box 4) | protein interactions | 5078 | 17 | 1 | 19454 | 50 |
NTM |
4.282e-02 | -3.15 | RASL12 (RAS like family 12) | protein interactions | 51285 | 17 | 1 | 19454 | 50 |
BMPR1B |
4.282e-02 | -3.15 | Shcbp1 (Shc SH2-domain binding protein 1) | protein interactions | 20419 | 17 | 1 | 19454 | 50 |
GPC5 |
4.282e-02 | -3.15 | DPP6 (dipeptidyl peptidase like 6) | protein interactions | 1804 | 17 | 1 | 19454 | 50 |
GPM6A |
4.283e-02 | -3.15 | central_nervous_system-brainstem-glioma-astrocytoma_Grade_III | COSMIC cancer mutations | central_nervous_system-brainstem-glioma-astrocytoma_Grade_III | 113 | 2 | 16828 | 49 |
ADCY2,STON2 |
4.286e-02 | -3.15 | ATF7IP (activating transcription factor 7 interacting protein) | protein interactions | 55729 | 128 | 2 | 19454 | 50 |
SOX5,MACF1 |
4.290e-02 | -3.15 | Inhibition of adenylate cyclase pathway | REACTOME pathways | R-HSA-997269 | 15 | 1 | 10285 | 30 |
ADCY2 |
4.290e-02 | -3.15 | N-Glycan antennae elongation | REACTOME pathways | R-HSA-975577 | 15 | 1 | 10285 | 30 |
MGAT4C |
4.290e-02 | -3.15 | Adenylate cyclase inhibitory pathway | REACTOME pathways | R-HSA-170670 | 15 | 1 | 10285 | 30 |
ADCY2 |
4.297e-02 | -3.15 | RAC1 (Rac family small GTPase 1) | protein interactions | 5879 | 1005 | 6 | 19454 | 50 |
DTNA,MACF1,FMN2,PREX2,STON2,SLC1A3 |
4.311e-02 | -3.14 | human chr5p15.31 | chromosome location | human chr5p15.31 | 23 | 1 | 26134 | 50 |
ADCY2 |
4.313e-02 | -3.14 | Lactose Degradation | SMPDB pathways | SMP0000457 | 12 | 1 | 1369 | 5 |
ATP1A2 |
4.313e-02 | -3.14 | Lactose Intolerance | SMPDB pathways | SMP0000458 | 12 | 1 | 1369 | 5 |
ATP1A2 |
4.318e-02 | -3.14 | G-alpha | pfam domains | PF00503 | 16 | 1 | 17795 | 49 |
GNA14 |
4.323e-02 | -3.14 | Cell-type Dependent Selectivity of CCK2R Signaling | WikiPathways | WP3679 | 13 | 1 | 5310 | 18 |
RYR3 |
4.329e-02 | -3.14 | ovary-carcinoma-mucinous_carcinoma | COSMIC cancer mutations | ovary-carcinoma-mucinous_carcinoma | 456 | 4 | 16828 | 49 |
BMPR1B,NTRK2,TNIK,FGFR3 |
4.334e-02 | -3.14 | ovary-carcinoma-clear_cell_carcinoma | COSMIC cancer mutations | ovary-carcinoma-clear_cell_carcinoma | 665 | 5 | 16828 | 49 |
BMPR1B,NTRK2,SPARCL1,TNIK,FGFR3 |
4.346e-02 | -3.14 | POLA2 (DNA polymerase alpha 2, accessory subunit) | protein interactions | 23649 | 129 | 2 | 19454 | 50 |
FGFR3,CPE |
4.346e-02 | -3.14 | Lima1 (LIM domain and actin binding 1) | protein interactions | 65970 | 129 | 2 | 19454 | 50 |
STON2,ABLIM1 |
4.350e-02 | -3.13 | cellular response to growth factor stimulus | biological process | GO:0071363 | 494 | 4 | 18204 | 49 |
NTRK2,BMPR1B,FGFR3,SOX5 |
4.388e-02 | -3.13 | mucinous_carcinoma | COSMIC cancer mutations | mucinous_carcinoma | 458 | 4 | 16828 | 49 |
NTRK2,BMPR1B,TNIK,FGFR3 |
4.400e-02 | -3.12 | basal part of cell | cellular component | GO:0045178 | 307 | 3 | 19108 | 49 |
AQP4,SLC4A4,SLC1A3 |
4.428e-02 | -3.12 | clear_cell_carcinoma | COSMIC cancer mutations | clear_cell_carcinoma | 669 | 5 | 16828 | 49 |
SPARCL1,NTRK2,BMPR1B,TNIK,FGFR3 |
4.432e-02 | -3.12 | endomembrane system | cellular component | GO:0012505 | 4764 | 18 | 19108 | 49 |
ATP13A4,RANBP3L,TNIK,SPARCL1,NTRK2,AQP4,PARD3B,ATP1A2,MGAT4C,FMN2,FGFR3,GLUD1,CPE,RYR3,STON2,GPC5,GABRB1,MACF1 |
4.440e-02 | -3.11 | protein-containing complex | cellular component | GO:0032991 | 6542 | 23 | 19108 | 49 |
HIF3A,GABRB1,SLC1A2,STON2,FBXL7,SOX5,SORBS1,CACHD1,RYR3,BMPR1B,NPAS3,FGFR3,NTRK2,PARD3B,CTNNA2,ATP1A2,GNA14,RFX4,RORA,GLI3,RANBP3L,SLC1A3,DTNA |
4.461e-02 | -3.11 | cerebral cortex development | biological process | GO:0021987 | 125 | 2 | 18204 | 49 |
GLI3,NTRK2 |
4.467e-02 | -3.11 | Formin, FH2 domain | gene3d domains | 1.20.58.2220 | 15 | 1 | 14470 | 44 |
FMN2 |
4.477e-02 | -3.11 | Helix-loop-helix DNA-binding domain | gene3d domains | 4.10.280.10 | 111 | 2 | 14470 | 44 |
NPAS3,HIF3A |
4.481e-02 | -3.11 | cell population proliferation | biological process | GO:0008283 | 726 | 5 | 18204 | 49 |
RORA,ZNRF3,SOX5,FGFR3,GLI3 |
4.481e-02 | -3.11 | cell communication by electrical coupling involved in cardiac conduction | biological process | GO:0086064 | 17 | 1 | 18204 | 49 |
ATP1A2 |
4.481e-02 | -3.11 | T-helper 17 type immune response | biological process | GO:0072538 | 17 | 1 | 18204 | 49 |
RORA |
4.481e-02 | -3.11 | embryonic digestive tract morphogenesis | biological process | GO:0048557 | 17 | 1 | 18204 | 49 |
GLI3 |
4.481e-02 | -3.11 | membrane depolarization during cardiac muscle cell action potential | biological process | GO:0086012 | 17 | 1 | 18204 | 49 |
ATP1A2 |
4.481e-02 | -3.11 | cell migration in hindbrain | biological process | GO:0021535 | 17 | 1 | 18204 | 49 |
CTNNA2 |
4.481e-02 | -3.11 | specification of animal organ identity | biological process | GO:0010092 | 17 | 1 | 18204 | 49 |
GLI3 |
4.481e-02 | -3.11 | retinal rod cell differentiation | biological process | GO:0060221 | 17 | 1 | 18204 | 49 |
NTRK2 |
4.481e-02 | -3.11 | microvillus assembly | biological process | GO:0030033 | 17 | 1 | 18204 | 49 |
TNIK |
4.481e-02 | -3.11 | cellular response to ATP | biological process | GO:0071318 | 17 | 1 | 18204 | 49 |
RYR3 |
4.481e-02 | -3.11 | cGMP metabolic process | biological process | GO:0046068 | 17 | 1 | 18204 | 49 |
RORA |
4.481e-02 | -3.11 | positive regulation of glycogen metabolic process | biological process | GO:0070875 | 17 | 1 | 18204 | 49 |
SORBS1 |
4.481e-02 | -3.11 | protein trimerization | biological process | GO:0070206 | 17 | 1 | 18204 | 49 |
SLC1A2 |
4.493e-02 | -3.10 | A/G_cyclase_CS | interpro domains | IPR018297 | 17 | 1 | 18521 | 50 |
ADCY2 |
4.493e-02 | -3.10 | PAC | interpro domains | IPR001610 | 17 | 1 | 18521 | 50 |
HIF3A |
4.507e-02 | -3.10 | ductal_carcinoma | COSMIC cancer mutations | ductal_carcinoma | 15798 | 49 | 16828 | 49 |
RANBP3L,BMPR1B,ATP1A2,NPAS3,GPM6A,PAMR1,SLC1A3,SHROOM3,PARD3B,GNA14,FMN2,GLIS3,RYR3,ATP13A4,AQP4,PITPNC1,ADCY2,NTM,NKAIN3,SOX5,MACF1,CACHD1,SLC4A4,GPC5,RFX4,GABRB1,RORA,GLI3,DTNA,SLC1A2,PREX2,ZNRF3,SPARCL1,FGFR3,ABLIM1,CPE,NTRK2,CTNND2,SORBS1,STON2,TNIK,MSI2,SFXN5,FBXL7,GLUD1,LSAMP,NHSL1,MGAT4C,HIF3A |
4.517e-02 | -3.10 | PROTEIN_KINASE_TYR | prosite domains | PS00109 | 94 | 2 | 12186 | 44 |
NTRK2,FGFR3 |
4.519e-02 | -3.10 | clathrin coat of coated pit | cellular component | GO:0030132 | 18 | 1 | 19108 | 49 |
STON2 |
4.525e-02 | -3.10 | limbic system development | biological process | GO:0021761 | 126 | 2 | 18204 | 49 |
ATP1A2,GLI3 |
4.529e-02 | -3.09 | OPCML (opioid binding protein/cell adhesion molecule like) | protein interactions | 4978 | 18 | 1 | 19454 | 50 |
NTM |
4.529e-02 | -3.09 | NKIRAS1 (NFKB inhibitor interacting Ras like 1) | protein interactions | 28512 | 18 | 1 | 19454 | 50 |
BMPR1B |
4.529e-02 | -3.09 | Cnot2 (CCR4-NOT transcription complex, subunit 2) | protein interactions | 72068 | 18 | 1 | 19454 | 50 |
MACF1 |
4.529e-02 | -3.09 | NECTIN1 (nectin cell adhesion molecule 1) | protein interactions | 5818 | 18 | 1 | 19454 | 50 |
FGFR3 |
4.529e-02 | -3.09 | TTC29 (tetratricopeptide repeat domain 29) | protein interactions | 83894 | 18 | 1 | 19454 | 50 |
MACF1 |
4.529e-02 | -3.09 | Tgfbr1 (transforming growth factor, beta receptor I) | protein interactions | 21812 | 18 | 1 | 19454 | 50 |
BMPR1B |
4.529e-02 | -3.09 | KLHL1 (kelch like family member 1) | protein interactions | 57626 | 18 | 1 | 19454 | 50 |
BMPR1B |
4.530e-02 | -3.09 | GPIHBP1 (glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1) | protein interactions | 338328 | 132 | 2 | 19454 | 50 |
FGFR3,CPE |
4.531e-02 | -3.09 | positive regulation of nervous system development | biological process | GO:0051962 | 296 | 3 | 18204 | 49 |
GLI3,NTRK2,MACF1 |
4.533e-02 | -3.09 | purine ribonucleoside triphosphate binding | molecular function | GO:0035639 | 1804 | 9 | 18094 | 48 |
NTRK2,ATP13A4,FGFR3,GNA14,TNIK,GLUD1,BMPR1B,ADCY2,ATP1A2 |
4.557e-02 | -3.09 | cytoskeletal protein binding | molecular function | GO:0008092 | 989 | 6 | 18094 | 48 |
ABLIM1,MACF1,SORBS1,FMN2,SHROOM3,CTNNA2 |
4.561e-02 | -3.09 | renal_pelvis | COSMIC cancer mutations | renal_pelvis | 16 | 1 | 16828 | 49 |
FGFR3 |
4.561e-02 | -3.09 | normal | COSMIC cancer mutations | normal | 16 | 1 | 16828 | 49 |
FGFR3 |
4.561e-02 | -3.09 | flank | COSMIC cancer mutations | flank | 16 | 1 | 16828 | 49 |
FGFR3 |
4.561e-02 | -3.09 | urinary_tract-carcinoma | COSMIC cancer mutations | urinary_tract-carcinoma | 16 | 1 | 16828 | 49 |
FGFR3 |
4.565e-02 | -3.09 | ovary-carcinoma-endometrioid_carcinoma | COSMIC cancer mutations | ovary-carcinoma-endometrioid_carcinoma | 464 | 4 | 16828 | 49 |
BMPR1B,NTRK2,FGFR3,TNIK |
4.569e-02 | -3.09 | muscle system process | biological process | GO:0003012 | 297 | 3 | 18204 | 49 |
RYR3,ATP1A2,DTNA |
4.570e-02 | -3.09 | PKA activation | REACTOME pathways | R-HSA-163615 | 16 | 1 | 10285 | 30 |
ADCY2 |
4.578e-02 | -3.08 | Neural Crest Differentiation | WikiPathways | WP2064 | 102 | 2 | 5310 | 18 |
FGFR3,SOX5 |
4.581e-02 | -3.08 | ZZ | pfam domains | PF00569 | 17 | 1 | 17795 | 49 |
DTNA |
4.590e-02 | -3.08 | response to amino acid | biological process | GO:0043200 | 127 | 2 | 18204 | 49 |
NTRK2,SLC1A2 |
4.596e-02 | -3.08 | CARBOXYPEPT_ZN_1 | prosite domains | PS00132 | 13 | 1 | 12186 | 44 |
CPE |
4.596e-02 | -3.08 | CARBOXYPEPT_ZN_2 | prosite domains | PS00133 | 13 | 1 | 12186 | 44 |
CPE |
4.615e-02 | -3.08 | cell cortex | cellular component | GO:0005938 | 313 | 3 | 19108 | 49 |
PARD3B,FMN2,SHROOM3 |
4.621e-02 | -3.07 | adenyl ribonucleotide binding | molecular function | GO:0032559 | 1528 | 8 | 18094 | 48 |
NTRK2,TNIK,GLUD1,BMPR1B,ATP13A4,ATP1A2,ADCY2,FGFR3 |
4.636e-02 | -3.07 | PROTEIN_KINASE_ATP | prosite domains | PS00107 | 377 | 4 | 12186 | 44 |
NTRK2,BMPR1B,FGFR3,TNIK |
4.648e-02 | -3.07 | ERK Pathway in Huntington's Disease | WikiPathways | WP3853 | 14 | 1 | 5310 | 18 |
NTRK2 |
4.665e-02 | -3.07 | Citrullinemia Type I | SMPDB pathways | SMP0000001 | 13 | 1 | 1369 | 5 |
GLUD1 |
4.665e-02 | -3.07 | Argininosuccinic Aciduria | SMPDB pathways | SMP0000003 | 13 | 1 | 1369 | 5 |
GLUD1 |
4.665e-02 | -3.07 | Urea Cycle | SMPDB pathways | SMP0000059 | 13 | 1 | 1369 | 5 |
GLUD1 |
4.665e-02 | -3.07 | Carbamoyl Phosphate Synthetase Deficiency | SMPDB pathways | SMP0000002 | 13 | 1 | 1369 | 5 |
GLUD1 |
4.665e-02 | -3.07 | Trehalose Degradation | SMPDB pathways | SMP0000467 | 13 | 1 | 1369 | 5 |
ATP1A2 |
4.665e-02 | -3.07 | Argininemia | SMPDB pathways | SMP0000357 | 13 | 1 | 1369 | 5 |
GLUD1 |
4.665e-02 | -3.07 | Ornithine Transcarbamylase Deficiency (OTC Deficiency) | SMPDB pathways | SMP0000205 | 13 | 1 | 1369 | 5 |
GLUD1 |
4.671e-02 | -3.06 | intracellularly gated calcium channel activity | molecular function | GO:0015278 | 18 | 1 | 18094 | 48 |
RYR3 |
4.671e-02 | -3.06 | NAD+ binding | molecular function | GO:0070403 | 18 | 1 | 18094 | 48 |
GLUD1 |
4.671e-02 | -3.06 | GABA receptor binding | molecular function | GO:0050811 | 18 | 1 | 18094 | 48 |
GABRB1 |
4.671e-02 | -3.06 | clathrin adaptor activity | molecular function | GO:0035615 | 18 | 1 | 18094 | 48 |
STON2 |
4.671e-02 | -3.06 | phosphatidylcholine transporter activity | molecular function | GO:0008525 | 18 | 1 | 18094 | 48 |
PITPNC1 |
4.716e-02 | -3.05 | Myo1c (myosin IC) | protein interactions | 17913 | 135 | 2 | 19454 | 50 |
STON2,ABLIM1 |
4.722e-02 | -3.05 | central_nervous_system-brain-glioma-astrocytoma_Grade_IV | COSMIC cancer mutations | central_nervous_system-brain-glioma-astrocytoma_Grade_IV | 15813 | 49 | 16828 | 49 |
NTM,CACHD1,NKAIN3,MACF1,SOX5,GPC5,SLC4A4,GABRB1,RFX4,RORA,GLI3,DTNA,SLC1A2,ZNRF3,SPARCL1,PREX2,ABLIM1,FGFR3,CPE,NTRK2,CTNND2,SORBS1,STON2,TNIK,MSI2,SFXN5,FBXL7,GLUD1,LSAMP,HIF3A,NHSL1,MGAT4C,RANBP3L,ATP1A2,BMPR1B,NPAS3,GPM6A,PAMR1,SLC1A3,GNA14,PARD3B,SHROOM3,GLIS3,FMN2,RYR3,ATP13A4,ADCY2,AQP4,PITPNC1 |
4.737e-02 | -3.05 | circulatory system process | biological process | GO:0003013 | 508 | 4 | 18204 | 49 |
SLC1A2,ATP1A2,SLC1A3,SLC4A4 |
4.738e-02 | -3.05 | negative regulation of anoikis | biological process | GO:2000811 | 18 | 1 | 18204 | 49 |
NTRK2 |
4.738e-02 | -3.05 | dicarboxylic acid catabolic process | biological process | GO:0043649 | 18 | 1 | 18204 | 49 |
GLUD1 |
4.738e-02 | -3.05 | negative regulation of sodium ion transport | biological process | GO:0010766 | 18 | 1 | 18204 | 49 |
ATP1A2 |
4.738e-02 | -3.05 | dendritic spine morphogenesis | biological process | GO:0060997 | 18 | 1 | 18204 | 49 |
CTNND2 |
4.738e-02 | -3.05 | positive regulation of circadian rhythm | biological process | GO:0042753 | 18 | 1 | 18204 | 49 |
RORA |
4.738e-02 | -3.05 | receptor catabolic process | biological process | GO:0032801 | 18 | 1 | 18204 | 49 |
ZNRF3 |
4.738e-02 | -3.05 | spinal cord patterning | biological process | GO:0021511 | 18 | 1 | 18204 | 49 |
GLI3 |
4.749e-02 | -3.05 | positive regulation of cell communication | biological process | GO:0010647 | 1792 | 9 | 18204 | 49 |
BMPR1B,NTRK2,TNIK,FGFR3,SLC1A3,SORBS1,MACF1,GPC5,GLUD1 |
4.752e-02 | -3.05 | Nucleotide_cyclase | interpro domains | IPR029787 | 18 | 1 | 18521 | 50 |
ADCY2 |
4.752e-02 | -3.05 | Leu-rich_rpt_Cys-con_subtyp | interpro domains | IPR006553 | 18 | 1 | 18521 | 50 |
FBXL7 |
4.752e-02 | -3.05 | A/G_cyclase | interpro domains | IPR001054 | 18 | 1 | 18521 | 50 |
ADCY2 |
4.758e-02 | -3.05 | GI Alpha 1, domain 2-like | gene3d domains | 1.10.400.10 | 16 | 1 | 14470 | 44 |
GNA14 |
4.761e-02 | -3.04 | postsynaptic density | cellular component | GO:0014069 | 317 | 3 | 19108 | 49 |
NTRK2,CTNND2,TNIK |
4.764e-02 | -3.04 | postsynaptic specialization, intracellular component | cellular component | GO:0099091 | 19 | 1 | 19108 | 49 |
TNIK |
4.764e-02 | -3.04 | cation-transporting ATPase complex | cellular component | GO:0090533 | 19 | 1 | 19108 | 49 |
ATP1A2 |
4.764e-02 | -3.04 | GABA-A receptor complex | cellular component | GO:1902711 | 19 | 1 | 19108 | 49 |
GABRB1 |
4.764e-02 | -3.04 | parallel fiber to Purkinje cell synapse | cellular component | GO:0098688 | 19 | 1 | 19108 | 49 |
GPM6A |
4.772e-02 | -3.04 | haematopoietic_and_lymphoid_tissue-abdomen-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-abdomen-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | 120 | 2 | 16828 | 49 |
FMN2,CTNND2 |
4.774e-02 | -3.04 | RIT2 (Ras like without CAAX 2) | protein interactions | 6014 | 19 | 1 | 19454 | 50 |
DTNA |
4.774e-02 | -3.04 | CNTNAP4 (contactin associated protein family member 4) | protein interactions | 85445 | 19 | 1 | 19454 | 50 |
MACF1 |
4.774e-02 | -3.04 | C3orf62 (chromosome 3 open reading frame 62) | protein interactions | 375341 | 19 | 1 | 19454 | 50 |
ATP1A2 |
4.774e-02 | -3.04 | SPZ1 (spermatogenic leucine zipper 1) | protein interactions | 84654 | 19 | 1 | 19454 | 50 |
DTNA |
4.774e-02 | -3.04 | PHYHIPL (phytanoyl-CoA 2-hydroxylase interacting protein like) | protein interactions | 84457 | 19 | 1 | 19454 | 50 |
GPM6A |
4.777e-02 | -3.04 | positive regulation of signaling | biological process | GO:0023056 | 1794 | 9 | 18204 | 49 |
GLUD1,GPC5,MACF1,SLC1A3,SORBS1,TNIK,FGFR3,NTRK2,BMPR1B |
4.785e-02 | -3.04 | anion binding | molecular function | GO:0043168 | 2412 | 11 | 18094 | 48 |
ATP13A4,PITPNC1,FGFR3,NTRK2,BMPR1B,SLC1A3,ATP1A2,ADCY2,GNA14,TNIK,GLUD1 |
4.793e-02 | -3.04 | skin-back-malignant_melanoma | COSMIC cancer mutations | skin-back-malignant_melanoma | 280 | 3 | 16828 | 49 |
PREX2,ATP1A2,TNIK |
4.809e-02 | -3.03 | cAMP signaling | KEGG pathways | hsa_M00695 | 16 | 1 | 7161 | 22 |
ADCY2 |
4.809e-02 | -3.03 | cAMP signaling | KEGG pathways | M00695 | 16 | 1 | 7161 | 22 |
ADCY2 |
4.809e-02 | -3.03 | N-glycan biosynthesis, complex type | KEGG pathways | M00075 | 16 | 1 | 7161 | 22 |
MGAT4C |
4.809e-02 | -3.03 | N-glycan biosynthesis, complex type | KEGG pathways | hsa_M00075 | 16 | 1 | 7161 | 22 |
MGAT4C |
4.839e-02 | -3.03 | skin-other-verrucal_keratosis_BRAF_inhibitor_related | COSMIC cancer mutations | skin-other-verrucal_keratosis_BRAF_inhibitor_related | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | skin-non_chronically_sun_exposed_site-malignant_melanoma | COSMIC cancer mutations | skin-non_chronically_sun_exposed_site-malignant_melanoma | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | breast-carcinoma-neuroendocrine_carcinoma | COSMIC cancer mutations | breast-carcinoma-neuroendocrine_carcinoma | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | non_chronically_sun_exposed_site | COSMIC cancer mutations | non_chronically_sun_exposed_site | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | verrucal_keratosis_BRAF_inhibitor_related | COSMIC cancer mutations | verrucal_keratosis_BRAF_inhibitor_related | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | skin-carcinoma-squamous_cell_carcinoma_BRAF_inhibitor_related | COSMIC cancer mutations | skin-carcinoma-squamous_cell_carcinoma_BRAF_inhibitor_related | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | squamous_cell_carcinoma_BRAF_inhibitor_related | COSMIC cancer mutations | squamous_cell_carcinoma_BRAF_inhibitor_related | 17 | 1 | 16828 | 49 |
FGFR3 |
4.843e-02 | -3.03 | oligoastrocytoma_Grade_II | COSMIC cancer mutations | oligoastrocytoma_Grade_II | 121 | 2 | 16828 | 49 |
FGFR3,DTNA |
4.844e-02 | -3.03 | Guanylate_cyc | pfam domains | PF00211 | 18 | 1 | 17795 | 49 |
ADCY2 |
4.848e-02 | -3.03 | PKA activation in glucagon signalling | REACTOME pathways | R-HSA-164378 | 17 | 1 | 10285 | 30 |
ADCY2 |
4.848e-02 | -3.03 | PKA-mediated phosphorylation of CREB | REACTOME pathways | R-HSA-111931 | 17 | 1 | 10285 | 30 |
ADCY2 |
4.852e-02 | -3.03 | carboxylic acid transmembrane transport | biological process | GO:1905039 | 131 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
4.859e-02 | -3.02 | human chr18q12.1 | chromosome location | human chr18q12.1 | 26 | 1 | 26134 | 50 |
DTNA |
4.918e-02 | -3.01 | inorganic anion transmembrane transport | biological process | GO:0098661 | 132 | 2 | 18204 | 49 |
GABRB1,SLC1A3 |
4.924e-02 | -3.01 | water transmembrane transporter activity | molecular function | GO:0005372 | 19 | 1 | 18094 | 48 |
AQP4 |
4.924e-02 | -3.01 | cargo adaptor activity | molecular function | GO:0140312 | 19 | 1 | 18094 | 48 |
STON2 |
4.924e-02 | -3.01 | alkali metal ion binding | molecular function | GO:0031420 | 19 | 1 | 18094 | 48 |
ATP1A2 |
4.924e-02 | -3.01 | transmembrane receptor protein serine/threonine kinase activity | molecular function | GO:0004675 | 19 | 1 | 18094 | 48 |
BMPR1B |
4.924e-02 | -3.01 | GABA-A receptor activity | molecular function | GO:0004890 | 19 | 1 | 18094 | 48 |
GABRB1 |
4.930e-02 | -3.01 | CNH | smart domains | SM00036 | 14 | 1 | 9717 | 35 |
TNIK |
4.940e-02 | -3.01 | ACTA1 (actin alpha 1, skeletal muscle) | protein interactions | 58 | 321 | 3 | 19454 | 50 |
DTNA,SORBS1,MACF1 |
4.941e-02 | -3.01 | MHD | prosite domains | PS51072 | 14 | 1 | 12186 | 44 |
STON2 |
4.966e-02 | -3.00 | cell division | biological process | GO:0051301 | 516 | 4 | 18204 | 49 |
PARD3B,SOX5,FBXL7,FMN2 |
4.968e-02 | -3.00 | SPCS2 (signal peptidase complex subunit 2) | protein interactions | 9789 | 139 | 2 | 19454 | 50 |
MGAT4C,GPC5 |
4.968e-02 | -3.00 | DUSP22 (dual specificity phosphatase 22) | protein interactions | 56940 | 139 | 2 | 19454 | 50 |
GNA14,CTNNA2 |
4.985e-02 | -3.00 | regulation of sequestering of calcium ion | biological process | GO:0051282 | 133 | 2 | 18204 | 49 |
ATP1A2,RYR3 |
4.995e-02 | -3.00 | cerebellar Purkinje cell layer morphogenesis | biological process | GO:0021692 | 19 | 1 | 18204 | 49 |
RORA |
4.995e-02 | -3.00 | response to potassium ion | biological process | GO:0035864 | 19 | 1 | 18204 | 49 |
ATP1A2 |
4.995e-02 | -3.00 | microvillus organization | biological process | GO:0032528 | 19 | 1 | 18204 | 49 |
TNIK |
4.995e-02 | -3.00 | vocalization behavior | biological process | GO:0071625 | 19 | 1 | 18204 | 49 |
GLI3 |
4.995e-02 | -3.00 | craniofacial suture morphogenesis | biological process | GO:0097094 | 19 | 1 | 18204 | 49 |
GLI3 |
4.995e-02 | -3.00 | regulation of neurotransmitter uptake | biological process | GO:0051580 | 19 | 1 | 18204 | 49 |
ATP1A2 |